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Abstract
In this thesis studies are presented which focus on autologous stem cells for autograft
cellular therapies in (i) improvement of early haematopoietic reconstitution by ex
vivo manipulation of graft cells, and (ii) assessment of the angiogenic potential of
available clinical sources for development of therapies for vascular regeneration in
ischaemic tissue.
The haematopoietic stem cell (HSC) is the best characterized of all adult tissue stem
cells and conventionally HSCs from bone marrow or from G-CSF mobilised
peripheral blood are reinfused to patients for haematopoietic restoration following
myeloablation. In such procedures there remains a period following HSC autograft
when patients are neutropenic and thrombocytopenic. A number of studies have
used complex cytokine combinations to attempt simultaneous ex vivo expansion of
progenitors of neutrophil and megakaryocyte lineages to reduce post transplant
neutropenia and thrombocytopenia. Our results show that CD34+ HSCs could
expand into mature functional neutrophils under the influence of SCF+Flt3-L+G-
CSF, but that the addition of other cytokines did not improve CD34+ expansion,
and the megakaryocyte growth factor TPO reduced neutrophil maturation.
Recent recognition that stem cells for tissues other than blood exist in the adult has
stimulated clinical interest in their use for a range of regenerative therapies.
Endothelial progenitor cells (EPCs) are stem cells with the potential to proliferate
and differentiate into mature endothelial cells and to form blood vessels in a process
resembling embryonic vasculogenesis. Autologous EPC transplantation may be
used to promote endothelial reconstitution in patients with ischaemic or infarcted
tissue. EPC appear to share many properties with haematopoietic stem cells (HSC),
but while haematopoietic potential is now assessed by numbers of HSC expressing
CD34, EPC determination remains ambiguous. Bone marrow and mobilised
peripheral blood are HSC-rich sources which have been used for vasculogenic
therapy. The studies presented here show that there is no correlation between the
diverse EPC phenotype definitions used in the literature. There is no obvious
relationship between the numbers of haematopoiesis-related CD34+ or CD133+ cells
and outcome of the CFU-EPC assay. Further studies revealed that the cells responsible
for these early outgrowth CFU-EPC colonies were CD14+ plastic-adherent
monocyte-like cells. Recent reports indicate that a peripheral blood monocyte-like
population may also be considered as an EPC source with potential angiogenic
clinical capability. Further work is required to better define the relative endothelial
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The studies in this thesis focus on autologous stem cells for autograft cellular
therapies, and are in two parts. The first part investigates possible improvement of
early haematopoietic reconstitution by ex vivo manipulation of haematopoietic graft
cells. The second part is an assessment of the angiogenic potential of available
clinical autologous graft sources for development of therapies for vascular
regeneration in ischaemic tissue. To place this in context and as an introduction, a
brief history of clinical studies underpinning current concepts is presented below.
However this is reinforced by major laboratory and animal studies which will be
discussed in subsequent sections.
1.1 A brief history of the clinical background to
regenerative cell therapy.
Current concepts of regenerative cell therapy have evolved principally from
developments in blood transfusion, haematology, immunology and latterly
embryology and developmental biology.
Advances in medicine have been driven by the continuing battle against disease.
Throughout history people have been intrigued by the therapeutic possibilities of
transplantation of organs and tissues from one body to another body, or from one
part of the same body to another. During the fifteenth century we can find references
in historical medical literature of attempted blood transfusions as well as the
transplantation of teeth (presumably from cadavers). However, an understanding
of the concept of blood circulation (1628 William Harvey) was critical to the
development of blood transfusion. Initially, transfusion was attempted between dogs
with some success (1665 Richard Lower). In the eighteenth century transfusions
were done only sporadically, and were generally animal to human. Transfusion
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was generally thought of as a cure for mental aberration or as a youth potion for
the aged rather than as a treatment for blood loss. In 1818 James Blundell performed
the first successful human blood transfusion for the treatment of postpartum
haemorrhage. In 1901, Karl Landsteiner and colleagues discovered the ABO blood
type system and subsequently in 1939 the Rh blood group system. Anticoagulant
use was developed during World War I which allowed blood storage. Reports of
organ transplantation, such as skin and corneal transplants appear in medical
journals dating as far back as 1880. However, the first successful organ transplant
was conducted by J Murray and colleagues in 1954 when they performed the first
successful kidney transplant between identical twins. They also performed the first
renal allograft in 1959 with the aid of immunosuppressive drugs. In 1958 Jean
Dausset described the first of many human histocompatibility antigens. Heart, liver,
and pancreas transplantation and the first successful bone marrow transplantation
followed soon after, and have progressed with better understanding of
histocompatibility and development of immunosuppressants.
In the 1970's a large number of allogeneic bone marrow transplantation procedures
were performed using HLA-matched sibling donors for patients with end-stage
leukaemia or aplastic anaemia, as reviewed by Chao and Blume, 1989. Bone marrow
transplantation soon became the definitive treatment for immune-deficiency
diseases, blood disorders, and numerous other indications, as reviewed by one of
the pioneers, (Good, 2002). These treatments rely on the patient lacking an immune
system as in some congenital immunodeficiencies, or on endogenous bone marrow
destruction through myeloablation and immunosuppression to prevent or reduce
graft rejection, but the patients are at risk of graft versus host disease. Patients also
suffer from a period of neutropenia and thrombocytopenia during which they are
at risk from infection and bleeding disorders. Use of autologous bone marrow, which
developed from the success of allogeneic bone marrow transplants, obviates the
need for histocompatible donors or immunosuppression, and avoids graft-versus-
host disease, but may lack a graft-versus-tumour effect in oncology cases and the
graft should be free of residual tumour. The main benefit of autologous bone marrow
is to set aside restorative amounts of a patient's haematopoietic cells which can
reconstitute the patient following intense or cumulative therapies which have
marrow toxicity (reviewed by Chao and Blume, 1990). Later, the use of autologous
peripheral blood stem cells was found to reduce the period of neutropenia and
thrombocytopenia. Today, while not applicable in all cases or diseases, autologous
peripheral blood, potentiated by mobilisation of haematopoietic cells from bone
marrow by recombinant cytokines, is the most common source of haematopoietic
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stem cells for transplant. Nevertheless, the period of neutropenia and
thrombocytopenia still remains clinically significant, and investigation of a means
to reduce this neutropenia is the topic of the first part of this thesis.
Organ transplantation has come a long way since the pioneering clinical procedures
of the 1950's and 1960's, with advances in histocompatibility assessment, surgical
techniques and development of more effective drugs to prevent organ rejection which
have enhanced graft preservation and allograft survival. However, the number of
patients awaiting organ transplant is large and growing. It was hoped that organ
preservation and xenotransplantation (the transplantation into people of organs
from other species) would provide a ready supply of organs, but immunologic
difficulties and concerns regarding transmission of zoonotic diseases currently limit
their use.
It may be that the solution to the shortage of organs for transplantation lies in stem
cell research and tissue engineering. During embryonic development pluripotent
stem cells divide and differentiate to form all the specialised somatic cells of the
body of which the various tissues and organs are composed. If such pluripotent
stem cells could be harvested and encouraged to differentiate into almost any type
of cell needed in the body then this might lead to cellular therapies for organ damage.
This could include new nerve cells for people with brain disorders or spinal injuries,
new heart muscle cells to repair damaged hearts and new and effective treatment
for strokes, burns and arthritis. Recent advances in embryology and developmental
biology have resulted in isolation and manipulation of pluripotent embryonic stem
cells (ES) whose clinical potential has excited much research and controversy. While
this potential advances towards clinical realisation, embryonic stem cells currently
suffer from two major clinical barriers. Firstly the concern that they may escape
growth limitation and regulation to generate teratoma-like tumours, and secondly
that they will be rejected by their recipients due to histocompatibility differences
since, unlike the recipients of haematopoietic stem cells, the patients who might
benefit from ES therapies are unlikely to be congenitally or therapeutically
immunocompromised or to be justifiably considered for chronic immunosuppression.
It has been recognised for some time that in adults certain tissues such as blood,
skin, hair, and organs such as liver, can extensively renew and regenerate,
presumably from stem cells specific for those tissues. Indeed therapies such as
haematopoietic reconstitution discussed above are predicated on the existence of
multipotent haematopoietic stem cells capable of generating the different mature
cellular components of blood. Pursuit of the fundamental adult multipotent
haematopoietic stem cell, whose definition still remains elusive, has been a
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contributing impetus which has led in recent years to a recognition that in adults
stem cells may participate in repair and regeneration of a variety of tissues and
organs whose constituent somatic cells were previously thought to rarely, if ever,
regenerate themselves. One recent controversial idea is that adult stem cells have
the potential for transdifferentiation; in other words, that they are able to transmutate
from one type of tissue cell to another, so that a haematopoietic stem cell might be
capable of generating other tissue such as, for example, muscle or nerve. Other
recent ideas are that different tissue specific stem cells of restricted potency reside
within specialised stem cell niches in different tissues; fundamental adult stem cells
exist which resemble embryonic stem cells in their pluripotency; novel cells are
incorporated into tissue by fusion between recognised stem cells such as
haematopoietic stem cells and resident tissue somatic cells; or that extraneous cells
contribute to tissue regeneration by paracrine influences on resident cells through
cytokine secretion. Whether some or all of these processes operate in the adult to
some extent remains to be confirmed conclusively, but it is becoming evident that
there is a potential for regenerative therapies based on adult stem cells beyond the
established haematopoietic therapies.
Therapeutic use of adult stem cells may solve the concerns relating to embryonic
stem cell potential for teratoma formation, but would still leave the problem of
tissue histocompatibility necessitating chronic immunosuppression, if allogeneic
donor stem cells were employed. However, none of these problems arise with the
use of autologous adult stem cells, which have the most immediate prospect of
early therapy development and implementation.
Currently, methods for expanding and specifically differentiating pluripotent stem
cells are the subject of intensive research. Certain adult stem cell lineage relationships
are emerging that appear promising for therapeutic exploitation. Prominent among
these are mesenchymal stem cells for bone and cartilage regeneration and the
haemangioblast, a common precursor of haematopoiesis and vasculogenesis that
persists in the adult. In the latter context, a number of recent clinical studies have
employed autologous sources of haematopoietic stem cells to elicit apparent
revascularisation of ischaemic tissues, backed up by a number of experimental
laboratory studies. However, there is no consistent definition of which cells are
active in this revascularisation, nor any means of assessing the qualitative or
quantitative vasculogenic potential of any autograft source for such therapy or its
response to any intended ex vivo manipulation or enhancement of clinical
vasculogenic potential. The second part of this thesis represents an attempt to
systematise and reconcile some of the various and conflicting definitions of endothelial
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progenitor cells (EPC) held to be responsible for vasculogenesis in the adult, to better
assess the available sources of autologous EPC which might be proposed for vascular
regenerative therapy of ischaemic heart disease and critical limb ischaemia.
1.2 What is a Stem Cell?
A stem cell is defined as a cell with the unique ability to self-replicate for indefinite
periods of time (maybe thorough the entire life of the organism), and which under
the appropriate signals can give rise (differentiate) to many different cell types that
make up the organism and with the potential for in vivo reconstitution of the given
tissue upon transplantation. Stem cells have the potential to develop into mature
cells that have characteristic morphology and specialized functions, such as heart
cells, bone cells, skin cells, nerve cells or blood cells (http://www.nih.gov/news/
stemcell/scireport.htm). Stem cells have the distinctive property, by comparison to
the large majority of cells of the body, to be uncommitted and remain as such until
they receive a signal to generate specialised cells (Lemoli et al., 2005). The potential
degree of cellular differentiation varies among stem cell populations. A fertilised
egg is a Totipotent stem cell that can produce cells that arise from all three germ
layers (endoderm, mesoderm and ectoderm) and are able to form extraembryonic
tissues such as the supporting trophoblast required for the survived of the developing
embryo. Pluripotent stem cells can produce cells that arise from all three germ
layers and germ cells but not extra-embryonic tissue. Pluripotent stem cells such as
embryonic stem cells (ES) and embryonic germ cells (EG) are isolated from the
inner cell mass of the blastocyst or from primordial germ cells of an early embryo
respectively (Lakshmipathy and Verfaillie, 2005). Unlike differentiated somatic cells,
ES cells do not require any external stimulus to initiate DNA replication and spend
most of their time in the S-phase of cell cycle. Multipotent stem cells give rise to all
tissues derived from one of these germ layers. Tissue-restricted multipotent stem
cells or oligopotent stem cells give rise to lineage-restricted tissue specific cell types
and Unipotent stem cells can only generate one cell type and may be better defined
considering the stem cell definition, as committed progenitor cells (Marshak et al.,
2001). Different groups have used different terminologies to define stem cell
differentiation potential. In this study, the classification described above is used until
a final consensus definition is reached (See also Figure 1.1).
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1.2.1. The human embryonic stem cell
Embryonic stem cells (ES cells) are pluripotent stem cells that can be grown in vitro
indefinitely in their undifferentiated state, undergoing an unlimited number of
symmetrical divisions, whilst maintaining a normal stable diploid karyotype (long-
term self-renewal). A single ES cell can also give rise to differentiated cell types that
are representative of all three primary germ layers of the embryo (endoderm,
mesoderm, ectoderm) (Amit et al., 2000; Laslett et al., 2003). An ES cell is defined
by its origin, the blastocyst, one of the earliest stages of embryonic development
before implantation in the uterine wall (http: //www,nih. gov/news/stemcell/
scireport.htm). The ES cells specifically come from the inner cell mass of the
blastocyst. These cells proliferate extensively in the embryo, and they are capable
of differentiating into all types of cells that occur in the adult both in vitro and in
vivo. (Pera et al., 2003; Reubinoff et al., 2000; Thomson et al., 1998). Human ES
cells have been shown to differentiate in vitro into a wide variety of cells including
mature neurons, astrocytes, oligodendrocytes, cardiomyocytes, endothelial cells,
insulin-producing cells, hepatocyte-like cells and haematopoietic colony-forming
cells. (Reviews; Verfaille a) et al., 2002; Passier and Mummery, 2003). Therefore,
these cells have potential for use in stem cell transplantation, gene therapy and
tissue regeneration applications (Passier and Mummery, 2003). Transplantation of
human derived-ES cells could replace or restore tissue which has been damaged by
disease or injury and be used to treat diseases such as Parkinson's disease, diabetes
or heart failure. Human blastocysts for the establishment of renewable hES cell
lines could be obtained from either supernumerary embryos or from embryos
specifically produced for research purposes. One of the advantages of using ES
cells as compared to adult stem cells is that ES cells have an unlimited ability to
proliferate in vitro and are more likely to be able to differentiate into a broad range
of cell types. Despite their vast potential, non trivial concerns such as ethical issues
about the moral rights of the embryo, scientific debates concerning teratoma
formation, and histocompatibility issues are delaying immediate clinical application
of ES cells.
1.2.2. The adult stem cell
Stem cells are also present in adult life and by contrast with ES cells their origin is
not well known. Adult stem cells are traditionally defined as undifferentiated, rare,
difficult to identify cells found in many differentiated tissues which can renew
themselves and with certain limitations, give rise to all the specialized cell types of
the tissue from which they originate (http://www.nih.gov/news/stemcell/
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scireport.htm). The main function of adult stem cells is to maintain homeostasis of
their stem cell compartment during the entire lifetime of the organism and with
limitation replace dying cells caused by injury or disease (Lemoli et al., 2005). Most
adult tissues are capable of some degree of regeneration and this function might be
attributed to the adult stem cell population. The definition of an adult stem cell is
that upon transplantation it should repopulate the tissue of origin, integrate into
the tissue and give rise to fully differentiated functional cells (Lemoli et al., 2005).
The list of adult tissues reported to contain stem cells is growing and includes bone
marrow, peripheral blood, spinal cord, dental pulp, blood vessels, skeletal muscle,
epithelia of the skin and digestive system, cornea, retina, liver, pancreas, brain and
heart (the last two organs were previously considered to have minimal or no cell
turnover in adult life) (http://www.nih.gov/news/stemcell/scireport.htm). These stem
cells are more abundant in tissues with a high renewal rate, such as blood or epithelia
and less frequent in tissues or organs with less renewal capacity such as myocardial
muscle or the central nervous system (Lemoli et al., 2005). However, the extent to
which stem cells actually participate in organ maintenance and repair in these low-
proliferative tissues such as heart or brain it is under discussion. It is also not known
whether adult stem cells are retained from the embryonic stage or they arise
genuinely in adult life.
Adult stem cells are thought to be in a quiescent state, where the in vivo environment
(also called the stem cell niche) plays a very important role in balancing their cellular
needs until they are activated by disease or tissue injury. The factors that stimulate
stem cells to become active and relocate to sites of injury or damage are also
unknown.
As defined above, adult stem cell function was assumed previously to be restricted
to cell lineages present in the organ from which they were derived and to be involved
only in their maintenance and repair (Passier and Mummery, 2003). However,
increasing evidence suggest that some adult stem cells under appropriate culture
conditions may be more pluripotent cells, switching cell fate, capable of crossing
tissue-lineage boundaries and producing cell types other than the cell type in the
tissue of origin (Krause et al., 2001; Martin-Rendon and Watt, 2003). These properties
have been termed adult stem cell plasticity. The discovery of adult stem cells in
many more tissues than previously thought provides new opportunities in stem cell
biology for novel therapeutic possibilities (Krause et al., 2001).
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1.2.2.1 Adult stem cell plasticity
Adult stem cells are an attractive source of cells for therapy, especially in view of the
recent claims that they are remarkably plastic in their developmental potential when
exposed to new environments. Proponents of plasticity maintain that neurons,
skeletal, epithelial, cardiac myocytes, hepatocytes, endothelial cells and bone cells
can all be derived from primitive pluripotent bone marrow cells. If stem cell plasticity
is real, we are challenged to reconsider the validity of long-held dogma regarding
stem cell single lineage specificity in adults. However, reports of stem cell plasticity
have caused both excitement and scepticism because some of these claims have
been either difficult to reproduce or shown to be misinterpretations, leaving the
phenomenon of adult stem cell plasticity unclear (Lakshmipathy and Verfaillie,
2005). Plasticity has to be defined as the capacity of a single cell to differentiate into
multiple cell lineages functionally in vitro and in vivo and the engrafted tissue has
to persist after cell transplantation (Lakshmipathy and Verfaillie, 2005). There are
at least four different ways which plasticity can be explained: Stem cell pluripotency;
transdifferentiation; cell fusion or multipotency heterogeneity (Martin-Rendon and
Watt, 2003).
Krause et ah, (2001) published that a single mouse bone marrow-derived stem cell
transplanted into lethally irradiated mice not only resulted in long-term
reconstitution of the haematopoietic system but also differentiated into mature
epithelial cells with a non-haematopoietic potential. Thus, they isolated a pluripotent
lineage-negative bone marrow-derived cell able to differentiate into haematopoietic
and non-haematopoietic cells. Also Theise et al. a), (2000) reported that injection of
unseparated mouse bone marrow-derived cells resulted in localisation of some of
these cells into the liver and their differentiation into hepatocytes. Similar results
were seen in humans (Theise et al. b), 2000). Thus, in both humans and in the
experimental animals, engraftment by bone marrow cells as hepatocytes could be
seen in the absence of severe injury (Theise et al. a) 2000; Theise et al. b), 2000).
Mezey et al., (2003) showed the presence of donor cells in human brains after bone
marrow transplantation for lymphoid leukaemias or immune deficiencies. Moreover,
murine and human neural stem cells have been reported to be able to generate
myoblasts in vitro (Tsai and McKay, 2000) and when transplanted into muscle (Galli
et al., 2000). Unfortunately, up to now, most of the studies examining the
phenomenon of stem cell plasticity by pluripotency have not definitively shown
that significant levels of unexpected multiple lineage differentiation are derived from
the same single cell and that these differentiated cells could function in vitro and in
vivo.
25
There is other evidence of the existence of a pluripotent stem cell in the adult
(Lakshmipathy and Verfaillie, 2005). Multipotent adult progenitor cell (MAPC) seem
to be capable of differentiating into many different tissues other than the tissue of
origin. Jiang et al., (2002) suggested that MAPC derived from bone marrow, brain
or muscle may be related to ES cells. Mouse MAPC like mouse ES cells required
leukaemia inhibitory factor (LIE) to be expanded whereas human MAPC, like human
ES cells, do not require it. Moreover MAPC express transcriptions factors such as
Rexl and Oct4 which are important in maintaining ES cells undifferentiated (Jiang
et al., 2002). In addition, like ES cells, mouse bone marrow-derived MAPC
contributed to all somatic cell types when injected in a mouse blastocyst. However,
these cells only showed this potential after in vitro culture. Thus, further studies
need to demonstrate that such cells exist in vivo. Whether these cells eventually are
the same as the bone marrow lineage-negative cells enriched by Krause et al., (2001)
is not known. Better MAPC phenotypic characterisation is needed.
Fernandes et al., (2004) identified a cell type derived from the skin (SKP) with
potential that is not restricted to skin. The assumption that each tissue contains a
specific stem cell subtype committed to tissue-restricted differentiation may not be
complete (Zipori, 2005).
Another explanation of stem cell plasticity would be transdifferentiation. This process
considers the ability of a lineage-committed stem cell from a specific tissue to
differentiate into cell types of another tissue. In this, the nucleus of the transplanted
cell would have to undergo reprogramming and up-regulate genes and proteins
consistent with the new lineage. There is evidence in nature that such a phenomenon
can occur (Lakshmipathy and Verfaillie, 2005); e.g. in young newts in which a limb
is removed, cells in the blastema undergo de-differentiation and then re-differentiate
to make most of the cell types of the regenerating limb (Brockes, 1997). Whether
such a phenomenon occurs in humans and if it does whether adult stem cells
normally exhibit transdifferentiation or they only transdifferentiate when
manipulated in the laboratory also remains unknown.
Recent findings also challenged the nature of the stem cell plasticity by pluripotency
or transdifferentiation when cells were shown to be able to express different
phenotypes by cell-cell fusions (Martin-Rendon and Watt, 2003). Fusion between
bone marrow and liver cells generated hepatocytes in mice (Vassilopoulos et al.,
2003; Wang et al., 2003). Alternatively, plasticity could be explained by heterogeneity.
Bone marrow could be considered a reservoir of a mixture of different lineage-
committed stem cells with different plastic potential capacities. Some of these cells
could still retain a high pluripotency capacity while others, as they mature, lose this
26
plasticity as genes are switched off at each step of differentiation. Most of the
experiments studying stem cell plasticity have used non-purified populations and
even where haematopoietic stem cells were enriched, the recovered population was
still heterogeneous and may still have contained some pluripotent non-HSC cells
which could differentiate into cells of non-haematopoietic lineage. Thus, we could
accidentally interpret that HSC were responsible for the non-haematopoietic cell
development, for example. Whether pluripotent plastic stem cells are somehow
retained into adult postnatal life from fetal development, restrained from
differentiating as proposed by Ratajczak et al., (2004), is not known. Ratajczak et
al. hypothesized that pluripotent stem cells circulate at a low level in the peripheral
blood under normal steady-state conditions, maintaining a pool of stem cells in
peripheral tissues, and their levels increase in peripheral blood during stress/tissue
injury. The nature of these highly pluripotent cells are not known and the lack of
definitive markers makes their identification even more difficult.
It is still unknown if pluripotency, transdifferentiation, cell fusion or heterogeneity
makes a progenitor/stem cell or a more mature cell change, and maybe all coexist
in the stem cell world. Research is continuing and many questions remain to be
answered. To verify or refute the various hypotheses requires careful
experimentation, but the potential clinical applications of adult stem cells in
transplantation are vast.
1.2.2.2 Adult stem cell therapy
Regenerative medicine and cell therapy have become a major focus of modern
therapeutic approaches for the treatment of a wide variety of different inborn,
acquired and degenerative diseases, otherwise untreatable conditions. Due to
histocompatibility issues, concerns about teratoma formation, and ethical
considerations, hES cells are at the moment restricted to experimental in vitro studies
and their therapeutic potential remains to be determined. In contrast, adult human
stem cells, with their newly documented plasticity, could be a more immediate
potential source for therapeutic application. However, more convincing experiments
are required with better adult stem cell characterisation (Conrad and Huss, 2005).
There is also a requirement for development of robust, safe and standardized
strategies for handling and preparing the cells for transplantation.
Adult haematopoietic stem cell transplantation has been extensively used clinically
for several decades for haematopoietic reconstitution after myeloablative
chemotherapy or in congenital immunodeficiencies. Using the haematopoietic
system as a model, this could be extended and adult stem cells might also be
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transplanted to restore other damaged tissues such as blood vessels, bone, or more
speculatively liver, myocardium or brain. Adult haematopoietic stem cells have been
used clinically across histocompatibility barriers from allogeneic sources because
their recipients had their immune system largely destroyed by myeloablative
chemotherapy Graft versus host disease (GvHD) is also a significant clinical problem,
making autologous HSC sources the preferred option in many instances of stem
cell transplant recipients for bone regeneration or vasculogenesis which are not likely
to receive myeloablation. In addition to the more favourable treatment related
toxicity profile of autologous transplantation, this approach eliminates the risks of
the recipients acquiring untoward infection from the donors and has none of the
ethical problems currently associated with the use of ES cells.
1.2.2.3 Haematopoietic adult stem cells
As described above, there are many different adult stem cells. The haematopoietic
stem cell (HSC) is the best characterized of all adult tissue stem cells. Mesoderm
derived, multipotent, rare (less than 1/1,000 nucleated bone marrow cells),
haematopoietic stem cells are considered capable of both self-renewal and
differentiation into any cell of the mature haematopoietic lineage (erythrocytes,
neutrophils, monocytes, B lymphocytes, T lymphocytes, NK cells, eosinophils,
basophiles and megakaryocytes) under the control of transcription factors. Although
these mature cells have distinct morphology and function they are derived from a
common multipotent stem cell pool (Forbes et ah, 2002; Orkin, 2000). HSCs can be
isolated from bone marrow, foetal liver, umbilical cord blood and although normally
rare in peripheral blood they can be enriched there by stimulation and release from
the bone marrow to peripheral blood by G-CSF administration. Haematopoietic
reconstitution has been proven in vivo by transplantation of single stem cells into
syngeneic animals (Krause et ah, 2001; Osawa et ah, 1996). Despite the ability to
culture haematopoietic progenitor cells to particular committed lineages, a reliable
method for in vitro culture of self-renewing stem cells which maintains them in an
undifferentiated state has not been achieved as yet for human HSC (Uher et ah,
2003). The intrinsic and extrinsic signals that regulate haematopoietic cell fate are
not yet fully understood.
Significally, some recent studies referring to stem cell plasticity indicate that HSC
also have the potential to generate cell types other than haematopoietic cells such as
bone, cartilage, neural cells, muscle, skin, blood vessel endothelia, epithelial cells,
hepatocytes (Orkin and Zon, 2002; Moore, 2002. Theise et al. showed that blood
and bone marrow stem cells can generate hepatocytes and vice-versa (Theise et al.
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a) 2000; Theise et al. b)). Similar results have been found in the brain following
human bone marrow transplants (Mezey et al., 2003). Once more whether it is due
to haematopoietic stem cell pluripotency, transdifferentiation, multipotency-
heterogeneity, or due to the existence among the enriched HSC of remaining pre-
HSC pluripotent stem cells that have still the potential to become non-haematopoietic
stem cells is still not resolved.
1.2.2.4 Non-Haematopoietic adult stem cells
Non-haematopoietic adult stem cells are adult stem cells capable of developing into
mature cells of tissues other than blood. Endothelial progenitor stem cells, skeletal
muscle stem cells, epithelial cell precursors in the skin and digestive system and
stem cells in the pancreas and liver have recently been found.
Mesenchymal stem cells (MSCs) are one kind of non-haematopoietic stem cell found
in bone marrow (Conget and Minguell, 1999), adipose tissue (Zuk et al., 2002) and
other tissues such as fetal liver, peripheral blood, lung and cord blood (reviewed in
Le Blanc and Pittenger, 2005). These cells are defined by their lack of haematopoietic
markers (CD45-negative), their expression of certain mesenchymal markers after
culture, their tendency to adhere to plastic and their ability to differentiate into
adipocytes, osteocytes or chondrocytes. More controversially, it has been shown
that they may also generate a wide variety of other cell types including skeletal
muscle, neuronal cells, hepatocytes and vascular endothelial cells under the correct
conditions (Le Blanc and Pittenger, 2005). MSC have already been used clinically
for the treatment of bone disorders such as osteogenesis imperfecta (Le Blanc and
Pittenger, 2005) and could be a potential useful source to treat bone, cartilage or
tendon diseases (Lakshmipathy and Verfaillie, 2005). Finally, others have shown
that a rare cell type, isolated from bone marrow and other tissues such as brain and
muscle, termed multipotent adult progenitor cell (MAPC) can be expanded with a
high proliferative rate and after culture show potential to differentiate into endothelial,
endodermal and neuronal lineages in vitro and in vivo (Reyes and Verfaillie, 2001;
Jiang et al., 2002, Muguruma et al., 2003). MAPC have many similarities to MSC,
which are also present in bone marrow, but their relationship to MSC and whether
MAPC exist in vivo, or are only induced during an extensive in vitro culture period,
is still unknown. (Lakshmipathy and Verfaillie, 2005) (See also 5.1.10).
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1.2.2.5 Identification parameters of the human haematopoietic stem cell
Attempts to isolate HSCs in early studies were developed by determining physical
parameters such as size, buoyant density, and electrical charge characteristics. Before
the widespread availability of flow cytometry for analysis, polyclonal antibodies,
colony assays, immunoreactive columns and immunomagnetic beads were used to
isolate and characterise haematopoietic cells (Metcalf et al., 1971). In 1980s, the
characterisation of human HSC progressed due to the use of the flow cytometry
and the advent of monoclonal antibody (MAb) technology. Many studies have been
made to identify the surface phenotype of HSCs. Availability of highly enriched
populations of stem cells should facilitate the research in haematopoiesis and clinical
stem cell transplantation. During the last two decades, investigators identified a
number of surface molecules to define a HSC. For more than a decade CD34 has
been the best-known marker of HSCs. In (1988) Berenson et al. using anti-human
CD34 antibody clone 12.8, reported successful haematopoietic reconstitution in
baboons with selected CD34+bone marrow cells. The discovery of CD34 accelerated
the development of protocols for the purification of human HSCs (Andrews et al.,
1986). It appears that there is a progressive decline in CD34 antigen expression
along with haematopoietic cell differentiation at later stages of haematopoiesis. The
CD34 molecule is a 115-KDa type 1 integral sialomucin membrane protein whose
function has proven enigmatic (Lanza et al., 2001). This antigen is highly
glycosylated, and differential susceptibility to enzymatic cleavage, tissue reactivity
and western blotting analysis have established a classification of the various epitopes
of the CD34 antigen. See table below (Lanza et al., 2001).
CD34 REACTIVITY
EPITOPE CLASS CLONES paraffin frozen western
section section blotting





Positive Positive Most positive
lb. Partially sensitive to
neuraminidase, sensitive
to glycoprotease
My 10, ICH3, Immul33,
14G3. ICO-115
Positive Positive Most positive
II. Resistant to neuraminidase, QBEndIO, 43A I. MD34.3, MD34.1*, Positive Positive Positive




TUK3, 115.2, 8G I2, CD34-9F2, 581, 553.




Neuraminidase from Vibrio cholera.
Glycoprotease from Pasteurella haemolytica.
'Although classified as class II reagents in the Vth Workshop, some participants found these MAbs to be partially sensitive to neuraminidase
using both serology and immunoblotting procedures, and assigned them to class lb (see text).
Chymopapain also cleaves class I and class II epitopes but in the hands of some Workshop participants, also cleaves class III epitopes (see text)
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The AC136 clone which recognizes a class III epitope of the CD34 antigen was used
for the experiments presented in this thesis. This monoclonal antibody clone
recognises a different epitope from the QBEND/10 clone used for MACS®
Microbeads (Miltenyi Biotech) and is therefore suitable for evaluatation of MACS®
Separations.
Currently adult haematopoietic stem cells are routinely isolated from the bone
marrow, umbilical cord and peripheral blood based on the expression of the CD34
antigen, however their isolation at sufficient purity and quantity remains difficult.
Controversy arose when different investigators found a CD34-negative-lineage-
negative-c-kit+ population that could produce a long-term lympho-haematopoietic
reconstitution of lethally irradiated mice (Osawa et al., 1996). Morel et al., (1996);
Morel et al., (1998) and Donnelly et al., (1999) have shown that in mice stem cells
are present in both CD34-positive and CD34-negative populations of the bone
marrow. Moreover, reports from Goodell et al. (1996); Goodell et al., (1997) observed
that side population (SP) cells, which are a fraction of stem cells defined by their
side scatter characteristics and exclusion of Hoechst dyes as measured by flow
cytometry, are highly enriched for haematopoietic stem cells which are CD34-
negative or low. Hence, such HSCs express the Bcrpl (also known as ABCG2)
transporter, which effluxes certain molecules including Hoechst 33342, a supravital
DNA stain. These low fluorescence-expressing cells are highly enriched for HSCs.
Human HSCs also express CD133 surface antigen (prominin-1) (Yin et al., 1997), a
120KDa five transmembrane domain glycoprotein (5-TM) found originally on
neuroepithelial stem cells in mice, and expressed on primitive cell populations such
as some CD34 haematopoietic stem cells, neural and endothelial cells. CD133+
neurosphere cells differentiate into both neurons and glial cells (Uchida et al., 2000).
The CD133 positive fraction of human bone marrow, cord blood and peripheral
blood has been shown to efficiently engraft in xenotransplantation models (de Wynter
et al., 1998). No natural ligand has yet been demonstrated for the CD133 molecule,
and, like CD34, its function in haematopoietic tissue is unknown. Anti-CD133
antibody provides an alternative to the widely used anti-CD34 antibody for the
selection and characterisation of cells necessary for both short- and long-term
engraftment in transplant situations and for studies of ex vivo expansion strategies,
and for gene therapy (Yin et al., 1997). Furthermore, Quesenberry et al. (2002)
suggested that HSCs are continuously altering their phenotype and these alternations
are reversible. Thus, many described HSC phenotypes could represent a single cell
in different functional states. The wide variety of different marrow-derived
haematopoietic stem cells may reflect a hierarchical stem cell system of extraordina-
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ry complexity in which phenotypes and functional status may overlap. Lemoli et
al., (2005) suggested that rather than a hierarchical transition from stem cell to
progenitor cell, fluctuations continue to exist in which stem cells adjust their
phenotype depending on the cell kinetic state, activated by their genetic program
or microenvironmental stimuli. Moreover, Zipori, (2005) suggested the concept of
"stem state" where sternness and plasticity are a state rather than cellular entity.
These studies have emphasised the heterogeneity of HSCs in terms of proliferative
and self-renewal capacities. Although these recent studies indicate that CD34 is not
the only marker of all human HSCs (Bonnet, 2002) and is also found on mature
endothelial cells ,it is still, almost universally, the most commonly used marker for
identification of HSC and for assessing the potency of clinical autograft and allograft




2.1 Cell sources and sampling
2.1.1 General sample collection procedures
All cells were obtained from samples from human sources. In all cases, appropriate
ethical committee consent and institutional procedures involving written informed
consent from each patient were applied. Ethical committee approval was obtained
(LREC/1993/4/76 - Lothian NHS Board) for sampling haematopoietic stem cell
sources (bone marrow, mobilised peripheral blood, umbilical cord blood) and normal
peripheral blood for ongoing studies in SNBTS R&D. These were originally granted
to Dr ML Turner. These were extended as necessary by Drs Turner and Barclay.
The most recent approved extension was granted for follow-up samples following
G-CSF administration (25th August 2005).
Peripheral blood cells were obtained from venous blood samples collected in heparin
unless otherwise stated or where it is stated that buffy-coat leucocytes were used,
where buffy coats were obtained in blood bags from the leucocyte-rich layer at the
sedimented red-cell/plasma interface following routine preparation of platelets from
fresh blood donations to the Scottish National Blood Transfusion Service. Umbilical
cord blood was aspirated from the umbilical placental veins following normal elective
caesarean delivery and collected into heparinised 50 ml containers. Bone marrow
samples (3ml) were obtained in EDTA5ml tubes by aspiration from the posterior
iliac crest of haematologically normal donors sampled for routine clinical
investigations of non-malignant diseases: residual fresh sample was made available
for these studies. Peripheral blood samples rich in haematopoietic stem cells (HSC)
following mobilisation of HSC by granulocyte colony stimulating factor (G-CSF)
were termed "mobilised peripheral blood" (mPB), and were venous blood samples
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(10ml) collected in heparin from donors immediately following cell-separator
leukapheresis collection of G-CSF mobilised peripheral blood stem cells (PBSC) for
transplant. In most cases these were adult patients donating for autologous PBSC
transplant during disease remission; in some cases donors were healthy adult
volunteers (usually patient relatives) donating for allogeneic PBSC transplant.
Patient samples of mPB were drawn from patients with the following underlying
diseases: Myeloma, Hodgkins and non-Hodgkins lymphoma, Chronic lymphocytic
leukaemia (CLL) and chronic myeloid leukaemia (CML).
In clinical studies 40 patients undergoing elective coronary angiography participated
in this study. All the patients were recruited from the Medical Day Case Unit at the
Royal Infirmary Edinburgh following referral for diagnostic angiography to
investigate symptoms suggestive of stable angina. Patients with a recent acute
coronary syndrome or coronary intervention (<3 months), renal or hepatic failure,
or a systemic inflammatory disorder or malignancy were excluded from the study.
20 patients underwent diagnostic coronary angiography alone, and 20 required
balloon angioplasty and stenting because of flow limiting coronary stenosis. Avenous
cannula (17-gauge) was inserted into a large subcutaneous vein of the ante-cubital
fossae for blood sampling before, immediately after and at 6 and 24 hours following
angiography. EDTAanti-coagulated blood (Sarstedt-Monovette, Germany) was
collected for flow cytometry, real-time PCR and for preparation of plasma for storage.
For other clinical studies 14 patients, who were undergoing elective abdominal aortic
aneurysm repair, were used. 5ml of blood was taken in EDTA coated tubes pre¬
operative and at the following times post-operatively: 24 hours, 48 hours and after
5 days following operation. Moreover 5ml of EDTA anti-coagulated blood samples
were collected from 45 patients with type I diabetes and from 34 controls subjects
(control group).
Full blood and differential counts using an autoanalyzer (Sysmex UK), including
monocyte counts, were obtained from each patient, and at each time point.
2.1.2 Collection of samples for study of platelet-leucocyte
aggregation
Platelets are able to adhere to leucocytes, forming Platelet Leucocyte Aggregates
(PLAs). Some endothelial markers such as vWf and PECAM (CD31) are also
expressed by the platelets, therefore elimination of the platelets bound to leucocytes
in the samples was considered necessary. A comparison between venous blood
samples collected into Heparin, EDTA or Citrate anticoagulant was carried out.
Also a heparinised sample was divided in different tubes and each tube was washed
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individually with EDTA/PBS (0.1%), Trypsin/EDTA (TVP), Chloroquin (2mM),
Lignocaine (2mM), Chloroquin/EDTA (2mM/0.1%) and Lignocain/EDTA (2mM/
0.1%) (see reagent list).
2.1.3 Endothelial cell lines
2.1.3.1 Human umbilical vein endothelial cell (HUVEC) lines
Mycoplasma free commercially supplied frozen HUVECs (Cambrex, UK) were
reconstituted according to the suppliers instructions into Endothelial Basal Medium
(EBM) (Clonetics, UK) supplemented with growth factors including (hydrocortisone,
hFGF-B, VEGF, R3-IGF-1, Ascorbic acid, Heparin, hEGF, FBS, GA-1000) (Clonetics,
UK) (Figure 2.1b). When cells were confluent, half of the medium was replaced
every 2-3 days. For passage, cells were detached using EDTA (0.01%)/Trypsin
(0.025%) (Clonetics, UK). Enzyme activity was neutralised using Trypsin neutralising
solution (Clonetics, UK). Cells used for subsequent flow cytometry analysis were
gently detached with EDTA/PBS (0.1%) without trypsin to avoid possible loss of
some cell surface marker expression.
2.1.3.2 Hybridoma endothelial cell line EA-hy-926
Mycoplasma free EA-hy-926 endothelial cells were a gift from Dr CJS Edgell. Frozen
cells were reconstituted in Iscove's Modified Dulbecco Media (1MDM) supplemented
with 10% fetal calf serum (FCS) (Biowhittaker,UK), 1% Antibiotic (penicillin/
streptomycin) (lOOOOUnits/ml /50ug/ml) respectively (Sigma, UK), 1 x Non-Essential
Amino Acids (NEAA) (Sigma, UK), 5x10 4 M 2-Mercapto-ethanol (2-Me) (Sigma,
UK), ImM sodium pyruvate (Sigma, UK), and 2mM glutamine (Sigma, UK),
Figure 2.1 Endothelial cell lines
a) Ea.Hy 926 cells cultured in IMDM and b) HUVEC cultured in EBM
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(Figure 2.1a). Medium was changed every 2-3 days or when cells were confluent,
adding back half of the old medium to half of the new medium. The cells were
detached by EDTA/Trypsin (TVP) (see reagent list). Cells used for subsequent flow
cytometry analysis were detached by EDTA/PBS (0.1%) without trypsin to avoid
possible loss of some cell surface marker expression.
2.1.4 Preservation of cells by freezing
0.5ml freezing medium (10% DMSO and 90% FCS) was gently added to 0.5 ml
mononuclear cells (lxlO6 to 5x107 cells/ml) suspended in complete culture medium
in 1.8ml DNAse and RNAse free tubes (Greiner, UK). Samples were frozen slowly
by placing at -20C for 1 hour, transferred to -80C overnight and stored at -140C in
a freezer.
2.2 Cell subpopulation isolation
2.2.1 Mononuclear cell isolation
Mononuclear cells (MNC) were separated by buoyant density centrifugation of
blood or marrow samples over Histopaque (1.077g/ml; Sigma Diagnostics, UK).
Samples were normally diluted 1:2 in PBS, layered over an equal volume of
Histopaque (in 15mL or 50mL polypropylene centrifuge tubes) and spun at 400g
for 20 minutes. Interface leucocytes were collected and washed twice in phosphate
buffer saline (PBS), counted and immediately transferred to 1MDM. Unless otherwise
stated, isolated mononuclear leucocytes were the basis of subsequent cell
subpopulation isolations.
2.2.2 Polymorphonuclear cell isolation
Polymorphonuclear leucocytes (PMNC) were used in bioluminescence studies.
Mature peripheral blood neutrophils were isolated from healthy adult venous blood
using Polymorphprep (Axis-Shield PC AS, UK). Polymorphprep is a solution for
the isolation of polymorphonuclear granulocytes from whole blood. The
mononuclear and polymorphonuclear leucocytes are separated into distinct bands
free from red cells. The top band at the sample/medium interface consists of
mononuclear cells and the lower band consists of polymorphonuclear cells. Carefully,
5ml of freshly-donated blood was layered over 5ml of Polymorphprep solution and
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centrifuged at 250g for 30 minutes. The lower polymophonuclear layer was
recovered, washed twice in PBS and resuspended in IMDM medium without phenol
red.
2.2.3 Purification of CD34+ cells
The CD34-positive subpopulation of mononuclear cells was enriched using either
positive selection (MACS CD34 isolation Kit; Miltenyi Biotec, Surrey, UK) or negative
selection (Rosette-Sep, Stem Cell Technologies, UK), according to the manufacturers
instructions. The efficiency of the purification of CD34+ cells was verified by flow
cytometry phenotyping analysis.
2.2.3.1 CD34 progenitor cell enrichment by depletion of mature leucocytes
The Rosette-Sep method (Stem Cell Technologies, UK) is a negative selection cell
separation procedure for the isolation of cell subpopulations directly from human
whole blood by removal of unwanted cells. It combines the specificity of antibody-
mediated cell separation with buoyant density centrifugation. Rosette-Sep is based
on complexes of monoclonal antibodies specific for a cell surface marker coupled to
monoclonal antibodies specific for red cells (glycophorin-A), to give bispecific
tetrameric binding capacity which binds red cells as rosettes around cells expressing
the surface marker. For immature HSC isolation, cocktails of tetrameric monoclonal
antibodies specific for mature leucocyte markers and red cells are used. The
specificities for mature human peripheral blood leucocytes markers include CD2 (T
cells, NK cells), CD3 (T cells), CD14 (monocytes), CD16 (neutrophils and NK cells),
CD19 (B cells), CD24 (B cells and granulocutes), CD56 (NK cells), CD66b
(granulocytes). An adaptation of the manufacturer's Rosette method was used. 2ml
of unseparated blood was retained: meanwhile the rest of the blood was diluted and
layered over 15 ml of Histopaque (1.077g/ml; Sigma Diagnostics, UK), centrifuged
at 500g for 20 minutes and the interface MNC layer was collected and washed in
PBS. The retained 2ml of blood and 75ul of the Rosette-Sep antibody cocktail were
then added to the mononuclear cells. After 20 minutes incubation at room
temperature the unwanted mature cells are cross-linked to red blood cells by the bi¬
specific antibodies in the Rosette-Sep cocktail. The sample was then centrifuged as
above over buoyant density medium (Histopaque), and the unwanted (resetted)
cells pellet along with the free RBCs, leaving the desired cells untouched and highly
enriched at the Histopaque-medium interface.
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2.2.3.2 CD34 progenitor cell enrichment by selection with immunomagnetic
beads
MACS® MicroBeads (Miltenyi Biotech) are superparamagnetic particles that are
coupled to specific monoclonal antibodies. They are used to magnetically label the
target cell population. The isolation by positive selection of CD34-expressing cells
was performed using anti-CD34 antibody coupled to magnetic microbeads. The
CD34+ haematopoietic progenitor cells in MNC isolates were magnetically labelled
using MACS CD34+Microbeads (Miltenyi Biotech, Surrey, UK). Washed MNC
(lxlO7) isolated by buoyant density centrifugation were first incubated with 100pi
Fc-receptor blocking reagent (Miltenyi Biotech) for 10 minutes at room temperature
to inhibit non-specific or Fc-receptor mediated binding of the CD34-MicroBeads to
non-target cells. The cells were then labelled by adding 100 pi of CD34-Microbeads,
mixed well, and incubated for 30 minutes at 4C. The cells were washed and
resuspended in the appropriate volume of medium ready for magnetic separation.
The magnetically labelled cells were retained and thus enriched on magnetic columns:
meanwhile the cells that did not bind to the CD34 antibody passed through the
column. Removal of the column from the magnetic field allowed retained cells to be
eluted. To improve purity the recovered CD34+ cells were passed through a second
magnetic isolation column.
2.2.4 General immunomagnetic bead enrichment procedure
Specific sub-populations of MNC were isolated by magnetic activated cell sorting
(MACS) either directly using specific MAb (CD34, CD133) as described above for
CD34 or indirectly using anti-fluorochrome (phycoerythrin) antibody (anti-PE)
conjugated to immunomagnetic beads (Miltenyi Biotech, Surrey, UK). For indirect
labelling the process was essentially the same. The cells were first labelled with
specific-fluorochrome labelled MAb of interest, washed and then labelled with
appropriate microbead-conjugated anti-fluorochrome MAbs. Labelled cells were
washed before loading to the column. Finally purity of the recovered population
was assessed by flow cytometry.
2.2.5 Isolation of short-term (2h) plastic-adherent
mononuclear cells
Mononuclear cells isolated by Histopaque buoyant density centrifugation were
washed twice with PBS and resuspended in Iscove's Modified Dulbecco's Medium
(IMDM) supplemented with 10% FCS (Biowhittaker,UK) and 1% Pen/Strep (Sigma,
UK). Approximately 30X106 MNC were plated in a 25cm2 tissue culture flask (430168
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polystyrene; Corning, UK) and incubated for 2h at 37C. After 2 hours the non¬
adherent cells were aspirated and set aside. 5ml of PBS were added and aspirated:
this procedure was repeated twice. The aspirated cells were added to the non-adherent
cell fraction and characterised. Adherent cells were detached using 1ml EDTA/
trypsin for 10 minutes at 37C. 5ml of IMDM with 10% FCS was added to neutralise
EDTA/trypsin activity. After washing harvested cells were resuspended in IMDM
and characterised by flow cytometry and used for further experiments.
2.2.6 Isolation of cells by fluorescence activated cell sorting
(FACS)
lOOul of pelleted MNC or 2h plastic adherent cells were directly stained using 5 pi of
the appropriate anti-human monoclonal antibodies (MAbs) conjugated to
phycoerythrin (PE), fluorescein isothiocynate (FITC) or Peridin Chlorophylla protein
(PerCP) (see flow cytometry methods, 2.3.1) for 30 minutes in the dark. Samples
were then centrifuged at 200g for 10 minutes and washed twice with PBS.
Appropriate antibody combination controls were used to set selection gates for FACS
sorting. Cells were sorted using a FACS Aria flow cytometer (Becton Dickinson,
UK) equipped with488nm and 633nm lasers. Dead cells were excluded using an
electronic SSC/FSC gate before applying sort gates to define cell populations to be
collected. A small sample of each collected fraction was re-run through the cytometer
to assess the success of sorting by measuring purity of the sample. Sorted populations
were recovered and characterised by further analysis.
2.3 Cell identification and phenotyping
2.3.1 Flow cytometry analysis
In general, distributions of cells were investigated in original unmanipulated samples
such as whole blood before these were disturbed by cell isolation and enrichment
procedures. Various MNC isolates and subpopulations such as CD34+-enriched
cells or cells recovered from culture were also phenotyped by flow cytometry. Three
colour analysis using a 488nm laser for excitation employed phycoerythrin (PE),
fluorescein isothiocynate (FITC) or peridin chlorophylla protein (PerCP)
fluorochrome antibody conjugates: four colour analysis was accomplished by adding
633nm excitation to the above and employing allophycocyanin (APC) fluorochrome
antibody conjugates.
MAbs used for analysis included anti-CD34-PE and anti-CD34-FITC (Becton
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Dickinson, Oxford, UK); anti-CD41-FITC (Becton Dickinson); anti-CD16b-FITC
(Immunotech, UK); anti-CD45-PercP (Becton Dickinson); anti-VEGFR2-PE (R&D
systems); anti-Ve-cadherin-PE (Santa Cruz Biotechnology); and anti-CD133-APC
(Miltenyi Biotec, UK) (see complete antibody list).
2.3.1.1 Simple CD34* population analysis
Cells were stained with PerCP-conjugated anti-human CD45 and PE-conjugated
anti-human CD34, fixed and gated for CD45+CD34+ cells with a low side scatter,
according to the ISHAGE CD34 enumeration protocol (Sutherland et al., 1996)
(Figure 2.2).
a) b) c)
FSC-Height CD45 PerCP CD34 FITC
Figure 2.2 CD34 enumeration protoeol.
Cells were stained with PercP-conjugated anti-human CD45 and FITC-conjugated anti-human
CD34, fixed and gated for CD45+ cells co-expressing CD34 with a low side scatter, according to the
ISHAGE CD34 enumeration protocol (Sutherland etal, 1996). a) Primary gate (Rl) set on forward/
side scatter properties (cell size and granularity), b) Expression of CD45 haematopoietic marker
(R2). CD45-negative cells here are mainly unlysed red cells, c) CD34-postive gate (R3)(magenta)
set in the CD34-positive area. In a) and b) also in magenta CD34+cells are backgated in the SSC/
FSC and in the CD45 axis
In early studies various isotype-matched negative control (non-binding) antibodies
were compared with unstained samples, and since these did not differ, unstained
samples were used to establish positive stain boundaries. The protocol for staining
comprised the following tubes (1) no antibody; (2) anti-CD45 alone; (3) anti-CD45
with anti-CD34. lOOul of sample (usually whole blood) was placed in a Falcon-type
5 ml tube and stained with each appropriate antibody (normally 5ul of undiluted
antibody) for 30 minutes in the dark. Where present, as in whole blood analysis,
erythrocytes were lysed by FacsLyse (Becton Dickinson, UK) (1 ml for 15 minutes),
and cells were spun down and washed at least twice with PBS at 200g (until free of
traces of haemoglobin in supernatant or pellet) with blotting of tube mouths to
fully remove decanted wash supernatants. The cells were resuspended in 0.5 ml of
40
CellFix (Becton Dickinson, UK) and analysed within 24h (analysed immediately or
stored in the dark at 4C). Events were collected by a FACS Calibur flow cytometer
linked to an Apple Macintosh computer equipped with CellQuest software (Becton
Dickinson) and calibrated and compensated using Becton Dickinson calibration
beads and software for the fluorochromes employed. Samples within any series
employed identical stored collection settings. In general collection regions were set
on forward-scatter v side scatter for all leucocytes, and on CD45 v side scatter for all
leucocytes and a collection gate was set on a combination of these two regions. At
least (normally) 50,000 events were counted through this gate, but all events (above
the debris exclusion barrier) were saved to allow inspection of CD45-negative events.
Data was saved to listmode files and moved to PC (Windows) computers for detailed
analysis, using FCS Express software (De Novo Software,
www.denovosoftware.com). In some cases data was represented graphically using
the WinMDI 2.8 free software for the PC (Windows) developed byJoe Trotter (http:/
/facs.scripps.edu/software.html).
2.3.1.2 Complex immunophenotyping
Essentially the same procedure as for simple CD34^ population analysis (above,
2.3.1.1) was carried out, but with a greater range of antibodies and tubes in the
protocol. The MAbs used included anti-CD34-FITC; anti-CD34-APC, anti-CD45-
PerCP, anti-CD45-FITC, anti-VEGFR2-PE; anti-CD3-PE, anti-CD19-PE, anti-CD16-
PE, anti-CD8-FITC, anti-CD14-PE, anti-CD14-FITC, anti-VE-cadherin-PE; and anti-
CD133-APC, anti-CD146-FITC, anti-CD29-FITC, anti-CXCR4-PercP, anti-CD31-
FITC, anti-CD63-PE, anti-CD105-APC and anti-Glycophorane-1 (Gpa-l)-PE (see
complete antibody list).
2.3.1.3 Staining for intracytoplasmic myeloperoxidase (MPO)
Anti-myeloperoxidase, MPO-7 MAb (Dako Cytomation Ltd, Cambridgeshire, UK),
strongly labels the cytoplasm of mature and immature neutrophils. Monocytes are
weakly positive while eosinophils are unreactive. Samples (50ul) were stained with
anti-CD34-PE and anti-CD45-PercP as above, then fixed using lOOul Dako
Intrastain Reagent A (fixation), incubated and washed with PBS. lOOul Dako
Intrastain Reagent B (permeabilisation) and 5-10ul of the anti-MPO-FITC
cytoplasmic antibody were then added, mixed, washed and resuspended in an
appropriate buffer (0.5 ml) for flow cytometry analysis.
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2.3.1.4 Dil-Ac-LDL uptake
Acetylated Low Density Lipoprotein (Dil-Ac-LDL), labelled with l,l'-dioctadecyl -
3,3,3',3'-tetramethyl-indocarbocyanine perchlorate, labels both vascular endothelial
cells and macrophages. Dil-Ac-LDL staining kit (Biomedical technologies; UK) was
diluted in medium to a concentration of lOug/ml. Adherent cells were incubated
with Dil-Ac-LDL for 4h at 37C in IMDM without FCS and washed several times
with PBS. The staining was observed using a fluorescence microscope with FITC
filters. Adherent cells were washed and detached with EDTA/trypsin for 10 minutes
at 37C. Complete medium was added to neutralise EDTA/trypsin activity and the
harvested cells were washed and analysed by flow cytometry. Positive staining was
assessed by comparison with unstained cells.
2.3.1.5 l//ex europaeus agglutinin-1 (UEA-1) lectin binding
Cells were stained with 500ul of lOug/ul of FITC conjugated UEA-1 (Ulex europaeus
agglutinin-1) (Sigma, UK) for lh at 37C. Cells were analysed by flow cytometry.
Positive staining was assessed by comparing with an unstained negative control.
2.3.2 Immunofluorescence microscopy
Cells were stained with various endothelial antibodies including anti-VEGFR2-PE
(R&D systems), anti-VE-cadherin-PE (Santa Cruz Biotechnology), anti-CD31-FITC
(Becton Dickinson, Oxford, UK), Dil-Ac-LDL-FFTC (Biomedical technologies; UK),
and UEA-1-FITC (ulex europaeus agglutinin-1) (Sigma, UK) were fixed and used to
prepare cytospins at a concentration of 5xl04 cells/ml. The slides were air dried and
fixed with Methanol (Fisher, UK) for at least 15 minutes. Then the cells were
visualised by a fluorescence microscope (Zeiss).
2.3.3 Morphological analysis (Giemsa staining)
The morphology of the cells was determined using a standard Wright-Giemsa-
stained cytospin preparation (Thermo Shandon,UK). Figure 2.3 shows how the
cells were scored according to their degree of neutrophil differentiation
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Pictures show our classification in neutrophil differentiation ranging from 0 (no




2.4.1.1 Haematopoietic cell colony assays
Colony-forming cells (CFC) were monitored by their growth in methylcellulose
(MC) medium. The use of the Methocult semi-solid matrix with a cocktail of
cytokines rhSCF, rhGM-CSF, rhG-CSF, rhIL-3, rhIL-6 and erythropoietin (EPO)
allows the proliferation of single haematopoietic progenitors to form distinct colonies
containing morphologically recognizable progeny. 50ul of nucleated cells (MNC)
were added at 1.5xl04 cells, or enriched CD34+ cells at 0.2xl04 cells, to 500ul of
Methocult containing cytokines (MethoCult GF+ H4435; Stem Cell Technologies,
UK), mixed by aspiration, and plated in 24-well plates (Greiner UK) Colonies (groups
of >100 cells) were scored after 14 days according to appearance and counted. The
colony-forming unit granulocyte macrophage (CFU-GM), burst-forming unit
erythroid (BFU-E), colony-forming unit macrophage (CFU-M) and colony-forming
unit granulocyte erythroid, macrophage, megakaryocyte (CFU-GEMM) were
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counted after 14 days of culture. Where cells were expanded ex vivo, colonies from
unmanipulated cells were compared with colonies produced by cells expanded in
the presence of various cytokine combinations. Pre-expansion (day 0) CFC were
measured on enriched CD34+ cells. Post-expansion (day 14) CFC were measured
using recovered expanded cells derived from the cultured CD34+ enriched population,
which by this time were generally all CD34-positive following culture in the cytokine
combinations studied (any CD34-negative cells did not appear to survive). The results
are expressed for each colony type as a percent of total CFC which because of the
different starting populations are intended for qualitative interpretation, but for
approximate quantitative guidance the colony numbers per thousand cells, and
CD34+ cell proportions are also given.
2.4.1.2 Colony Forming Units- Endothelial Progenitor Cells (CFU-EPC).
This assay is based on that described by Hill et al., (2003) but is carried out using
commercial kit reagents according to the recommendations of the kit suppliers (Stem
Cell Technologies). Mononuclear cells were isolated by buoyant density
centrifugation, washed twice with PBS and finally resuspended at 2.5xl06 cells/ml
in Complete Endothelial Culture Medium (CECM) comprising Endocult Basal
Medium (Stem Cell Technologies, UK) supplemented with 1/5 dilution of Endocult
supplements (Stem Cell Technologies, UK). Cells were plated at 2ml/well in
fibronectin-coated 6-well plates (Becton Dickinson, UK) and incubated for two days
at 37C, 5% C02 with 95% humidity. After two days when mature endothelial cells
and monocytes had adhered (Hill et al., 2003) the non-adherent cells containing the
EPC, were counted and pelleted at 0.5-lxl06 cells/ml. 1 ml of fresh CECM was
added over the cells and transferred to a fibronectin-coated 24-well plate (Becton
Dickinson, UK) for a further three days at 37C, 5% CO., with 95% humidity. The
colonies per well were then counted and the number of colonies were divided by the
number of cells plated in the fibronectin 24-well plate The colonies were defined
following the published method (Hill et al., 2003) and Stem Cell Technologies
technical manual as a central core of "round" cells with elongated "sprouting" cells
at the periphery and are classified as colony forming unit endothelial progenitor
cell or CFU-EPC, recently reclassified as early-outgrowth CFU-EPC.
2.4.2 Neutrophil Chemiluminescence assay
Bioluminescence assays were carried out to measure the superoxide respiratory burst
activity of freshly isolated peripheral blood neutrophils and of CD34+ derived cells
expanded ex vivo with different cytokines. This was measured by detecting luminol-
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amplified chemiluminescence responses to phorbol myristate acetate (PMA) (Sigma,
UK). lOOul of mature peripheral blood neutrophils or expanded cultured progenitors
at 0.5xl06 cells/ml in IMDM without phenol red and without FCS were plated into
96-well opaque microplates (Greiner, UK), with lOOul of luminol (ImM) (Sigma,
UK) and lOOul of PMA (lug/ml final concentration) in IMDM, and the emitted
light activity (relative light units, rlu) was measured on a microplate luminometer
(Labsystems Luminoskan) at 37C at 3 minute intervals over 90 minutes controlled
by a computer linked to the luminometer and on which measurements were collected
for subsequent processing.
2.4.3 Matrigel tube formation
Matrigel® Matrix (Becton Dickinson) is an endothelial cell matrix (ECM) preparation
composed primarily of laminin, collagen IV and a number of growth factors. Matrigel
solution is thawed slowly overnight on ice/water at 4C and pipettes and plates are
pre-cooled. 300ul of matrigel was added over the pelleted cells (usually endothelial
cell lines) (3-5 x 104 cells/well) in a pre-cooled 24-well plate (Greiner, UK) and cultured
for 5h-22h at 37C with 5% COr Capillary-like structures and endothelial cell
networks were examined by phase-contrast microscopy.
2.5 Cell cultures
2.5.1 Ex vivo expansion cultures for neutrophil precursor
studies
Iscove's Modified Dulbecco's Medium (IMDM) (Invitrogen, Paisley, UK)
supplemented with 10% FCS (Sigma, UK) and 1% antibiotic (Pen/Strep, Invitrogen,
UK) was used for cell culture. CD34+-enriched MNC (2xl05 total cells per ml) of
known CD34+ purity were plated in 24-wells plates in 1ml medium with or without
various cytokines. The following recombinant purified human cytokines were used
in these studies: flt-3 ligand (Flt3-L), stem cell factor (SCF), thrombopoietin (TPO),
interleukin-6 (IL-6) and interleukin-3 (IL-3), all from (PeproTech Ec Ltd, London,
UK). Recombinant human granulocyte colony-stimulating factor (G-CSF;
lenograstim) was a gift from Chugai Pharma, UK (See combinations ofcytokinesfor
neutrophil precursor studies list). Cells were cultured in lOOng/ml SCF, lOng/ml
Flt3-L unless otherwise stated, with or without 100 ng/ml G-CSF. Cells were cultured
in a fully humidified atmosphere of 5% CO, in air at 372C, for 14 days. Following a
vigorous pipetting, aliquots of non-adherent cells were removed for cell counts,
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differential morphology, flow cytometer analysis and colony assays. Few residual
adherent cells remained in wells, and those appeared to have stromal morphology.
CD34+ numbers were calculated from total cell numbers and CD34+ proportions:
CD34+ expansion was expressed as a "fold expansion" over starting CD34+ numbers,
where fold expansion is the final number of cells after expansion divided by the
initial CD34+ numbers before culture. In most cases cytokine expanded cells
exhibited some degree of expression of CD34: cells cultured without cytokines died.
It was therefore supposed that the expanded cells derived from the starting CD34+
population and that the starting CD34-negative (mature) MNC did not contribute
to the expansion.
2.5.2 Ex vivo expansion cultures for endothelial precursor
studies
The CD34+ enriched fraction of MNC cell suspensions isolated by magnetic-activated
cell sorting (MiniMacs CD34+ isolation Kit; Miltenyi Biotec, Surrey, UK) from
peripheral blood, cord blood, mobilised blood and bone marrow were cultured in
expansion culture medium (Iscove's Dulbecco's medium; Invitrogen, Paisley, UK)
supplemented with 10% FCS (Sigma, UK), and 1% Pen/Strep (Sigma, UK). 0.2xl06
total cells/ml of known CD34+ purity were plated in 24-well plates in 1ml medium
with the addition of VEGF alone, or with lOOng/ml SCF plus lOng/ml Flt-3L alone,
or with different combinations of cytokines as stated [such as 50-100ng/ml of VEGF,
lOng/ml of bFGF, lOOng/ml of GM-CSF, 10 units of heparin/ml, and lOOng/ml of
Endothelial cell growth supplement (ECGS)] (See combinations of cytokines for
endothelial precursor studies list) in a fully humidified atmosphere of 5%C02 in air,
at 37C for 14 days. Cultured cells were harvested by adding 0.5ml of EDTA/PBS
(0.1%) for 15 minutes at room temperature followed by vigorous pipetting to recover
adherent and non-adherent cells, which were counted, and characterized by flow
cytometry, to assess any expansion. In some cases cells were then plated on
fibronectin-coated 24-well plates in CECM medium (Stem cell Technologies, UK)
and assessed for the generation of CFU-EPC colonies, and also assessed for
endothelial tube formation in Matrigel.
The following recombinant purified human cytokines were used in these studies.
Human flt-3 ligand (Flt3-L), human stem cell factor (SCF), human basic Fibroblast
growth factor-basic (bFGF), and human Vascular endothelial growth factor (VEGF)
were all from (PeproTech Ec Ltd, London, UK). Endothelial cell growth supplement
(ECGS) and Heparin were from Sigma, UK. Human granulocyte-monocyte colony
stimulating factor (GM-CSF) was from Sandoz, UK. Interleukin-4 was from RD
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Systems, UK. Human granulocyte colony-stimulating factor (G-CSF; lenograstim)
was a gift from Chugai Pharma, UK. (See combinations ofcytokines for endothelial
precursor studies list).
In some cases fibronectin and gelatin coated dishes were used. In most cases we
used a commercial fibronectin coated plated from (Becton Dickinson, UK) but some
cases we used our own coating. Here fibronectin (0.5mg/ml) (Sigma, UK) was
sterilised by filtration using a 0.22um filter (Millipore, UK), diluted into carbonate/
bicarbonate pH 9.6 buffer at a final concentration of lOng/ml per well in 24-well
plates and incubated overnight at 4C. On the day of the experiment the wells were
washed twice with PBS and once with medium with FCS and the cells were plated.
Alternatively, for gelatine-coated plates, 500ul of Gelatine (0.1%) (Sigma, UK) was
added to the 24 well plates and left for 30 minutes at 37C. The wells were then
washed with PBS and the cells were plated. A Clonetics endothelial medium (EBM)
was also studied in comparison to IMDM.
2.5.3 Dendritic cell differentiation
MNCs from peripheral blood were incubated in a 25cm2 flask (430168 polystyrene)
(Corning, UK) with IMDM for 2h as described in 2.2.5. Recovered adherent cells
(>80% CD14+) were cultured in a 24 well plate in IMDM in the presence of 100ng/
ml of GM-CSF (Sandoz, UK) and 15ng/ml of IL-4 (RD Systems, UK). After 7 days
culture the cells were characterised by flow cytometry immunophenotyping for
markers of dendritic cells (CD209, CD58 (Becton Dickinson, UK), CD1 lc, CD86,
CD80, HLA Class I and HLA Class II (Caltag, UK)) and transferred to a 24-
fibronectin-coated plate in CECM medium (Stem Cell Technologies) for 5 days to
test for the generation of CFU-EPC colonies.
2.6 Other manipulations and analyses of cells
2.6.1 Cell preparation for Western blotting for detection of
SHP-1, SHP-2 and PTEN expression
Cells were cultured as for neutrophil precursor studies (above, 2.5.1) with cytokine
combinations as stated in results. After appropriate culture times cells were
recovered, washed twice with Ca2+/Mg2+ free PBS. After counting cells were
resuspended at lxl06 in 50ul lysis buffer (1% Triton-X 100,150mM NaCl, 25mM
Tris-HCl pH 7.4, ImM EDTA, plus protease inhibitor cocktail tablets, ImM NaF,
ImM Na3V04, ImM Levamisole, ImM (/-glycerophosphate), mixed and incubated
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on ice for 20 minutes. Following centrifugation at 20,000g for 15 minutes the
supernatant was transferred to a fresh eppendorf tube, 25ul of double-strength
Laemmli buffer (125mM Tris HC1 pH 6.8, 4% SDS, 10% beta-mercaptoethanol,
20% Glycerol, and a trace of bromphenol-blue powder) was added and the samples
heated for 5 minutes at 95C before storage at -20C.
2.6.2 Western blotting
Protein separation was carried out using 8% SDS-page gels (30% Acrylamide), and
transferring the proteins to PVDF membranes. The membranes were washed in
PBS, blocked for lh in 2% casein and incubated with the indicated primary antibody
(Transduction Lab) in blocking buffer overnight at 4C. The membrane was then
washed for 30 minutes with PBS/Tween (0.05%) and incubated with the anti-mouse
HRP secondary antibody for lh. Finally, after washing for 45 minutes with PBS/
Tween (0.05%) the membrane blot was developed with ECL Plus and digitalised
using a Versadoc imaging System (Biorad).
2.6.3 Transfectlon of ex vivo differentiated cells derived from
CD34+ cells
Cells were transfected using Amaxa® transfection reagent (Amaxa, Cologne,
Germany) according to the manufacturer's protocol. In brief, after appropriate
culture times cells were washed with Ca2'/Mg2 free PBS and the supernatant was
discarded. lOOul of Amaxa buffer was added to the pellet plus 2ug of either SHP-1-
GFP-control-GFP or SHP-1-GFP construct. The cDNA encoding human tyrosine
phosphatase SHP-1, and SFIP-2 were a kind gift from Paul Crocker (University of
Dundee, UK) and were cloned into the pEGFP-Nl vector (Clontech, Basingstoke,
UK)(Avril et al.,2004).The mixture was transferred into a cuvette, and cells were
electroporated (Amaxa, Cologne, Germany) using the appropriate program. Using
a thin Pasteur pipette cells were recovered, washed and plated in a 12-well plate in
pre-warmed RPMI medium overnight. After 20h, apoptosis of the transferred cells
was analysed by assessment of phosphatidylserine expression using Annexin-V-PE
staining (Caltag, UK) by FACS analysis (Coulter Epics XS). lxl05 cells were washed
with PBS and resuspended in lOOul of Annexin buffer (lOmM Hepes/NaOH, pH
7.4,140mM NaCl, 2.5mM CaCl2) plus Annexin-V-PE (Caltag, UK) and incubated
for 15 minutes at room temperature in the dark. Cells were washed by centrifugation




Plasma troponin I concentrations were measured using an automated
immunometric assay (Ortho-clinical Diagnostics, High Wycombe, UK). Serum was
prepared for measurement of C-reactive protein (CRP) concentrations using an
immunonephelometric assay (Behring BNII nephelometer, Marburg, Germany).
2.6.5 RNA extraction and quantitative real-time PCR
Total leucocyte RNA extraction from 1 mL of whole blood was performed using
QIAGEN's RNeasy Mini Kit (QIAGEN Ltd., Crawley, UK). RNA concentration
and purity were estimated by UV absorbance at 260 and 280 nm. The 260:280 nm
ratios were all greater than 1.8 indicating that little protein contamination was present.
One microgram of total RNA was transcribed into cDNA in each reverse
transcription reaction with 200 units of M-MLV reverse transcriptase for 60 minutes
at 37°C in 20 mL reactions containing 1 mL (0.5mg/ml) of random hexamer primers,
with 0.625 mL (40 units/mL) of RNAse inhibitor, 5 mL of dNTP mix (containing
dATP, dCTP, dGTP and dTTP, each at a concentration of 10 nM in water) and 5 mL
of 5X RT reaction buffer (containing 50 mM Tris-HCl pH 8.3 at 25°C, 75 mM KCL,
3 mM MgCl2 and 10 mM DTT).
Real-time PCR was carried out using the ABI Prism a7900HT system (Applied
Biosystems, Warrington, UK) to determine the relative quantity of mRNA for selected
genes. Relative quantity can be defined as a comparison of a target signal in different
samples to a reference sample and normalised to an endogenous control. PCR
primers and probes for amplification of cDNA derived from CD34 and CD14, and
the mature endothelial markers, VE-cadherin and von Willebrand factor (vWF),
transcripts were obtained from Applied Biosystems (Foster City, CA, USA). Each
assay contained forward and reverse PCR primers (final concentration of 900 nM
each) and one Taqman MGB probe (6-FAM dye-labelled, to a final concentration of
250 nM). All primer-probe sets had been quality control checked and validated.
The ribosomal 18s gene was used as an internal control. Four mL of the reverse
transcription reaction was analysed in each PCR reaction. The PCR reactions were
run in triplicate in 20 mL assays, each containing cDNA, 1 mL of primer/probe, 10
mL of universal PCR mastermix and distilled water. The cycling program was as
follows: (a) initial activation for 10 minutes at 95C; (b) 50 amplification cycles with
a 15 second denaturing step at 95C, and a 1 minute combined annealing and
extension step at 60C. Analysis was performed using ABI 7900HT SDS software




The medians of the different sets of results were compared using non-parametric
tests (Wilcoxon matched pairs test or Mann-Whitney test depending on whether
pairing was possible). A probability value was considered significant if it was p<0.05
(represented in results as p<0.05 a" *, p<0.01 a" ** and p<0.001 a" ***). GraphPad or
NCSS statistical packages were used.
2.8 Clinical studies
2.8.1 Coronary angiography and PCI
All patients were treated for two weeks with 75 mg clopidogrel prior to angiography
or PCI. Coronary angiography was performed via right femoral or radial artery
approach with 6F arterial catheters. Elective PCI was performed in all patients after
7,500 IU intravenous heparin administration and in one patient after intravenous
glycoprotein Ilb/IIIa inhibitor. Coronary stents (Liberte, Boston Scientific) were




-Acetylated Low Density Lipoprotein (Dil-Ac-LDL) (Biomedical Technologies, UK)
-CellFix (Becton Dickinson, UK)
-Chloroquin (2Mm) (Sigma, UK)
-Chloroquin/EDTA (2Mm/0.1%) (Sigma, UK/ Fisher, UK)
-Dako Intrastain Reagent A (fixation) (Dako Cytomation Ltd)
-Dako Intrastain Reagent B (permeabilisation) (Dako Cytomation Ltd)
-EDTA (0.01%)/Trypsin (0.025%) (Clonetics, UK) (Used only in HUVECs)
-EDTA/PBS (0.1%) (Fisher, UK/ Oxoid, UK)
-FacsLyse (Becton Dickinson, UK)
-Fetal Calf Serum (FCS) (10%) Biowhittaker, UK
-Gelatin (0.1%) Sigma, UK
-Histopaque (1.077g/ml; Sigma Diagnostics, UK).
-Laemmli buffer (125mM Tris HC1 pH 6.8, 4% SDS, 10% beta-mercaptoethanol,
20% Glycerol, and a bit of bromphenol-blue powder).
-Lignocain (2Mm) (Lidocain) (Hameln Pharmaceuticals Ltd)
-Lignocain/EDTA (2Mm/0.1%)) (Hameln Pharmaceuticals Ltd/ Fisher, UK)
-Luminol (IMm) (Sigma, UK)
-Lysis buffer (1% Triton-X 100,150mM NaCl, 25mM Tris-HCl pH 7.4,1 mM EDTA,
plus protease inhibitor cocktail tablets, lmM NaF, lmM Na3V04, ImM Levamisole,
ImM ^-glycerophosphate).
-MACS CD34 Isolation Kit (Miltenyi Biotec, Surrey, UK)
-MatrigeKDMatrix (Becton Dickinson, UK)
-Methanol (Fisher, UK)
-PBS/Tween (0.05%) (Oxoid, UK/ Fisher, UK)
-Penicillin/Streptomycin (lO.OOOUnits/ml (Penicillin)+ lOug/ml (Streptomycin)
(Sigma, UK).
-Phorbol myristate acetate (PMA) (lug/ml) (Sigma, UK)
-Phosphate buffered saline (PBS) tablets (Oxoid, UK)
-Polymorphprep (Axis-Shield PC AS, UK)
-Rosette-Sep (Stem Cell Technologies, UK)
-Trypsin neutralising solution (Clonetics, UK). (Used only in HUVECs)
-Trypsin/EDTA (TVP): 0.078g EDTA (Fisher, UK)+ 2.5ml Trypsin (xlO solution
2.5%)(Sigma, UK)+ 2.5ml chick serum (Gibco, UK)+ 245ml of PBS (Oxoid, UK)
-Ulex europaeus agglutinin-1 (UEA-1) lectin binding (Sigma,UK)
-Wright-Giemsa staining (Thermo Shandon, UK)
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Culture mediums
-Endothelial basal medium (EBM) culture medium (Clonetics, UK) plus added
growth supplements (hydrocortisone, hFGF-B, VEGF, R3-IGF-1, Ascorbic acid,
Heparin, hEGF, FBS, GA-1000) (Clonetics, UK).
-Freezing medium (10% Dimethyl sulphoxide (DMSO) (Sigma, UK) and 90% FCS)
-Iscove's Modified Dulbecco Media (IMDM) with 10% FCS (Biowhittaker,UK) 1%
Antibiotic (penicillin/streptomycin) (10000Units/ml/10ug/ml)respectively (Sigma,
UK).
-Iscove's Modified Dulbecco Media (IMDM) with 10% FCS (Biowhittaker,UK) 1%
Antibiotic (penicillin/streptomycin) (lOOOOUnits/ml /10ug/ml)respectively (Sigma,
UK), lx Non-essential aminoacids (NEAA) (Sigma, UK), 5x104 M of 2-Mercapto-
ethanol (2-ME) (Sigma, UK), ImM sodium pyruvate (Sigma, UK), and 2mM
glutamine (Sigma, UK), (Hybridoma endothelial cell line EA-hy-926 only).
-Mesencult media (Stem Cell Technologies, UK) supplemented with 10% FCS
(Biowhittaker,UK), 2mM glutamine (Sigma, UK), and 1% Antibiotic (penicillin/
streptomycin) (10000Units/ml/10ug/ml)respectively (Sigma, UK).
Colony assay mediums
-Complete Endothelial Culture Medium (CECM) comprising Endocult Basal
Medium (Stem Cell Technologies, UK) supplemented with 1/5 dilution of Endocult
supplements (Stem Cell Technologies, UK).
-MethoCult GF H4435; Stem Cell Technologies, UK




anti-CD146-FITC (RD Systems, UK)
anti-CD14-FITC (Becton Dickinson,UK)




anti-CD209-PE (Becton Dickinson, UK)
anti-CD29-FITC (Caltag, UK)





anti-CD3-PE (Becton Dickinson, UK)
anti-CD41-FITC (Becton Dickinson, UK)
anti-CD45-FITC (Becton Dickinson, UK)
anti-CD45-PercP (Becton Dickinson, UK)




anti-CXCR4-PercP (Becton Dickinson, UK)
anti-Glycophorane-1 (Gpa-l)-PE (Serotec, UK)
anti-HLA-Class I-FITC (Caltag, UK)
anti-HLA-Class Il-PercP (Caltag, UK)
anti-myeloperoxidase (MPO-7Mab) (Dako Cytomation Ltd)
anti-Ve-cadherin-PE (Santa Cruz Biotechnology)
anti-VEGFR2-PE (R&D systems)
Combinations of cytokines for neutrophil precursor
studies.
SCF (10,100 ng/ml) (PeproTech Ec Ltd, UK)
Flt3-L (10,100 ng/ml) (PeproTech Ec Ltd, UK)
SCF (10,100 ng/ml)+ Flt3-L (10,100 ng/ml)
TPO (10,100 ng/ml) (PeproTech Ec Ltd, UK)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ TPO (10,100 ng/ml)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ IL-6 (lOng/ml) (PeproTech Ec Ltd, UK)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ IL-3 (lOng/ml) (PeproTech Ec Ltd, UK)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ IL-6 (lOng/ml) + IL-3 (lOng/ml)
G-CSF (lenograstim) (10,100 ng/ml) (gift from Chugai Pharma, UK)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ G-CSF (10,100 ng/ml)
SCF (100 ng/ml)+ G-CSF (100 ng/ml) + TPO (100 ng/ml)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ G-CSF (100 ng/ml) + TPO (100 ng/ml)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ G-CSF (100 ng/ml))+ IL-6 (lOng/ml)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ G-CSF (100 ng/ml))+ IL-3 (lOng/ml)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ G-CSF (100 ng/ml))+ IL-6 (10ng/ml)+ IL-3
(lOng/ml).
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Combinations of cytokines for endothelial precursor
studies.
VEGF (50,100ng/ml) (PeproTech Ec Ltd, UK)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ VEGF (50,100ng/ml)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ VEGF (50,100ng/ml)+10 ng/ml bFGF
(PeproTech Ec Ltd, UK)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ VEGF (50,100ng/ml)+10 Units Heparin/ml
(Sigma, UK)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ VEGF (50,100ng/ml)+100ng/ml Endothelial
growth factor supplement (ECGS) (Sigma, UK)
SCF (100 ng/ml)+ Flt3-L (10 ng/ml)+ GM-CSF (lOOng/ml) (Sandoz,UK)
GM-CSF (lOOng/ml) (Sandoz, UK) +15 ng/ml IL-4 (RD Systems, UK)
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Chapter 3:
Formation of functional neutrophil precursors from
human peripheral blood haematopoietic stem cells.
3.1 Research aims
The principal aim of this section of the project was to examine at a laboratory level
the feasibility of supporting mobilised peripheral blood stem cell (PBSC)
transplantation by setting aside part of the PBSC harvest for ex vivo manipulation
to achieve accelerated in vivo neutrophil recovery. A subordinate aim was also to
explore conditions for ex vivo manipulation to achieve simultaneous accelerated in
vivo platelet recovery. These investigations were intended to inform preclinical
translation of the findings from research laboratory to good manufacturing practice
(GMP) grade laboratory facility for development for possible clinical application.
3.2 Introduction
3.2.1 Therapeutic use of Haematopoietic stem cells
The concept of regenerative medicine using the body's own or histocompatible donor
haematopoietic stem cells for a rapid haematological reconstitution has been studied
and applied as a treatment of haematological disorders. Myeloablation by
chemotherapy followed up by haematopoietic stem/progenitor cell transplantation
is indicated in the treatment of a wide variety of leukaemias, lymphoproliferative
diseases, solid tumours, bone marrow failure syndromes, immunodeficiency states
and non-malignant haematological disorders (Barrett, 1991). Neutrophils are one
of the body's first line of defences and work by going to the site of infections, damage,
or inflammation causing phagocytosis of particles such as bacteria. Patients receiving
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high doses of chemotherapy are at risk for serious infections and bleeding during
the neutropenia and thrombocytopaenia phase induced by their treatment.
3.2.2 Autologous and allogeneic haematopoietic stem cell
transplantation
Autologous (from the same person) and allogeneic (from a histocompatible donor)
haematopoietic stem cell transplantation have been used successfully for more than
three decades in the treatment of haematological diseases to reconstitute
haematopoiesis after myeloablation (Verfaillie, 2002).
3.2.3 Different sources of HSC for transplantation.
The classic source of haematopoietic stem cells is the bone marrow. For more than
40 years, clinicians performed bone marrow transplants from patients (autologous)
or donors (allogeneic) as an effective form to restore haematopoiesis following high
doses of chemotherapy (Chao and Blume, 1989; Chao and Blume, 1990). The
development of bone marrow transplantation provided a method where higher
doses of chemotherapy could occur (not possible with previous therapies limited by
bone marrow toxicity) and therefore higher tumour cell kill with expected better
outcomes (Chao and Blume, 1989). Alternatively, the use of peripheral stem cells
has also been studied. In 1979 Goldman reported successful autologous peripheral
blood stem cell transplantation in patients with chronic myelogenous leukaemia
(Goldman, 1979). However, circulating human HSC in the bloodstream are very
low. In the recent years researchers have found that by injecting the cytokine
granulocyte-colony stimulating factor (G-CSF) a few days before the cell harvest,
haematopoietic stem cells can be mobilised in significant numbers and migrate
from marrow to blood increasing the numbers of stem/progenitor cells in peripheral
blood (www.nih.gov/news/stemcell/scireport.htm). Currently, cytokine mobilised
peripheral blood stem cells (PBSC) are replacing bone marrow to become the most
common source of HSC for transplantation, generally with a reduced period of
post transplant neutropenia and thrombocytopenia (To et al., 1992; Hartmann et
al., 1997; Paquette et al., 2000). This method reduces complications associated with
high doses of chemotherapy, shortens hospital stay, decreases costs, and accelerates
and enhances haematopoietic recovery (www.nih.gov/news/stemcell/scireport.htm).
Alternatively, in the late 1980s and early 1990s, researchers began to recognise that
blood from human umbilical cord was also a rich source of HSCs for allogeneic
transplantation. HSCs derived from cord blood (CB) seem to have many advantages
for transplantation, but the recipients are restricted to paediatric patients because
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of the small cord blood volume (Cairo and Wagner, 1997; Rubinstein et al. 1998).
3.2.4 The period of neutropenia following PBSC HSC
transplantation.
Myeloablative chemotherapy destroys the bone marrow's capacity for
haematopoiesis. Infusion of CD34+ HSC harvested pre-myeloablation following G-
CSF mobilisation restores haematopoiesis allowing more aggressive chemotherapy
However HSC transplant does not immediately restore completely mature blood
cells. There is a period of neutropenia until the restorative HSC transplant takes
effect. The neutropenia following HSC transplant can result in life-treating infections
and plays an important role in the design, schedule, and doses of cancer treatment
regimes (Tutschka, 1986; Ringden et al., 1988). The development of an optimal
therapy to augment this recovery will be a great advantage (Bender; Smith and
Unverzagt, 1995). A previous approach to the treatment of neutropenia included
granulocyte transfusions (Pizzo, 1984). However, this therapy was not widely used
because of the difficulties in obtaining adequate granulocytes from allogeneic
donors, their short half-life, impossible storage and the potential of the transmission
of infections (Strauss, 1993).
The HSCs identified by the CD34 cell surface marker (Sutherland et al., 1996), are
commonly mobilised into peripheral blood by administration of G-CSF (lenograstim)
(Thomas et al., 2002). A cell harvest is collected by aphaeresis (on a cell separator)
when appropriate numbers of CD34' cells are present in peripheral blood. Locally,
for autologous peripheral blood stem cell transplantation >2.5x106 CD34+ cells/kg
is felt to be an adequate dose. This is similar for allogeneic PBSCT although the
ideal dose is 5x106 CD34+cells/kg with greatest benefit for graft versus host disease
(GVHD) (H.R Consultant Haematologist, personal communication). Peripheral
blood stem cell harvests are then stored frozen (the CD34+ cells can survive intact)
and recovered for administration at the appropriate time, following intense
chemotherapy. The stem cell source may be autologous (collected from the patient
after initial chemotherapy-induced remission) or allogeneic, from a histocompatible
donor (usually a relative) not in receipt of chemotherapy. Cytokine mobilised
peripheral blood stem cell transplantation after chemotherapy shortens the period
of neutropenia when compared to whole bone marrow (Kasai et al., 2002). However,
there remains a period of many days, about 10 to 15 days, of clinically significant
neutropenia, during which the patient is at high risk of infection and which cannot
be reduced by increasing CD34+ doses (Thomas et al., 2002). Thus, this neutropenia
period is probably related to the normal maturation time for the re-infused cells to
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proliferate and differentiate into mature cells in vivo.
3.2.5 The period of thrombocytopaenia following PBSC HSC
transplantation.
Thrombocytopaenia is a disorder of reduced platelet counts in which the patients
are at high risk of serious bleeding (Geissler et al., 2003). Support for
thrombocytopaenia is routinely available from transfusion centres through
allogeneic leukodepleted platelet transfusions, which present low risk of virus
transmission since they are not nucleated cells (To et al., 1992). Prolonged and severe
chemotherapy-induced thrombocytopenia is a major cause of morbidity in patients
receiving intensive chemotherapy and especially in those undergoing stem cell
transplantation following intensive myeloablative chemotherapy (Tornebohm et
al., 1993). Following HSC transplantation platelet engraftment requires 11-25 days,
so extends beyond the period of neutropenia. This has prompted a search for a
growth factor that stimulates platelet production, comparable to G-CSF for
neutrophils or erythropoietin (EPO) for red cells. Thrombopoietin (TPO) or
megakaryocyte growth and development factor (MGDF) is the most specific and
effective growth factor identified to date for the treatment of thrompocytopaenia.
Exogenously administered MGDF might further stimulate megakaryogenesis and
platelet production (Nomura et al., 2002). However, Li et al. (2001) showed that a
small but significant proportion of subjects resulted in thrombocytopaenia due to
the development of neutralising antibodies to endogenous TPO.
3.2.6 The residual period of neutropaenia and
thrombocytopaenia. A proposal to reduce it by ex vivo
haematopoietic stem cell expansion.
Haematopoietic stem cell transplantation after chemotherapy resolves neutropenia
and thrombocytopenia but there remains a period of many days of clinically
significant lack of functional numbers of neutrophils and platelets. Selective
manipulation of the cellular composition of the grafts may offer the potential for
reducing the post-transplant period of neutropenia and thrombocytopaenia, thus
reducing the morbidity and mortality generally associated with these therapies
(Noga, 1992; Berenson et al., 1995). The availability of recombinant cytokines has
allowed investigation of the role of different cytokines in driving ex vivo proliferation
and maturation of CD34+ cells with different haematopoietic potential, and
investigation of the use of different combinations of cytokines for expansion of HSC
for different clinical objectives. This approach first proposed by Haylock et al.,
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1992 was to give unmanipulated HSC to ensure the long-term haematopoietic
engraftment and as an adjunct to give ex vivo expanded HSC for reduction of the
period of neutropenia. However, many studies have targeted ex vivo expansion of
the entire graft, including all classes of HSC encompassing primitive long-term
reconstituting cells and mature lineage-committed progenitors, to provide sufficient
reconstitutive graft material from smaller starting amounts of PBSC, without support
from unmanipulated PBSC. However, Holyoake et al., 1997 demonstrated clinically
that transplantation solely with ex vivo expanded CD34+ cells does not confer durable
haematopoietic reconstitution, and that unmanipulated PBSC are required for
durable reconstitution. Of necessity this remains the target of advocates of the use
of umbilical cord blood HSC for allogeneic transplantation where due to volume
limitations HSC numbers are too low for use in adults.
Some studies have focussed, like Haylock, on using only part of the PBSC harvest
to deliberately expand neutrophils. Here there is no critical requirement in culture
at least for maintenance, at best expansion, of long-term haematopoietic potential
which are in such cases given by the unmanipulated harvest component of the
graft. However, most ex vivo protocols and preclinical trials, have aimed to achieve
simultaneous expansion of both neutrophil and megakaryocytes precursors to
address the dual problems of neutropenia and thrombocytopenia (McNiece et al.,
2000; Paquette et al., 2000; Prince et al., 2004; Reiffers et al., 1999). Reviews of such
studies (Heike and Nakahata, 2002; McNiece and Briddell, 2001; McNiece, 2004)
affirm the safety of the infused manipulated material and generally more rapid
neutrophil engraftment than historical controls, even resulting in abolition of
neutropenia in some cases Reiffers et al., 1999, which appears to support some role
for ex vivo expansion of neutrophil precursors in further reducing neutropenia.
However, with few exceptions, such "dual expansion" ex vivo manipulated cells
have not demonstrated any significant effect on thrombocytopenia. There are few
clinical studies which have assessed the efficacy of selectively expanded
megakaryocyte progenitors and none yet which have shown any clinical benefit in
reducing thrombocytopaenia as an adjunct to autologous PBSC transplantation
(Bertolini et al., 1997; Decaudin et al., 2004, Scheding S et al., 2004).
Further studies and new combinations of cytokines are needed to determine the
optimal ex vivo protocol application for the treatment of thrombocytopenia.
Platelet transfusions are currently available whereas there are only few centres
offering routine granulocyte transfusion. There have been some laboratory studies
which have focussed on the selective generation of neutrophil progenitors from cord
blood (De Bruyn et al., 2003) or PBSC (Hino et al., 2000; Scheding et al., 2000;
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Brugger et al., 1993) but the cytokine combinations used were complex, and these
have not been tested clinically.
Also, in the scale-up of any preclinical procedure for clinical use it is necessary to be
aware of good manufacturing practice, cost-benefit and regulatory issues (Giordano
et al., 2004; Wall and Prince, 2003). To date, part of the reason none of these ex vivo
protocols has been adopted for routine clinical use may be because most of them do
not compare favourably on a cost-benefit basis to conventional support for HSC
transplantation such as transfusion of blood or blood components or antibiotic
administration for 5 to 7 days. However, support for neutropenia by allogeneic
donor granulocyte transfusion is not routinely available and neutropenia is still a
major cause of death as patients remain at high risk from life-threatening infections.
In this context, it may be important to examine specific expansion of neutrophil
precursors from autologous PBSC, as an intended adjunct to unmanipulated
autologous PBSC transplantation. We therefore undertook a study to examine
selective generation of neutrophil progenitors from PBSC which might rationalise
and simplify the combination of cytokines employed, with a view to clinical




3.3.1 CD34+ cell enrichment
CD34+ cells were enriched to a purity of around 15-65% using the Rosette-Sep
(negative-selection) method or 60-90% using the Miltenyi (positive selection) method.
The negative selection method might retain primitive CD34-negative HSC. Figure
3.1 illustrates side by side the two selection methods, showing the different cell
populations and the degree of CD34+ stem cell purification. Improved yields of CD34+
cells were obtained by the positive-selection method, which was used in most cases,
but similar outcomes were obtained with CD34+ cells enriched by the negative
selection method and these were included in the results.
Rosette-Sep (negative selection) MACS (positive selection)
Figure 3.1 CD34+ cell enrichment.
Comparison ofan individual example between Rosette-Sep (CD34+ negative selection) with MACS
(CD34+ positive selection) both described in the materials and methods (see 2.2.3). Higher purity of
CD34+ cells was obtained by the positive-selection method. However some residual mature cell
populations still remained. Blood source: G-CSF mobilised peripheral blood.
13 Haematopoietic stem cells (CD34+)
□ Monocytes (CD 14+)
□ NK cells (CD 16+)
^ □ Neutrophils (CD16b*)
gg T lymphocytes (CD3+)
■ B lymphocytes (CD19+)
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3.3.2 Phenotype of the initial cell population before expansion.
Flow cytometry analysis (Figure 3.2) illustrates that the CD34+ cell population (blue
area) is located in the correct place in the forward scatter/side scatter (FSC/SSC)
distribution and is mostly CD45+ (haematopoietic lineage) as defined by ISMAGE
(Sutherland et ah, 1996). Before culture, few of the CD34+ cells co-expressed myeloid
differentiation markers such CD16b, which is a neutrophil-specific marker. Staining
for co-expression of CD34+/CD38+ the majority of stem cells from mobilised patients
expressed CD38. It is known that CD34+CD38" cells are more immature stem cells
compared to CD34+CD38+ stem cells (Terstappen al., 1991; Huang and Terstappen,
1994). Here the initial CD34+ stem cell population was predominantly CD38+






Figure 3.2 Phenotype analysis of the starting population
CD34+ fraction (blue area) in (a) FSC/SSC. (b) SSC/CD45+, (c) SSC/CD34' and in (d)CD34+/CD45+.
CD 16b expression: (e) control; CD34+cells without the CD 16b antibody and (f) with the presence
of the CD 16b antibody. None of the CD34+ cells express CD 16b. Co-expression CD34/CD38 in (g)
control; CD34+ cells without the addition of anti-CD38 and (h) with the presence ofCD38 antibody.
Most of the cell co-expressed both antibodies. Blood source: G-CSF mobilised peripheral blood.
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3.3.3 PBSC expansion
Doses and combinations of cytokines were examined for expansion of CD34+ PBSC
in 14-day cultures. Stem Cell Factor (SCF) is a haematopoietic growth factor that
exerts its activity by signalling through the c-Kit receptor. SCF and c-Kit are essential
for the survival, proliferation and differentiation of haematopoietic cells (Heike et
al., 2002). Flt3-Ligand is a growth factor that regulates proliferation of early
haematopoietic cells. Flt3-Ligand binds to cells expressing the tyrosine kinase receptor
Flt3. Flt3-Ligand, by itself does not stimulate proliferation of early haematopoietic
cells, but synergizes with other CSFs and interleukins to induce growth and
differentiation (Heike et al., 2002).Initially stem cell factor (SCF) and Flt-3 ligand
(Flt3-L) were examined alone and in combination. Concentrations of SCF and Flt3-
L (0,10 and 100 ng/ml) were tested alone or in combination in chequerboard culture
experiments (Figure 3.3). SCF and Flt3-L, gave similar expansion cell numbers when
used alone, but appeared to synergise when used in combination in that the
expansion (more than 20-fold in some cases) exceeded the sum of expansion seen
with either alone. There was no significant difference using 10 or lOOng of the Flt3-
L in combination with lOOng of SCF (p=0.25, Wilcoxon matched pairs test), therefore
a combination of lOOng/ml of SCF and lOng/ml of Flt3-L was selected as optimal
for expansion of CD34+ cells over 14 days in culture to conserve Flt3-L use. This
mixture of SCF and Flt3-L was referred to as the "expansion cocktail".
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Figure 3.3 Expansion of CD34+ cells
Stem cell factor (SCF) and Flt-3 ligand (Flt-3L) in optimal concentrations can expand CD34+ cells
more than 20-fold in some cases in 14-day cultures (100 ng/ml SCF + 10 ng/ml Flt3-L). Data is
presented as mean± SD (n=6 independent experiments). Blood source: G-CSF mobilised peripheral
blood.
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Figure 3.4 shows the expanded CD34+ cells stained in Wright-Giemsa. The expanded
cells are still quite undifferentiated cells with no indication of mature neutrophil
morphology. The relative expansion of the cells could be easily seen as increased cell
density in culture in phase contrast images (Figure 3.5). The flow cytometry
histogram data (Figure 3.6) shows that enriched CD34+ cell population cultured
with SCF/Flt3-L for 14 days still retained expression of CD34.
Figure 3.4 Morphology of expanded CD34+ cells
Expanded CD34+ cells after 14-day in cytokine culture conditions stained in Wright-Giemsa. Blood
source: G-CSF mobilised peripheral blood.
66
Figure 3.5 Expansion of CD34+ cells. Phase-contrast images
Expansion of CD34+ enriched cells after 14 days in a 24-well plates (a) without and (b) with SCF/Flt-
3L cocktail (phase contrast images). Blood source: G-CSF mobilised peripheral blood.
100 SCF& 10FLT-3
Figure 3.6 CD34 phenotype of the expanded cells
Flow cytometry analysis with (open, purple) and without (shaded, grey) anti-CD34-PE antibody
(gated on CD45-PercP bright population). Mostly all of the cells after culture express CD34. Also
a brighter CD34+ population appears, possibly being a more primitive stem cell population. Blood
source: G-CSF mobilised peripheral blood
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3.3.4 Addition of other growth factors to improve the previous
expansion cocktail.
The addition of other cytokines was examined to determine whether their presence
improved expansion of CD34+ cells over that obtained with "expansion cocktail"
culture conditions and to assess their effectiveness for differentiation and maturation
of the desired cell lineages.
3.3.4.1 Addition of TPO (SCF+Flt3-L+TPO)
TPO is a lineage specific growth factor. It stimulates the proliferation and maturation
of megakaryocytes, and promotes increased circulating levels of platelets in vivo.
TPO signals through the c-mpl receptor and acts as an important regulator of
circulating platelets (Heike et al, 2002). It is also been shown to stimulate primitive
stem cell expansion and trigger stem cell self-renewal (Heike et al., 2002).In six
identical experiments, the addition of TPO (either 10 or 100 ng/ml) to SCF/Flt3-L
showed no significant change in cell expansion compared to SCF/Flt3-L alone. SCF/

























Figure 3.7 Effect of the addition of TPO to the SCF / Flt-3L optimal expansion cocktail
The effect ofTPO alone and in combination with "expansion cocktail" (SCF/Flt3-L) on expansion
of CD34+ cells in 14-day cultures. Data is presented as mean±SD (n=6 independent experiments).
Blood source: G-CSF mobilised peripheral blood.
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3.3.4.2 Addition of IL-3 and IL-6
The addition of IL-3 and/or IL-6 to the previous SCF/Flt3-L expansion cocktail was
also assessed for improving expansion of CD34+ cells (Figure 3.8). IL-3 is a
haematopoietic growth factor that promotes the survival, differentiation and
proliferation of committed progenitor cells of the megakaryocyte, granulocyte-
macrophage, erythroid, eosinophil, basophil and mast cell lineages (Heike et al.,
2002).IL-3 also acts on more immature haematopoietic cells promoting self-renewal
(Heike et al., 2002). IL-6 is a pleiotropic cytokine that plays an important role in
host defense by regulating immune and inflammatory responses. IL-6 alone does
not have distinct biological activity on HSC expansion. IL-6 and IL-3 induce
synergistically the proliferation of pluripotent hematopoietic progenitors in vitro
(Heike et al., 2002). There was no significant change in expansion cell numbers
compared to that seen with SCF/Flt3-L alone. For simplicity and to facilitate
laboratory procedures in possible GMP clinical application, IL-3 and IL-6 were


































Figure 3.8 Effect of the addition of IL-3 and IL-6 to the SCF/Llt-3L optimal expansion cocktail.
The effect of the addition of IL-3 and IL-6 to the "expansion cocktail" (SCF/Flt3-L) alone or both
together on expansion of CD34+ cells in 14-day cultures. Data is presented as mean± SD (n=5
independent experiments). Blood source: G-CSF mobilised peripheral blood.
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3.3.4.3 Effect of addition of G-CSF to the SCF/Flt3-L expansion cocktail.
We studied the addition of G-CSF (0,10 or 100 ng/ml) to the final expansion cocktail
(lOOng/ml SCF+ lOng/ml Flt3-L)(Figure 3.9). G-CSF is a haematopoietic growth
factor that stimulates the development of committed progenitor cells to neutrophils
and enhances the functional activities of the mature end-cell (Dexter, 1994). It is
produced in response to specific stimulation by a variety of cells including
macrophages, fibroblasts, endothelial cells and bone marrow stroma (Dexter, 1994).
Addition of lOOng/ml G-CSF to the SCF/Flt3-L cocktail acted synergistically resulting
in expansion of the enriched CD34+ cells (to over 30-fold compared to cells before
culture)(p=0.03, Wilcoxon matched pairs test). Addition of lOOng/ml G-CSF was
superior to lOng/ml G-CSF (p=0.03, Wilcoxon matched pairs test). lOng/ml was
not sufficient to stimulate the cells to neutrophil differentiation. The effect of addition
of G-CSF to the SCF/Flt3-L combination at the start of the cultures (day 0) was in
general greater to than that seen when G-CSF was added midway (day 7) through
culture (p=0.04, Wilcoxon matched pairs test) and generated cells which showed a
more mature myeloid morphology. This implies that G-CSF not only acts to
differentiate and mature expanded by SCF/Flt3-L but also synergises with SCF/
Flt3-L during early proliferation and expansion.
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Figure 3.9 Addition of G-CSF to te SCF/Flt-3L optimal expansion cocktail
14-day response to SCF/Flt-3L expansion cocktail with the addition of G-CSF (10 or 100 ng/ml) at
day 0 or at day 7. Addition of lOOng/ml G-CSF to the SCF/Flt3-L cocktail acted synergistically
resulting in expansion of the enriched CD34+ cells (to over 30-fold compared to cells before
culture)(p=0.03). Addition of I (Xing/ml G-CSF was significally superior to 1 Ong/ml G-CSF (p=0.03).
The effect of addition of G-CSF to the SCF/Flt3-L combination at the start of the cultures (day 0)
was significally greater than that seen when G-CSF was added midway in culture (day 7)(p=0.04).
Data is presented as mean± SD (n=6 independent experiments). Arrows indicate significant
differences (Wilcoxon matched pairs test). Blood source: G-CSF mobilised peripheral blood.
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3.3.5 Phenotypes of expanded cells
After 14 days stimulation with SCF/Flt3-L, all cells were positive for CD34 expression
(Figure 3.10c). The majority of cells stained at medium fluorescence intensity with
a small population of CD34-bright cells. When G-CSF was added with SCF/Flt3-L
on day 0 (Figure 3.10d) the CD34-bright population disappeared and the
fluorescence of the major population (medium fluorescence intensity) had down
regulated CD34 expression, becoming dimmer. The addition of G-CSF to SCF/Flt3-
L cultures at day 7 (Figure 3.10e) gave similar dimming of the major population
medium-fluorescence-intensity CD34 staining-peak was seen through this appeared
less marked than when G-CSF was added at day 0. The bright CD34' population
was still present. In no case were there any obvious surviving CD34-negative cells
at 14 days, except when G-CSF was used alone without SCF/Flt3-L (Figure 3.10b),
which may have prevented apoptosis of myeloid cells.
CD16 was not used in this study since it is not neutrophil specific (positive also in
monocytes and NK cells) and our observations indicate that it is labile and rapidly
lost from mature neutrophils in vitro (data not shown). The expression of CD16b
was used to identify neutrophils, as it is a non-labile neutrophil-specific marker.
Cells cultured with SCF/Flt3-L+G-CSF showed a small increase in CD16b staining
compared to the unstained. However, there was no real difference in CD16b
expression between SCF/Flt3-L alone and SCF/Flt3-L+G-CSF (Figure 3.11). The
expression was dim in all the cases as compared to mature peripheral blood
neutrophils which stain brightly with CD16b. In contrast, there was a major increase
in intracyoplasmic myeloperoxidase expression in cells cultured with SCF/Flt3-L/
G-CSF compared to cells cultured with SCF/Flt3-L alone (Figure 3.12). Flow
cytometry data shows that the expanded cells were relatively positive for the
neutrophil CD16b marker and strongly positive for the myeloperoxidase antibody
(MPO) demonstrating that the expanded cells were neutrophil precursors.
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Figure 3.10 Characterisation ofexpanded CD34+ cells with or without the addition of G-CSF.
Flow cytometry analysis with (open, purple) and without (shaded, grey) anti-CD34-PE antibody
(gated on CD45-PercP bright population): a) No cytokines, b) G-CSF alone, c) SCF/Flt3L, d) SCF/
Flt3L+G-CSF added at day 0 and e) SCF/Flt3L+G-CSF added at day 7 ofculture. Cultures with SCF/
Flt3L alone retain relatively right expression ofCD34 on the expanded cells, whereas when G-CSF
is added there is dimming ofCD34 expression. Blood source: G-CSF mobilised peripheral blood.
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Figure 3.11 Expression of CD16b with or without the addition of G-CSF
Expression ofCD 16b: Flow cytometry analysis with (shaded grey) and without (open orange) anti-
CD 16b-FITC antibody (gated on CD45-PercP population); (a SCF/FU3-L alone and b) SCF/Flt3-L +

















Figure 3.12 Myeloperoxidase expression with or without the addition ofG-CSF
Myeloperoxidase (MPO) expression. Flow cytometry analysis (gated on CD45-PercP population);
cells cultured in a,b) SCF/FU3-L alone or c,d) SCF/Flt3-L + G-CSF, a,c) negative control without
antibody and b.d) with MPO antibody. Cells cultured in SCF/FU3-L alone showed less MPO
expression compared to cells cultured in SCF/Flt3-L with G-CSF. Blood source: G-CSF mobilised
peripheral blood.
3.3.6 Morphology
CD34+ cells expanded with SCF/Flt3-L alone stained with Wright-Giemsa appeared
to be morphologically undifferentiated, with no clear indication of development of
granulocytic morphology (Figure 3.4). The addition of G-CSF of to cultures gave
extensive development of neutrophil morphology. Cells in different stages of
neutrophil maturation were found and around 80% of the cells had reached a quite
mature stage with apparent segmentation and lobulation of the nuclei and
granularity in the cytoplasm (Figure 3.13).
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Figure 3.13 Morphology of the cells expanded with G-CSF
These pictures show the expanded CD34+ stem cells after 14-day in cytokine culture conditions
stained in Wright-Giemsa. a) SCF/Flt-3L+G-CSF x 100 field and (b) SCF/FU-3L+G-CSF x40field.
Blood source: G-CSF mobilised peripheral blood
3.3.7 Effect of the G-CSF mobilising agent
The number of CD34+ cells recovered following culture was compared between G-
CSF mobilised samples and cord blood samples, which are not exposed to mobilising
or chemotherapy agents in vivo, to determine the effect if any of mobilisation with
G-CSF on the potential expansion of CD34+ cells. In mobilised blood from patients
the expanded cells showed a shift to CD16b expression even without the addition of
G-CSF to cultures (expansion cocktail alone) whereas cord blood cells showed little
CD16b expression without the addition of G-CSF (Figure 3.14). The addition of G-
CSF as a mobilisation agent or even the chemotherapy treatment could have been
the cause of this earlier detection in neutrophil expression markers in CD34 cells
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Figure 3.14 Effect of the Mobilisation agents on CD16b expression.
a,c) SCF/Flt3L alone and b,d) SCF/Flt3L+G-CSF; a.b) G-CSF mobilised peripheral blood (mPB)
expanded cells and c,d) cord blood (CB) expanded cells. In the G-CSF mobilised patient's blood
the cells showed a shift to CD 16b expression on expansion even without the presence of G-CSF
in culture, whereas cord blood cells showed little CD 16b expression without the addition of G-
CSF.
3.3.8 Neutrophil superoxide activity.
An important index of neutrophil function is the production of superoxide radicals
upon activation. This was measured by detecting luminol-amplified
chemiluminescence responses to phorbol myristate acetate (PMA). The respiratory
burst activity of peripheral blood neutrophils from healthy adult donors was
compared with that of CD34+ enriched mobilised PBSC expanded in SCF/Flt3-L
alone or in SCF/Flt3-L+G-CSF (Figure 3.15). CD34+ PBSC cultured with SCF/
Flt3-L alone showed no bioluminescence response to PMA, whereas those cultured
with SCF/Flt3-L and G-CSF respond like mature healthy neutrophils. Although
the starting cell number was the same, the lower response value in vitro expanded
cells compared to the healthy blood neutrophils was probably because peripheral
blood neutrophils are all mature functional cells whereas expanded cells have a
difference in functional maturity range.
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Figure 3.15 Bioluminescence of mature neutrophils and ofCD34+ cells expanded w ith or w ithout
G-CSF.
Respiratory burst activity of peripheral blood neutrophils from healthy adult donors and that of
CD34+ enriched mobilised PBSC expanded in SCF/Flt3-L alone or in SCF/Flt3-L+G-CSF. Neutrophils
from healthy blood (a) were compared to ex vivo expanded CD34+ cells (b) Cells cultured in SCF/
Flt3-L alone showed no chemiluminescence response, whereas the cells cultured with SCF/Flt3L
and G-CSF respond like mature healthy neutrophils.
3.3.9 Duration of cell expansion capacity in vitro
To test the period over which expansion could be sustained the initial 14-day culture
was extended by additional 14 day periods to 28 and 42 days. At each time point
cytokines. Table 3.1 shows CD34+ cell expansion after 14,28 Find 42 days. The cells
expanded maximally in the first 14-day period but showed only a small further
increase in the second 14-day period (to 28 days) and decreased, probably due to
cells dying, in the last 14-day period (to 42 days) (Table 3.1). After 28 days of culture
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neutrophils were more segmented and mature and after 42 days of culture the cells
were blasting and dying (Figure 3.16). Figure 3.17 shows the expression of the
neutrophil marker CD16b in cells recovered following culture with SCF/Flt3-L+G-
CSF. A brightly staining CD16b+subpopulation appeared at day 28 which may
represent a more mature neutrophil population. Figure 3.16 shows the morphology
of these cells at day 28 of culture, which were smaller in size, as compared to day
14, though had more clearly segmented-nuclei characteristic of neutrophils.
CD34+ fold expansion After 14 days After 28 days After 42 days
100 SCF & 10 Flt3-L 15.44 1.53 0.79
100 SCF & 10 Flt3-L +100 G-CSF 19.85 1.6 0.2
Table 3.1 CD34+ fold expansion on extended culture periods.
The cells expand maximally in the first period (14 days) but show only a small increase in the
second period (28 days) and start to die in the last period (42 days). Blood source: G-CSF mobilised
peripheral blood.
^ I f #•* /£
_ » ♦, » u *
• 'A ••.
Figure 3.16 Duration of the expansion cell capacity in vitro: morphology of surviving cells.
Extension ofculture times by further 14 days periods were performed. Cells were harvested, densities
adjusted, and placed in fresh cultures after 14 days (to 28 days). This was repeated after a further
14 days (to 42 days). Wright-Giemsa staining a) after 14 days b) After 28 days of culture the
neutrophil are more segmented and mature, c) After 42 days of culture the cells are blasting and
dying. Blood source: G-CSF mobilised peripheral blood.
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Figure 3.17 The expression of the CD16b+ in extended cultures with SCF/FU3-L+G-CSF after a)
14 days culture, b) 28 days and c) 42 days culture.
A brightly staining CD 16b+ subpopulation appeared at day 28 which may represent a more mature
neutrophil population. At day 42 the cells were blasting and dying and did not express CD 16b
above background. Blood source: G-CSF mobilised peripheral blood.
3.3.10 Colony assays
Methocult colony assays were carried out for some PBSC blood samples on cells
before culture (day 0) and at day 14 following cytokine expansion culture (Table
3.2) to assess their capacity to form colonies for comparison with their behaviour
following expansion. To illustrate how colonies were scored typical colonies from
the cultures are shown in Figure 3.18. Pie charts (Figure 3.19) show that the potential
of the cells before and after expansion is very different. Before expansion, the
predominant colonies generated were erythroid BFU-E, but after culture in the
presence of SCF/Flt3-L or SCF/Flt3-L+G-CSF cells showed a pronounced shift
towards myeloid commitment. There was a marked shift towards CFU-GM myeloid
colonies and away from BFU-E in all expanded cultures. CFU-GM were consistently
higher and BFU-E lower in cultures with G-CSF compared to SCF/Flt3-L alone,
but the switch to CFU-GM with SCF/Flt3-L alone compared to unexpanded cells is
almost as large as that with SCF/Flt3-L+G-CSF, and may indicate that most of
expanded cells are myeloid committed, even without addition of G-CSF.
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Exp 28 74 26 35.9 12.4 22.7
Exp 29 74 26 8.6 3 62.33
Exp 32 72 28 5 1.9 16.56
Day 14
Exp 28 SF 10 90 3 28.5 100
Exp 28 SFG 5 95 0.8 16.1 100
Exp 29 SF 18 82 1.1 4.9 100
Exp 29 SFG 9 91 0.4 4.5 100
Exp 32 SF 13 87 0.67 4.7 100
Exp 32 SFG 0 100 0 4.7 100
Table 3.2 Methocult colony capacity before and after cell expansion
Colony forming cell (CFC) comparisons in 3 sets of mobilised PBSC before culture (day 0: CD34+
enriched cells) and after culture (day 14: expanded CD34+ enriched cells) with SCF/Flt3-L (SF) and
with SCF/Flt3-L+G-CSF (SFG). The proportional (percent) results were used for qualitative
comparisons. Some indication of quantitative responses can be obtained from CFC numbers,
which may relate to CD34+ numbers allowing for CD34+ expansion.
a) b) c)
Figure 3.18 Methylcellulose colony scoring
Colonies in Methylcellulose. Phase contrast images (X100 field) a) CFU-GEMM. b) BFU-E, c) CFU-














Figure 3.19 Methylcellulose colony assay: frequencies ofcolony types before and after culture
with cytokines.
Before culture (day 0) the predominant colonies generated were BFU-E, but after culture with SCF/
Flt3-L+G-CSF (day 14) a major generation of myeloid CFU-GM colonies was observed. Blood
source: G-CSF mobilised peripheral blood
3.3.11 Do CD34 negative cells contribute to the observed
CD34+ expansion?
Because the CD34+ enriched samples were not completely CD34+ pure, the
contribution of the remaining CD34-negative cell population after positive
enrichment of CD34+ cells was assessed. Using the same culture conditions as
previously described both CD34-negative and CD34+ fractions were cultured with
the addition of the expansion cocktail (SCF/Flt3-L) with or without G-CSF. As shown
in Figure 3.20 the CD34-negative fraction showed no cell expansion in the presence
of any cocktail of cytokines used. Thus, only the CD34+ cells were responsible for
cell expansion after 14-days. Moreover, before culture CD34-negative cells did not
form colonies in methylcellulose (data not shown). Thus, any remaining CD34-
negative cells such as monocytes or lymphocytes did not contribute to the cell-
expansion seen after 14 days in culture. However, it is not known whether their
presence in the culture is beneficial for expansion of CD34+ cells as they may secrete
positive or negative growth factors.
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Figure 3.20 Examination of whether CD34-depIeted MNC eontrihute to cell expansion
a) The CD34+ isolated from MACS had a fold expansion of 45 when cultured with SCF/Flt-3L+G-
CSF in this experiment b) The CD34-negativepopulation did not show any expansion at all after 14
day of cytokine culture. Blood source: G-CSF mobilised peripheral blood
3.3.12 Comparison of the expansion/maturation cocktail (SCF/
Flt3-L ± G-CSF) with cytokine combinations described in the
literature.
Recently, many investigators have published their optimal PBSC expansion cocktails.
Clinical studies carried out by McNiece et al. have used the following cocktail of
cytokines: lOOng/ml of (SCF+TPO+G-CSF). Our "expansion cocktail" defined here
(lOOng/ml SCF+ lOng/ml Flt3-L+ lOOng/ml G-CSF) was compared to McNiece et
al. cytokine cocktail and no significant improvement was found both in terms of
cell expansion (Figure 3.21) and differentiation (3.22). Piciabello et al. used a complex
cytokine combination with the addition of IL-3 and IL-6. The addition of either 11-3
or IL-6 alone or together slightly decreased expansion compared to optimal SCF/
Flt-3-L/G-CSF expansion. Changes were not significant both in terms of cell
expansion and differentiation (Figure 3.23a and 3.24). Since these effects were not
incremental, and for the sake of simplicity for any implementation of clinical
protocols for cell expansion, it was decided that inclusion of IL-3 and IL-6 gave no
apparent advantage, and that the SCF/Flt-3-L/G-CSF cocktail would be used for
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Figure 3.21 Comparison ofcell expansion between our SCF/Flt3-L±G-CSF optimal cocktail with
that published by McNiece et aI..
Our shown "expansion cocktail" ± G-CSF defined here (1 OOng/ml SCF+lOng/ml Flt3-L±l OOng/ml G-
CSF) is compared to McNiece etal. cytokine cocktail (1 OOng/ml SCF+1 OOng/ml G-CSF+1 OOng/ml




Figure 3.22 Comparison ofneutrophil maturation between ourSCF/Flt-3L+G-CSFoptimal cocktail
with that published by McNiece et al.
af'Expansion cocktail" +G-CSF defined here (1 OOng/ml SCF+1 Ong/ml F11-3L+1 OOng/ml G-CSF) and
b) McNiece etal cytokine cocktail (1 OOng/ml SCF+1 OOng/ml G-CSF+1 OOng/ml TPO). Our combination
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Figure 3.23 Comparison ofexpansion between our SCF/Flt-3L±G-CSF optimal cocktail with that
published Piciabello eta I.
Our "expansion cocktail" ±G-CSF defined here (I OOng/ml SCF+ lOng/ml FR-3L ± I OOng/ml G-CSF)
was compared to Piciabello etalcytokine cocktail (lOOng/ml SCF+lOng/ml Flt-3L+1OOng/ml G-CSF
±l0ng/ml IL-3 ± lOng/ml 1L-6). Data is presented as mean± SD (n=3 independent experiments).
Blood source: G-CSF mobilised peripheral blood
84
Figure 3.24 Comparison of maturation of neutrophils between our SCF/Flt-3L+G-CSF optimal
cocktail with that published Piciabello etui.
a)"ExpansioncocktaU'"+G-CSF(100ng/ml SCF+IOng/ml Flt-3L+100ng/ml G-CSF)
b) 100 SCF+10 Flt3-L+ 100G-CSF+ 10IL-3,c) 100SCF+10Flt3-L+ICX)G-CSF+10IL-6and
d) 100 SCF+10 Flt3-L+100 G-CSF+10IL-3+ 10IL-6. Expansion cocktail''+ G-CSF appears to be the
best combination of cytokines for neutrophil differentiation. Blood source: G-CSF mobilised
peripheral blood.
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3.3.13 Effects of TPO on optimal expansion and maturation
of CD34+ enriched mobilised PBSC.
The effect of addition of TPO to the SCF/Flt3-L/G-CSF neutrophil expansion/
differentiation cocktail was tested by examining cell expansion, morphology and
function. The addition of TPO to SCF/Flt3-L showed no significant change in
expansion compared to SCF/Flt3-L alone as described above (3.3.4.1). The addition
of TPO to SCF/Flt3-L/G-CSF resulted in a slight reduction or had no effect (p =
0.0625, Wilcoxon matched pairs test, n=5) on the expansion achieved with SCF/
Flt3-L/G-CSF alone (Figure 3.25). Certainly TPO offered no advantage over SCF/
Flt3-L/G-CSF alone in terms of cell expansion, and could be omitted for the sake of
simplicity on these grounds alone. Cells expressing CD41 were found in small
numbers in cultures to which TPO was added, but were not found in any cultures
where TPO was omitted (Figure 3.26). When cells were counted and scored
according to their degree of neutrophil differentiation, cells stimulated with SCF/
Flt3-L/G-CSF+ TPO were less differentiated with a less mature neutrophil
morphology than cells cultured with SCF/Flt3-L/G-CSF alone (Figure 3.27).
Myeloperoxidase (MPO) activity is found in mature neutrophils and myelocyte
progenitors. The CD34+ cells cultured with SCF/Flt3-L/G-CSF and TPO showed a
marginal decline in intensity of expression of MPO compared with the cells cultured
without TPO (Figure 3.28). However, since MPO stains most of the stages of the
committed neutrophil differentiation pathway then an effect of TPO on the stage of
neutrophil maturation achieved might not be clearly detected by this method.
Neutrophil superoxide activity is a good indicator of neutrophil functional maturity.
CD34' cells cultured with SCF/Flt3-L/G-CSF showed a maximal superoxide response
to PMA comparable to fresh mature peripheral blood neutrophils (3.3.8). CD34"
cells cultured with SCF/Flt3-L without G-CSF showed little superoxide response
whether or not they were cultured with TPO. When TPO was added to CD34+ cells
cultured with SCF/Flt3-L/G-CSF, the superoxide response was reduced, but not
abolished (Figure 3.29). In this respect, TPO appears antagonistic to the effect of G-

































Figure 3.25 Effect of the addition ofTPO on SCF/FH3-L+G-CSF cell expansion.
Our "expansion cocktail" ± G-CSF defined here (1 OOng/ml SCF+1 Ong/ml Flt-3L± 1 OOng/ml G-CSF)
was compared to the addition ofTPO (lOOng/ml SCF+lOng/ml Flt-3L± lOQng/ml G-CSF +100 ng/ml
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Figure 3.26 Megakaryocyte differentiation in expansion cultures with or without TPO
The expression of the CD41 platelet marker in cultures with or without TPO. Left column control
without CD41 antibody and right column with the presence of the antibody, a) SCF/FU3-L alone, b)
SCF/FH3-L+G-CSF, c) SCF/Flt3-L+TPO and d) SCF/Flt3-L+G-CSF+TPO. Blood source: G-CSF
mobilised peripheral blood.
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Figure 3.27 Effect of the addition of TPO on neutrophil maturation morphology in expansion
cultures.
Cells cultured with SCF/Flt3-L/G-CSF + TPO showed a delay in neutrophil differentiation by
morphology compared to cells cultured without TPO (SCF/Flt3-L/G-CSF alone). Scoring was
determined by assessing neutrophil morphology (see methods) ranging from 0 (no differentiation)
to 3 (most mature). Others represent cells which had no neutrophil or stem cell morphology. Blood
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Figure 3.28 Effect ofTPO on MPO expression in cells undergoing ex vivo neutrophil expansion
a,b) SCF/FH3-L+G-CSF and c,d) SCF/Flt3-L+G-CSF+TPO; a,c) negative controls without antibody
and b,d) witlt MPO antibody. Cells cultured with SCF/FU3-L/G-CSF+ TPO showed a decline in
intensity of expression of MPO(83.44%) compared with the cells cultured without TPO(93.37%).
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3.4 Discussion
Here it has been demonstrated that a CD34+ cell population enriched from
whole mobilised peripheral blood either from patients or healthy G-CSF
mobilised donors can be optimally expanded in culture for 14 days using lOOng/
ml SCF+lOng/ml Flt3-L combination of growth factors. SCF and Flt3-L
synergised to provide considerable proliferative stimulus to expand PBSC
CD34" cells in culture. This expansion is entirely derived from the CD34+
population, as CD34-depleted population has been shown not to contribute to
this growth. Addition of G-CSF to SCF and Flt3-L further expanded total PBSC
CD34+ cells and differentiated and matured them towards the neutrophil
lineage. The resultant cells down-regulated the expression of CD34 compared
to SCF/Flt3-L alone and acquired neutrophil morphology and function as
assessed by myeloperoxidase activity and superoxide generation in response
to PMA. Expression of CD16b by expanded cells was dim compared to mature
neutrophils and differences in CD16b expression between SCF/Flt3-L and SCF/
Flt3-L/G-CSF expanded cells were marginal. Intracytoplasmic
myeloperoxidase activity (MPO) appears in earlier stages of myeloid
differentiation than CD16b expression therefore, MPO was a more useful
marker in terms of the study of its expression in early-mid stages of neutrophil
cell maturity. Addition of G-CSF to SCF/Flt3-L was required for major expression
of myeloperoxidase activity and essential for superoxide production.
Bioluminescence assay ofneutrophil function showed that only the cells cultured
in the presence of SCF/Flt3-L+G-CSF were mature enough to respond like
mature healthy neutrophils. In this study colony assays showed slight
differences between cells expanded with SCF/Flt3-L and cells expanded with
SCF/Flt3-L/G-CSF. More BFU-E colonies were retained in the absence of G-
CSF, but myeloid colonies predominated in both expansion cultures, whereas
erythroid colonies clearly predominated before ex vivo expansion, in agreement
with results reported by Reichle et al., 2003. Thus colony assays did not
sensitively assess the effects of the addition of other cytokines to SCF/Flt3-L.
These results are comparable with early preclinical studies reported on ex vivo
expansion of PBSC CD34+ even where more complex cytokine combinations
were used to accelerate neutrophil maturation in vitro (Haylock et al., 1992;
Brugger et al. 1993). No significant increase of significant cell numbers or
neutrophil differentiation was detected in here by supplementary addition of
IL-3, IL-6 or TPO, alone or in combination. Flt3-L might not have been available
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to these investigators, and it appears that it may substitute for other cytokines
previously used in expansion cocktails, synergising with SCF to induce HSC
expansion. This indicates that for selective ex vivo expansion of neutrophil precursors
from PBSC, it is sufficient to use Flt3-L with SCF and G-CSF for maximal expansion,
and that supplementary inclusion of TPO, IL-3 and/or IL-6 used by other authors
is superfluous and increases the complexity and cost of the protocol. This early
preclinical studies (Haylock et al, 1992) promoted expansion of autologous CD34+
PBSC to the myeloid lineage while retaining part of the harvest unmanipulated.
Alternatively, many studies have been trying to achieve simultaneous expansion of
committed progenitors and preservation or expansion of more primitive multipotent
FISC in the same system. Holyoake et al., 1997 demonstrated clinically that
transplantation solely with ex vivo expanded CD34+ cells does not confer durable
haematopoietic reconstitution. Similar results have been found using cord blood.
As has recently been reviewed (Robinson et al., 2005) the goal of many cord blood
expansion protocols remains a single complex expansion system delivering mature
erythroid, myeloid and megakaryocyte precursors for rapid reconstitution with
retention of multipotent stem cells for durable reconstitution. The lack of durable
reconstitution by expanded cord blood cells alone has been confirmed in animal
studies (McNiece et al., 2002), and indicates the necessity of ensuring retention of
multipotent long-term reconstituting HSC, for which single system protocols are
still being sought (Peled et al., 2004). Some cord blood studies therefore propose the
use of multiple cords for a single transplant, some of which may be manipulated ex
vivo for selective lineage expansion for more rapid resolution of neutropenia (Pecora
et al., 2000; Shpall et al., 2002; Jaroscak et al., 2003). It was not possible nor was the
aim of this study to maintain an immature expanded CD34+ cells population. After
culture all CD34+ PBSC were in some degree of neutrophil differentiation. In a clinical
perspective to ensure long-term reconstitution an unmartipulated part of the harvest
would be given as an adjunct to the differentiated cells. This study has shown that
the primary wave of CD34+ stem cell expansion occurred in the first 14 days of
culture (proliferative phase). After 14-days in culture the cells lost proliferative
potential having probably already become committed cells. During further 14-days
(28 days) of culture the cells appeared to advance their maturation process. This
point is important to consider for future clinical practice, suggesting that CD34+
cells fully matured to neutrophils in vitro may have little further proliferative
potential, and therefore may not expand further in vivo. Any infusion would
therefore have to deliver an adequate number of cells directly and could not rely on
these being supplemented in the short term by proliferation of manipulated
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precursors in vivo. However it may be possible to manipulate the cells to a less
mature, but more proliferative point in their development, which could be more
optimal for clinical use, providing both early and adequate neutrophil recovery
from manipulated cells until long term recovery from the unmanipulated PBSC
graft takes over. This would depend on the clinical purpose. More mature functional
neutrophils ready to work as soon as they are injected or less differentiated
neutrophils with retained proliferative capacity could be recovered before or after
14 days of cultured and infused when the patient requires them. Further investigation
is required before safe and effective clinical application is possible. Cells may require
storage before use, if so, should they be manipulated after freezing since neutrophils
do not survive freezing. Also the timings of harvest, manipulation and engraftment
need to be addressed. In addition it will be necessary to the procedure to apply
GMP standards.
Cord blood samples were also used in comparison with G-CSF mobilised peripheral
blood and ex vivo neutrophil differentiation was equally achieved with no noticeable
differences. In some G-CSF mobilised samples even in the absence of G-CSF in
culture (that is SCF/Flt3L alone), the CD34+ expanded cells shifted towards the
myeloid phenotype whereas cord blood samples did not. This was probably due to
the preceding clinical mobilisation process where the cells were exposed to G-CSF
in vivo, thus SCF/Flt3-L alone was able to push the cells along the differentiation
pathway to which prior exposure to G-CSF may have made them susceptible.
A small number of studies have investigated selective ex vivo expansion exclusively
of neutrophil progenitors from PBSC (Reichle et al. 2003; Hino et al., 2000; Scheding
et al., 2000; Zimmerman et al., 2000) and in two such studies the expanded cells
have been used clinically to supplement autologous PBSC. Results were inconclusive
in one clinical study (Zimmerman et ah, 2000) but reduced neutropenia in the other
(Reichle et al. 2003). Most of the ex vivo protocols and preclinical trials, have aimed
to achieve simultaneous expansion of both neutrophil and megakaryocytes
precursors to address the dual problems of neutropenia and thrombocytopenia
(McNiece et ah, 2000; Paquette et ah, 2000; Prince et al., 2004; Reiffers et al., 1999).
Therefore addition of TPO, favoured in protocols aimed to produce simultaneous
expansion of both neutrophil and megakaryocyte precursors was examined. As
presented above combining the CD34+ cell expansion cocktail (SCF/Flt3-L) with
the platelet progenitor cytokine (TPO) gave no benefits in terms of cell expansion.
Cells expressing CD41 (megakaryocyte marker) were found in small numbers only
in cultures to which TPO was added. Thus, it appears that the addition of TPO is
essential to megakaryocyte (platelet) formation, but a synergistic stimulus from
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other cytokines seems to be required as we did not achieved major platelet
differentiation in any of our cultures. On the other hand, supplementary addition
of TPO to SCF/Flt3-L/G-CSF resulted in a retardation of neutrophil maturation in
both morphology and function. MPO expression was reduced when TPO was added
to the SCF/Flt3-L/G-CSF combination, and less differentiated neutrophils also
resulted in cultures with the presence of TPO. These results are consistent with the
findings of others that TPO is not necessary for selective neutrophil expansion from
PBSC (Reichle et al. 2003; Hino et al., 2000; Scheding et al., 2000; Zimmerman et
al., 2000) or cord blood (De Bruyn et al., 2003). Its inhibitory effect on neutrophil
maturation is probably marginal, but it is certainly superfluous for induction of
specific neutrophil precursor expansion. No obvious advantage in megakaryocyte
production was detected either, therefore its addition to the SCF/Flt3-L/G-CSF
cytokine combination is unfounded. Consistent with the in vitro observations
reported here, it has been reported that in vivo administration of TPO delays myeloid
recovery following chemotherapy (Geissler et al., 2003). Others have also suggested
that selective megakaryocyte expansion may be best achieved with quite different
cytokine combinations from those required for neutrophil precursor expansion
(Bertolini et al., 1997). More complex combined expansion protocols do not appear
to have been evaluated clinically. Selective ex vivo expansion of megakaryocyte
precursors by relatively simple protocols including SCF, TPO and IL-3 (Scheding
et al., 2004), or SCF and TPO only (Decaudin et al., 2004), showed no clinical benefit
for thrombocytopenia reduction when expanded cells were administered as an
adjunct to unmanipulated autologous PBSC compared with that achieved using
unmanipulated autologous PBSC. The reported clinical effect on reduction of
thrombocytopenia ranged from no effect (McNiece et al., 2000; Reiffers et al., 1999)
to a reduction in post-transplant platelet transfusion requirement (Prince et al., 2004)
or a mean reduction in thrombocytopenia duration by 1 day (Paquette et al., 2000).
It therefore appears that so far, clinical thrombocytopenia, associated with autologous
PBSC transplantation is not amenable to reduction by simple cytokine ex vivo
expansion protocols.
From the data presented here it would appear that the use of two separate protocols
might be beneficial. One to expand/differentiate neutrophil precursors (SCF/Flt3L/
G-CSF) and the other to generate megakaryocyte progenitor cells. These two
different cell populations appear to follow quite separate differentiation pathways
in the haematopoietic maturation system, and very probably may require
completely different stimuli and culture conditions to generate each cell type. PBSC
expansion protocols all employ SCF as the major direct proliferative stimulus for
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primitive and committed HSC. Other cytokines are used with SCF to provide
additional direct stimuli, or synergistic stimuli, for proliferative expansion. Cytokines
are employed to stimulate mature and immature HSC to differentiate and mature
along specific lineage-committed progenitor pathways, and may also provide
proliferative and survival signals for these committed cells. It may be naive to assume
that all of these processes can procede simultaneously in the same system without
competition or inhibition within different HSC expansion and differentiation
pathways. It may be best clinically to focus on selective neutrophil precursor
expansion as a feasible and needed goal for reduction of neutropenia, and if
megakaryocyte generation is to be considered then separate protocols should be
devised to optimise this in distinct cultures rather than attempting simultaneous
neutrophil and megakaryocyte generation in the same system. Hence, while support
for thrombocytopaenia is routinely available from transfusion centres through
allogeneic leukodepleted platelet transfusions, which present low risk of virus
transmission (van de Watering, 2004), there are only few centres offering routine
granulocyte transfusion. Granulocyte donations can only be stored for hours and
the logistical difficulties in recruiting histocompatible and virus-screened donors
are substantial. Moreover, ethical considerations regarding mobilisation of
granulocytes in such donors have not been fully assessed, nor the efficacy of
granulocyte transfusion for treatment of neutropenia (Briones et al, 2003; Price,
1998; Strauss, 1999; Yeghen and Devereux, 2001).
In summary, the results presented here suggest that the combination of SCF, Flt3-L
and G-CSF enables CD34+ HSCs to differentiate into functional neutrophils and
should be investigated for the development of protocols suitable for clinical scale-
up and compliance, as a possible cost-effective means of reducing neutropenia
following autologous PBSC transplant which is not addressed by availability of
donor granulocyte transfusion. Further studies are required to investigate the
generation of functional megakaryocytes precursors but extensive literature reports
suggest that this remains unfeasible so far. These results could be also used as a
CD34+ HSC differentiation model where expression of different genes and proteins
could be studied along their differentiation pathway. In the next chapter the
expression of different phosphatases is studied while CD34" HSCs differentiated
towards the neutrophil lineage.
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Chapter 4
Control of neutrophil survival and function.
(A study in collaboration with Isabelle V. W. M. Hcinisch, Centre for Inflammation Research,
University of Edinburgh Medical School, QMRI, Edinburgh, UK)
4.1 Introduction
A collaborative study was undertaken to combine ex vivo expansion and
differentiation of CD34+ cells to neutrophils with investigation of the role of tyrosine
phosphatases SHP-1 and SHP-2 in regulating apoptosis in neutrophils. I provided
neutrophils at different time points of maturation as well as immunophenotype
analysis, measurement of cell death after culture, transfection of CD34+ differentiated
cells and cell morphology by Giemsa staining. Dr. Isabelle Heinisch conducted the
westernblotting separations. Protocols were modified and adjustments of cell culture
times were discussed in accordance with the results obtained.
Neutrophil granulocytes play a key role in the innate immune system protecting
the host from invading bacteria. Neutrophils are produced in great number in the
bone marrow, and released into the blood stream. Once a neutrophil is released into
circulation and tissue, it remains there only a few hours. In the absence of activating
stimuli provided by invading bacteria, neutrophils undergo spontaneous apoptosis
(programmed cell death) and are cleared by phagocytes. This cellular homeostasis
must be tightly regulated to provide an effective host defence and to avoid self-
damage.
Apoptosis seems to be critically involved in the control of elimination of cells within
the body and thus contributes to the maintenance neutrophil turnover in the
circulation, helping to keep a balance between cell proliferation and cell death
(Weinmann et al.r 2003). A dysregulation of neutrophil apoptosis may contribute
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to the expansion or the reduction in the number of peripheral neutrophils in the
pathogenesis of leukaemia and infections (Weinmartn et ah, 2003).
Tyrosine phosphorylation, controlled by the coordinated action of protein tyrosine
phosphatases (PTPs) and kinases (PTKs), is a critical control mechanism for
numerous physiological processes, including growth and differentiation, cell survival
and death (Tonks and Neel, 1996). Tyrosine phosphatases containing SH2 domains
(SHPs) have been identified in a variety of species but only two SHPs exist in higher
organisms; SHP-1 and SHP-2.
SHP-1 is expressed at highest level in haematopoietic cells and in a murine model
of SHP-1 deficiency mice displayed a range of haematopoietic abnormalities (Tonks
and Neel, 1996). SHP-2 is expressed ubiquitously and a recent study has identified
mutation in human SHP-2 as the cause of the inherited disorder Noonan syndrome
and might also contribute for the pathogenesis of some leukaemias (Neel et ah,
2003). Moreover, Chan et ah, (2003) showed that SHP-2 function is critical for the
maintenance of a proper balance of ES cell differentiation, pluripotency and
apoptosis.
Phosphatase and tensin homologue (PTEN) is one the most frequently mutated
tumour suppressor in human cancer and it is also essential for embryonic
development. Functions of PTEN have been identified in the regulation of many
normal cell processes including growth and apoptosis (Yamada and Araki, 2001;
Di Cristofano and Pandolfi, 2000).
Pathways regulated by the two SHPs have been specified and several potential
targets identified. Remarkably, despite their shared domain structure and
considerable (55%) overall sequence identity, the SHPs appear to have different
roles. Early studies indicated that SHP-1 was predominantly a negative regulator
of PTK signalling, whereas SHP-2 played a positive (i.e. signal-enhancing) role
(Tonks and Neel, 1996).
To get a better understanding of the role of tyrosine phosphatases involved in the
regulation of neutrophil survival and cell death we investigated the expression of
the SHP-1, SHP-2 and PTEN in ex vivo cultured CD34+ haematopoietic stem cells.
Our working hypothesis is that either a balance between the inhibitory tyrosine
phosphatase SHP-1 and the activating tyrosine phosphatase SHP-2, or the
equilibrium between phosphatases and kinases might regulate the commitment of
neutrophils to cell death before well-defined apoptotic changes occur (I. Heinisch et
ah, unpublished data). Furthermore, we assume that SHP-1 regulates spontaneous
neutrophil cell death, and SHP-2 prolongs neutrophil survival and the balance of
SHP-1 and SHP-2 determines neutrophil cell fate. SHP-2 is very weakly or not
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expressed in healthy peripheral blood neutrophils, and expression could not be
induced by the survival factor GM-CSF (I.Heinisch et ah, unpublished data).
Furthermore, we showed (I.Heinisch et al., unpublished data) that in two leukaemic
cell lines K562 and KG-1 an inverse SHP-l/SHP-2 balance in favour of SHP-2, can
be found, which might explain the failure of cell death in these cells. The purpose of
this collaboration is to evaluate the use of our ex vivo CD34-derived neutrophils as
an in vitro differentiation model to further test this hypothesis, and to follow up the
expression and function of the phosphatases SHP-1 and SHP-2 and PTEN on
neutrophil differentiation.
4.2 Experimental procedure
CD34+ cells were cultured in the presence of SCF/Flt-3L for 7,14, 21 day with or
without the addition of G-CSF. Whole cell lysates were collected at each time point
and SHP-1, SHP-2 and PTEN expression studied by Western blotting. As
demonstrated in Chapter 3, CD34+ cells cultured for 14 days in the presence of G-
CSF resemble functionally mature neutrophils in many respects while in the absence
of G-CSF the expanded CD34+ cells expressed few mature neutrophil functions.
Cells were collected at different stages of the differentiation process and were also
transfected with a SHP-1-GFP (and control GFP) construct in order to investigate
the effect of SHP-1 on the life span of these cells. The SHP-1 -GFP plasmid was a




Two forms of SHP-1 (one of 62kDa and 70kDa) were detected. Neutrophils isolated
from healthy adults as well as in vitro differentiated neutrophils from CD34+
haematopoietic cells cultured for 14-days expressed a 62kDa and 70kDa form of
SHP-1. In contrast, the promyelocytic leukaemic HL-60 cells only expressed the
70kDa form or no SHP-1 at all (Figure 4.1) (Heinisch, I et al, manuscript in
preparation).
Healthy neutrophils expressed higher amounts of the 62kDa SHP-1 band than
70kDa SHP-1 band (Figure 4.1a) whereas ex vivo expanded CD34+ cells expressed
higher amounts of the 70kDa than the 62kDa SHP-1 (Figure 4.1b). There was no
difference in SHP-1 expression between cells cultured for 14 days in the presence or






Fit;lire 4.1 SHP-1 expression in peripheral blood neutrophils, HL-60 cell line and G-CSF-
stimulated CD34+ cells at 14 days ex vivo.
SHP-1 expression in a) healthy neutrophils (PMN) and HL-60 (promyelocytic leukaemic cell line) b)
ex vivo differentiated neutrophils from CD34+ cells after 14 days culture with SCF/Flt3-L and with
(+) or without (-) G-CSF.
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To follow SHP-1 protein expression during the in vitro differentiation process CD34+
cells were analysed in terms of SHP-1 expression at day 7,14 and 21 days. There is
a reduction of the 70kDa SHP-1 expression as the cells differentiate towards a more
mature neutrophil cell population with almost no expression at day 21. There also
seems to be a reduction of 62KDa SHP-1 band with its disappearance at day 21
(Figure 4.2). There was not a significant difference in expression between cells
cultured in SCF/FLt3-L alone or with the addition of G-CSF or TPO at any time
point analysed. However, this reduction of SHP-1 expression seems to be slightly
enhanced by the addition of G-CSF (Figure 4.2).
7 days 14 days 21 days
+ + - + + - + +
TPO TPO TPO
Figure 4.2 SHP-1 expression in G-CSF-stimulated CD34+ cells at 7 day intervals.
Ex vivo differentiated neutrophils from CD34+ cells after 7,14 and 21 days culture with G-CSF(+),
without it (-) or with G-CSF and TPO (+ TPO) or without TPO (-TPO)(all cultures included SCF/FH3-
L). At day 0 and 7 of the culture where more immature cells were found, the 70kDa band is much
stronger compared to the 62kDa band. As long as the cells mature tire upper 70kDa band got
smaller. Similarly, as the cells differentiate towards a more mature neutrophil cell population the
SHP-2 band got slighter. Beta actin is added as a loading control.
Extended in vitro CD34+ differentiation for up to 21 days resulted in 93.8% apoptosis
and protein analysis at this time point was not possible anymore.
Increase of culture period resulted in an increase of mature neutrophils in culture
and correlated with an increase of Annexin-V staining (Figure 4.3). At day 7 of
culture, with or without G-CSF, most of the cells retained high proliferative capacity
and low expression of Annexin-V (19.84% SCF/Flt-3L alone compared to 29.77%
(SCF/Flt-3L+G-CSF). At day 14 of culture more functional differentiated neutrophils
are found with the presence of SCF/Flt-3L+G-CSF compared to with SCF/Flt-3L
alone (see also Chapter 3). Thus some mature neutrophils cultured with SCF/Flt-
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3L+G-CSF started to apoptose showing a higher expression of Annexin-V (50.19%)
compared to SCF/Flt-3L alone (26%). At day 21 almost all the cells cultured in the
presence of SCF/Flt-3L+G-CSF were apoptotic (93.80%) compared to cells cultured
with SCF/Flt-3L alone (45.11%). Double staining with propidium iodide (PI)
confirmed that these cells die due to apoptosis and not because of necrosis. The
morphology of cultured cells at the different time points are shown in Figure 4.4.
Cells at day 7 had an undifferentiated morphology in both SCF/Flt-3L alone or
SCF/Flt-3L+G-CSF. The addition of G-CSF increased expression of granulocytic
cytoplasm and the frequency of segmented nuclei at day 14 compared with cells
cultured with SCF/Flt-3L alone, and at day 21 of culture cells started to blast and
die.
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Figure 4.3 Apoptosis and cell death in CD34+ cells at 7 day intervals with/without G-CSF.
Measurement ofcell death after 7, 14,21 days of culture with SCF/Flt-3L with or without G-CSF by
PI uptake and Annexin-V staining determined by flow cytometry.
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a) Day 7 of culture with SCF/Flt3-L
c) Day 14 of culture with SCF/Flt3-L
34
e) Day 21 of culture with SCF/Flt3-L
b) Day 7 of culture with SCF/FH3-L+ G-CSF
© a
d) Day 14 of culture with SCF/Flt3-L+G-CSF





Figure 4.4 Morphology in CD34+ cells at 7 day intervals with/without G-CSF..
Cell morphology after 7. 14, and 21 days of culture with SCF/Flt-3L with or without G-CSF.
4.3.2 SHP-2 and PTEN expression
There is no or very weak expression of SHP-2 in peripheral blood neutrophils from
healthy donors (I.Heinisch et al, unpublished data). In contrast to mature
neutrophils, high levels of SHP-2 were detected in CD34+ expanded cells. There is a
considerable reduction of the SHP-2 expression as the cells differentiate towards a
more mature neutrophil cell population with a minimal level of expression at day
21. However, there was not a significant difference in expression between cells
cultured in SCF/FLt3-L alone or with the addition of G-CSF or TPO (Figure 4.2).
The expression of protein tyrosine phosphatase (PTEN) in CD34 differentiated cells
was comparable with that of mature neutrophils isolated from healthy adults
(I.Heinisch et al, unpublished data) (data not shown).
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4.3.3 Cord blood samples versus G-CSF mobilised samples
CD34+ differentiated cells from cord blood or from G-CSF mobilised PBSC samples
had the same SHP-1 and SHP-2 expression pattern (data not shown). All the samples
used above were mobilised peripheral blood.
4.3.4 Transfection of CD34+ differentiated cells
CD34+ derived neutrophils were successfully transfected at different stages of
maturation using the Amaxa electroporation system. Cells transfected with SHP-1 -
GFP construct resulted in increased induction of cell death in comparison with cells
transfected with a control GFP construct (Figure 4.5).
The same result was seen using promyelocytic leukaemic HL-60 cells (data not
shown).
Figure 4.5 Transfection of CD34+ differentiated cells
Ex vivo differentiated cells were successfully transfected. Flow cytometry analysis (a.b) FCS/SSC,
(c,d) double staining with PI-PE and GFP-FITC, (e.f) R2 gated GFP-positive cells double staining
with PI-PE and GFP-FITC. SHP-I GFP expression induces cell death of these CD34+-derived
differentiated cells (72%) compared to 58% when the cells were transfected with control-GFP.
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4.4 Discussion
Neutrophil turnover is very rapid and a tight homeostasis has to exist to guarantee
control of functionality. An ex vivo protocol for the generation of neutrophils from
CD34+ cells was employed to simulate in vivo neutrophil differentiation. This was
used to test if this tight equilibrium was due to the balance between the inhibitory
phosphatase SHP-1 and the activating phosphatase SHP-2 and whether an
unbalance equilibrium of these phosphatases is the cause of situations like leukaemia.
Higher expression of SHP-2 over SHP-1 is detected in leukaemic cell lines whereas
healthy mature neutrophils do not express SHP-2. Ex vivo generated neutrophil
precursors at different stages of their differentiation process (at day 7 and 14)
expressed SHP-2 with no apparent difference over the time period analysed.
However, SHP-2 expression was hugely reduced at further culture times (day 21)
when cells reached total maturity. SHP-2 is known to be an activating phosphatase
and might be present while the cell is able to proliferate, possibly as a survival
factor. At day 14 ex vivo expanded cells are still able to proliferate and SHP-2
expression might need completion of cell maturity to be switched off.
SHP-1 is expressed in healthy neutrophils at 70kDa. A different lower molecular
weight form of SHP-1 (62kDa) can be found in both healthy individuals or in ex
vivo generated neutrophil precursors. Myelocytic leukaemic cell lines only expressed
the 70kDa SHP-1 band or no SHP-1 at all.
The two SHP-1 forms were detected in both ex vivo generated neutrophil precursors
cultured with SCF/Flt-3L alone, with SCF/Flt-3L+G-CSF or with SCF/Flt-3L+TPO
at day 7 and 14. We hypothesised that SHP-1, known as an inhibitory phosphatase
(Tonks and Neel, 1996), would increase or maintain its expression during neutrophil
maturation and together with a reduction of SHP-2 expression be responsible for
inducing neutrophil cell death. Cells transfected with a SHP-1-GFP construct resulted
in an increased induction of cell death. Leukaemic cell lines have a SHP-l/SHP-2
balance in favour of SHP-2 expression. Thus, we hypothesised that the loss of SHP-
1 was the reason why leukaemic cell lines lost the ability to apoptose. However,
SHP-1 expression did not increase during neutrophil maturation. SHP-1 expression
was detected in very early stages of CD34+ cell differentiation.
Two different SHP-1 bands were detected in our samples. Mature peripheral blood
neutrophils expressed more of the lower molecular weight SHP-1 band (62kDa)
than the higher molecular weight SHP-1 band (70kDa) whereas CD34 cells showed
stronger expression of the 70kDa band compared to the 62kDa SHP-1 band. Ex
vivo generated neutrophils showed a significant decrease of expression in the 70kDa
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band as they differentiated towards the neutrophil lineage as well as a slightly
decrease of the 62kDa band with almost no expression at day 21. Healthy neutrophils
have a stronger expression of the 62kDa band over the 70kDa band. Therefore,
expanded mature neutrophils at day 21 have a very distinct SHP-1 expression which
is different from isolated healthy neutrophils. Further studies are needed to
understand SHP-1 expression pattern though neutrophil differentiation. Whether
a balance of the two SHP-1 forms regulates neutrophil cell death and what
physiological consequences this might have is currently under investigation.
There are four different transcripts of this gene due to alternatively spliced mRNA.
Therefore, the two bands could be due to differentially spliced mRNA transcripts. It
is intriguing that leukaemic cell lines only expressed the 70kDa or no SHP-1 at all.
Any relevance to leukaemia awaits further investigation.
In summary, the use of our in vitro CD34+ neutrophil differentiation system is a







The recent work describing stem cells with regenerative capacity for a variety of
tissues has encouraged a number of groups to pursue stem cell based solutions for
clinical problems in specific tissues. However, in most cases it is not known if or
where stem cells may reside in specific tissues, how to recognise such cells, how to
access and harvest such cells for clinical procedures, and whether such cells persist
in damaged or diseased tissue. Unlike cases where haematopoietic stem cell
transplant can be employed, where there is innate or myeloablation-induced
immunity deficiency which can permit allograft HSC use, in most other tissue repair
circumstances the potential patients have intact immune systems which would reject
allograft stem cells, restricting practical clinical solutions to autologous stem cells.
Concurrent and compatible concepts that pluripotent stem cells originate in bone
marrow and transit via circulating blood to sites where they are required for tissue
repair, coupled with the success of bone marrow or blood sources of HSC in clinical
haematopoiesis restoration and the availability of these sources for clinical use, has
stimulated examination of bone marrow or blood mononuclear cells as sources of
cells for repair of other tissues. While there is an accumulating body of experimental
evidence for generation of a variety of tissue-differentiated cells from, especially,
bone marrow, the precise cells from which such differentiated cells arise and the
processes by which these outcomes take place remain obscure, as was discussed in
the general Introduction (Chapter 1).
Many such differentiation phenomena have been described for in vitro
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investigations, and have proved difficult to reproduce in experimental animal studies,
let alone develop for clinical application. However, there are two emerging
phenomena deriving from the bone marrow/blood repertoire which are beginning
to build consistent reproducible characterisation in laboratory and animal
experimentation and in clinical investigation and application. These are centred
around mesenchymal stem cells (MSC) and on endothelial progenitor cells (EPC).
The mesenchymal stem cells (or marrow stromal cells) are in part defined by their
ability to differentiate into either bone, cartilage or fat under appropriate stimuli in
vitro, and it is probable that their main clinical use will be in bone or cartilage
regeneration. However, they have been attributed with the ability to differentiate
into a variety of other tissues, including endothelium, and therefore they will be
discussed tangentially below (see 5.1.10). The endothelial progenitor cells are the
focus of the remainder of this thesis, and will be reviewed in detail.
Current concepts of endothelial progenitor cells and their role in vascular repair
and regeneration represent a convergence of perspectives from transfusion medicine,
transplant immunology and haematology, including HSC transplantation, which
is the background of our laboratory and clinical interests, with perspectives from
cardiovascular experimental and clinical research and from recent embryology and
developmental biology developments. These have caused a paradigm shift from
the concept that in post natal life vascular repair and regeneration arose only from
outgrowth and budding from existing mature vasculature, to a recognition that
significant vascularisation and angiogenesis results from a contribution from
endothelial progenitor cells (EPC) requisitioned from a circulating population that
may originate in bone marrow from a common precursor of EPC and HSC.
It has been known for many years that during embryo development blood and the
vascular system develop from a common stem cell termed the haemangioblast.
The recent demonstration by Asahara et al, (1997) that a subpopulation of cells
apparently within the HSC (CD34+) population can differentiate into endothelial
cells (EC) has stimulated a range of experimental studies which support the existence
and role of endothelial progenitor cells and their precursor, a haemangioblast with
dual haematopoietic and vasculogenic potential, in the adult. This has also
stimulated clinical trials employing HSC sources to remedy tissue ischaemia, which
have on the whole indicated clinical benefit. In some cases such as critical limb
ischaemia increased vascularisation can be demonstrated directly. In other cases
such as myocardial ischaemia the recovery of myocardium might be due to a
contribution by myocardial stem cells or transdifferentiating HSC in the locally
injected autograft, as was originally sought, but is increasingly being attributed to
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revascularisation by the autograft of infracted tissue permitting myocardial recovery
from dormant local myocardial cells. This is supported by post-mortem or biopsy
examination of tissue from solid organ or HSC allograft recipients, where the most
extensive circulatory contribution of crossover cells to local tissue is to vascular tissue
where e.g. in transplanted heart host cells may reach almost 25% of vascular
endothelial cells (Minami et al., 2005).
While increasing numbers of clinical trials indicate benefit in both cardiac and critical
limb ischaemia, such trials have mostly employed autologous haematopoietic stem
cell sources, mainly bone-marrow, but also G-CSF mobilised PBSC. While such
sources can be assessed for haematopoietic potential by CD34+ cell content, there is
no equivalent agreed phenotype definition for EPC or assessment criteria for clinical
efficacy. Intriguingly there are reports in which CD34+-low cultured normal
peripheral blood MNC (not HSC enriched by G-CSF infusion) are as efficacious as
CD34+-high fresh bone-marrow MNC in autograft treatment of acute myocardial
infarct cardiac by intracoronary infusion (Assmus et al., 2002). Neither is there any
consensus on which cell, or cells, in the graft are critical for mediating vascular
repair, nor which source (bone-marrow, normal peripheral blood MNC, mobilised
PBSC) is best, which agent may mobilise EPC to the circulation, whether
subpopulation-enriched cell sources are better clinically, or whether clinical
performance can be enhanced by ex vivo stimulation.
In the face of an uncertain phenotype, the EPC colony forming unit assay (CFU-
EPC) has emerged as an alternative specific enumeration system for EPC. Hill et
al., (2003) first described a version of this colony assay based on spontaneous
mononuclear cell colony outgrowth on fibronectin coated plates in simple medium
without growth factors, in which these colonies stained for mature endothelial
markers. Hill et al., (2003) used the assay to assess whether the level of circulating
endothelial progenitor cells correlated withthe presence or absence of conventional
cardiovascular risk factors (Hill et al., 2003). This colony assay is available as a
standardized commercial kit which should allow inter-laboratory comparison of
results, and has been applied in a number of recent studies of different clinical
conditions either alone (Hill et al., 2003; Burnham et al., 2005; Ghani et al., 2005;
Hoetzer et al., 2005; Sugawara et al., 2005) or together with phenotype studies
(Grisar et al., 2005; Laufs et al., 2005; Lev et al., 2005), to demonstrate increased or
reduced numbers of circulating endothelial progenitor cells.
In this thesis we compare available putative autologous EPC sources by phenotype
and in vitro functional characteristics which may indicate parameters for prediction
of clinical efficacy of these sources, and also in Chapter 6 study expression of these
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characteristics in certain clinical groups who may be candidates for EPC autograft
therapy
5.1.2.The haemangioblast as precursor of both HSC and EPC
5.1.2.1 The embryonic haemangioblast
Vasculogenesis is de novo formation of blood vessels from the in situ differentiation
of undifferentiated mesodermal cells into endothelial cells. Mesodermal precursor
cells named haemangioblasts were first identified in chick blastoderms (Sabin, 1920;
Murray 1932). In culture these cells were shown to produce both blood and
endothelial cells (Murray 1932). It was proposed that endothelial and haematopoietic
stem cells due their close development within the yolk sac arise from a common
precursor; the hemangioblast progenitor cell (Risau and Flamme, 1995; Tavian et
al., 1996; Bailey and Fleming, 2003; Oberlin et al., 2002; Asahara et al, 1997).
Classical studies in developmental biology have used amphibians to examine
embryogenesis but the general principles of embryonic development are maintained
in higher organisms (Zon, 1995). The process begins in the embryo with the
formation of cell clusters or blood islands, which initially contain a homogenous
collection of progenitor cells, presumed to be haemangioblasts. With development,
endothelial progenitor cells (EPCs) are located at the periphery of the blood islands
and an inner layer of red blood cell precursors haematopoietic stem cells (HSCs)
are found in the centre of the blood islands (Cogle and Scott, 2004). The process of
haematopoiesis begins in the yolk sac blood islands, which primarily producing
nucleated red blood cells and goes in the intra-embryonic sites of blood produce
(Zon, 1995; Yoder and Hiatt, 1997; Kennedy et al., 1997). Concurrently the
angioblasts derived from endothelial progenitors begin to form lumens via a process
called vasculogenesis. Later in development, an area described as the para-aortic
splanchnopleura mesoderm contains haemangioblasts, giving rise to both intra-
embryonic blood vessels and definitive haematopoiesis (Dieterlen-Lievre et al., 2002).
Growth and fusion of the multiple blood islands ultimately give rise to the capillary
network structure (Cogle and Scott, 2004). After that, this network differentiates
into an arteriovenous vascular system; EPCs give rise to vascular ECs, whereas
HSCs develop into mature blood cells (Cogle and Scott, 2004).
Investigation of development of the early human embryonic haematopoietic and
vascular systems showed similar results. The accumulation of CD34+ cells densely
clustered on the ventral wall of the developing aorta was seen during the fifth week
of gestation (Tavian et al., 1996). Phenotypic characterization of these intra-aortic
110
clusters revealed both haematopoietic and endothelial cells. Moreover highly purified
human embryonic endothelial cells were shown to produce both myeloid and
lymphoid haematopoietic colonies (Oberlin et al., 2002).
The differentiation of HSC and EPC appear to be closely related both temporally
and physically. Both share a number of surface markers in the developing yolk sac
and embryo and genetic disruption of numerous genes affects haematopoietic and
endothelial development (Ingram et al., 2005). Targeted gene mutation studies using
the ES in vitro culture system have been used to evaluate the molecular signals that
specify haematopoietic and endothelial outcomes. This approach has identified
several genes such as Flk-1, cloche, SCL, Runxl which may play important roles in
the development of both endothelial and haematopoietic systems (Bailey and
Fleming, 2003).
Flk-1 deficient mice embryos die in utero between days 8.5 and 9.5 as a result of
haematopoietic and endothelial defects (Shalaby et al., 1995). Mutation of the cloche
gene in zebrafish affects both endothelial and haematopoietic lineages at a very
early stage (Stainier et al., 1995). Notably these mutant embryos are both deficient
in viable blood cells and lack an endothelial lining of the heart (Cogle and Scott,
2004). SCL-/- embryos contained no primitive or definitive HSCs in the yolk sac
although they develop a primary vascular network (Robb et al., 1995; Shivdasani
et al., 1995). On the other hand, Runx-1 deficient embryos (a mouse homologue to
human AML-1) produce normal blood islands and develop primitive erythrocytes
but they have a complete block in definitive haematopoiesis resulting in death
between day 11 and 13 of gestation (Wang et al., 1996; Okuda et al., 1996).
HSCs appear to be critical for early embryonic blood vessel development. Wild-
type HSCs rescue impaired angiogenesis in acute myeloid leukaemia 1 (AML-1)-
deficient embryos (Takakura et al., 2000).
Several lines of investigation demonstrated that many of the genes activated during
early haematopoietic development are also expressed in the vascular endothelium
such as Flk-1, Tie-2, c-Kit, Sca-1, CD133 and CD34 (Murasawa and Asahara, 2005).
In vitro ES cells express genes common to both haematopoietic and endothelial cell
lineages including Flk-1 and CD34. ES cell derived embryoid bodies (EB) give rise
to a transient precursor blast colony forming cell (BL-CFC) which when
differentiated can generate primitive erythrocytes, multilineage haematopoietic cells
and an adherent endothelial population (Kennedy et al., 1997 Choi, 2002). However,
due to the low frequency of BL-CFC it is yet to be determined if all these
subpopulations are produced by a single EB-derived cell (Cogle and Scott, 2004).
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5.1.2.2 Postnatal vascularisation
Vasculogenesis also contributes to postnatal vascularisation, which requires the
mobilisation of bone marrow-derived endothelial stem cells, which home to sites of
ischaemia, and contribute to new blood vessel formation. Until recently, it was
thought that blood vessel formation in postnatal life was only mediated by sprouting
of endothelial cells from existing mature vessels (angiogenesis) (Reyes et ah, 2002).
The finding that vasculogenesis also exists in the adult life offers novel therapeutic
strategies for the use of circulating endothelial progenitor cells or their precursors
for cell therapy of tissue-ischaemia (Urbich and Dimmeler, 2005).
Adult blood vessel formation also occurs through other processes such as
arteriogenesis or angiogenesis. Arteriogenesis describes the growth of collateral
vessels, whereas angiogenesis refers to the growth of new capillaries to carry blood
to ischaemic tissues by sprouting of pre-existing vessels through migration and
proliferation of mature endothelial cells under the control of multiple factors in the
embryo and in the adult life (Urbich and Dimmeler, 2005; Moldovan et ah, 2000).
5.1.2.3. Evidence for an adult hemangioblast
In contrast to embryonic development, the complex functional relationships between
haematopoiesis and the vascular compartment in postnatal life have only recently
been investigated (Montfort et ah, 2002). For many years, it had been assumed that
the haemangioblast was a transient bipotent cell restricted to the developing blood
and vascular system of the yolk sac and in the early embryo (Bailey and Fleming,
2003). Recent evidence suggests that a sub-set of progenitor cells having a function
resembling that of the embryonic haemangioblast is present in adult bone marrow.
These cells, and their endothelial lineage progeny termed endothelial progenitor
cells (EPC) can be actively recruited to the peripheral circulation, can migrate to
ischaemic tissues and to tumour microenvironments and can differentiate into
mature endothelial cells (Ingram et ah, 2005; Zammaretti and Zisch, 2005; Asahara
et ah, 1997; Asahara et al. (a),1999; Hristov et ah (a), 2003).
The first evidence for an adult stem cell contributing to blood vessel production was
reported in 1997 when Asahara et ah identified in humans circulating EPCs
contributing to active sites of neovascularisation. Subsequently Raffi's group (1998)
reported the existence of circulating bone marrow derived endothelial progenitor
cells in the adult (Shi et ah (a), 1998). Most convincingly, evidence for a bone marrow
derived circulating adult EPC has come from transplantation of specific subsets of
bone marrow cells (Shi et ah (a), 1998; Shi et ah (b), 1998). Shi et ah, (1998)
demonstrated that a subset of transplanted human bone marrow derived cells
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participated in the endothelisation of implanted Dacron grafts in a canine model of
vascular graft healing (Shi et al. (a), 1998; Shi et al. (b), 1998). Transplantation of
adult mouse bone marrow side population cells (SP) into irradiated mice, followed
by myocardial injury, resulted in donor-derived endothelial cells in the region of
injury repair (Jackson et al., 2001). Moreover Grant et al., (2002) using serial long-
term transplants, in a mouse injury model of diabetic retinopathy, to ensure that
activity arose from self-renewing stem cells, found that clonal progeny of a single
bone marrow (c-Kit+, Sca-1+, lineage-negative) cell (KSL) exhibited functional
haemangioblast activity. These clonally derived cells differentiated into all
haematopoietic cell lineages as well as endothelial cells with the formation of donor-
derived functional blood vessel which integrated into the vascular system. Moreover,
mice transplanted with bone marrow derived KSL cells following irradiation were
found to have donor derived endothelial cells in many tissues (Bailey et al., 2004).
Cell fusion was excluded as the principal mechanism responsible for the generation
of functional endothelial cells in these two cases.
Transplanted EPCs incorporated into sites of active angiogenesis and differentiated
into mature ECs with clear benefits of augmentation of angiogenesis and
collateralisation in animal models of tissue ischaemia (Kalka et al. (a), 2000;
Kawamoto et al., 2001; Murohara et al., 2000).
Furthermore, Reyes et al., (2002) have isolated a population of multipotent adult
progenitor cells (MAPC) from human bone marrow, which in culture differentiated
into cells with phenotypic and functional characteristics indistinguishable from
mature endothelial cells. In vitro generated MAPC-derived endothelial cells
responded to angiogenic stimuli by migrating to tumour sites and contributed to
tumour vascularisation in a mouse model of tumour and wound neoangiogenesis
(Reyes et al., 2002).
Some human HSC subsets such as CD34+VEGFR2+ cells have been shown to
generate, at a single cell level, both haematopoietic and endothelial cells in culture
(Pelosi etal., 2002).
All these findings support the hypothesis that cells with hemangioblast activity reside
within adult bone marrow. However, in the absence of a definitive haemangioblast
phenotype it is impossible to be certain that de novo vascularisation following
transplantation of specific subsets of bone marrow cells is not due to HSC or EPC,
as all these cell types share expression of surface markers. To address the question
of haemangioblast activity in the adult, single cell transplantation experiments must
be performed in order to demonstrate the existence of a cell that is capable of
generation of both haematopoietic and endothelial cell outcomes (Bailey and Fleming,
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2003).
It will also be important to evaluate the interaction between blood vessels and blood
production. There is preliminary evidence that HSC transplantation efficiency
increases when HSC are co-cultured with endothelial cells, (Chute et al. (a), 2004;
Chute et al. (b), 2004). These studies indicate that blood vessels either prime HSC
by providing survival and proliferation factors or directly serve as a haematopoietic
repopulation cell source. However it is yet to be determined if the vascular
endothelium has the potential to differentiate into haematopoietic cells (Cogle and
Scott, 2004).
Currently, it is thought that EPCs involved in neovascularisation are bone marrow-
derived cells which are mobilised into the systemic circulation in response to certain
cytokines and/or tissue ischaemia and home into sites of neovascularisation.
However, it is possible that resident tissue-specific stem cells are responsible for
regenerating damaged tissue and maintaining tissue homeostasis. Recently tissue
resident c-Kit+ cells isolated from the heart have been shown to differentiate into
endothelial lineage cells (Beltrami et al., 2003).
Similarly, Wurmser et al., (2004) demonstrated that neural stem cells could
differentiate into endothelial lineage cells in vitro and in vivo. These findings suggest
that it is possible that stem cells remain in some/all tissues and organs beyond
embryonic development and that these stem cells can self-renew and generate cells
of different lineages in case of cell damage and senescence (Guo et al., 2003).
5.1.3 Identification of endothelial progenitor cells
Interest in circulating angiogenic cells comes from at least 30 years ago when
circulating cells with endothelial cell morphology were isolated from a variety of
experimental models of vascular injury (Wright and Glacometti, 1972; Yarnal and
Hollis, 1974). Further investigation was hampered by the lack of reagents to
specifically identify these cells as endothelial cells. Even though definitive marker(s)
for endothelial cells have still to be identified the discovery of monoclonal antibodies
and the use of magnetic bead-immunoselection and/or fluorescence-activated cell
sorting have improved our ability to isolate, enumerate and characterize endothelial
progenitor cells (EPCs) and circulating mature endothelial cells (CECs). Even though,
these cells remain very rare in the adult peripheral blood (0.01% CECs and 0.0001%
EPCs) (Ingram et al., 2005).
Typically, mononuclear cells are isolated from bone marrow, peripheral blood and
cord blood by density gradient centrifugation. These may then be subpopulation-
enriched by separation by magnetic beads or by flow cytometry with antibodies
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against surface antigens such as CD34 or CD133. Although there has been an intense
effort to define EPC and CEC cell populations, there is still no consensus on their
exact phenotype definition and it is still unclear what cell type(s) induced angiogenesis
(Ingram et al., 2005). Given the similarities between blood and blood vessel
production in the embryo, HSCs were initially proposed as candidates for an EPC
precursor in the adult (Asahara et al., 1997). The EPCs identified by Asahara et al.,
1997 were in a fraction of adult bone marrow which comprised 15% CD34+ cells. In
vitro these cells generated spindle-shaped cells, defined as endothelial cells based
on morphology, expression of surface markers and immunohistochemical staining.
The circulating EPC reported by Shi et al., (1998) were also derived from a CD34+
HSC subset. These cells differentiated to the endothelial lineage, expressing von
Willebrand factor (vWf) and incorporated acetylated low-density lipoprotein (ac-
LDL). Similarly, the endothelisation of Dacron grafts implanted in a canine model
of vascular injury was derived from a CD34+HSCs bone marrow subset (Shi et al.
(a), 1998; Shi et al. (b), 1998). According to these initial discoveries, EPCs were defined
as cells that share HSC markers such as CD34 and also express a more endothelial
specific marker such as vascular endothelial growth factor receptor 2 antigen
(VEGFR2) also termed (in humans) kinase insert domain receptor (KDR) (equivalent
to Flk-1 in mice).
Since then, attempts to define and quantify the number of EPCs in different
experimental and clinical situations have grown year by year. However, it is still
difficult to distinguish an immature EPC from primitive HSCs, due to their shared
expression of common markers. Furthermore, neither of these markers are specific
for EPCs alone or together because VEGFR2 and CD34 are also expressed by mature
endothelial cells. The lack of specific EPC markers complicates the detection and
quantification of true EPCs in the circulation. The discovery of CD133 permits the
detection of more primitive HSCs (www.miltenyibiotec.com). During maturation
CD133 expression is lost by both EPCs and HSCs, whilst VEGFR2 expression is
maintained only by EPCs throughout maturation (Hristov et al. (b), 2003). Therefore,
hypothetically, the co-expression of these three markers (CD34+CD133+VEGFR2)
could identify an EPC population whereas positivity for CD34 and CD133 but not
for VEGFR2 (i.e. CD34+CD133+VEGFR2~) could be a more appropriate definition
of an HSC (Hristov et al. (b), 2003). Through differentiation EPCs begin to express
more mature endothelial markers such as VE-cadherin, CD31 (PECAM), CD146
(also known as S-endo), endothelial NO synthase, E-selectin and Von Willebrand
factor (Hristov et al. (b), 2003). Moreover, mature endothelial cells are supposed to
be CD45 negative (CD45 is expressed in all haematopoietic cells), actively take up
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the low-density lipoprotein (acetylated LDL) and bind ulex-lectin (UEA-1).
Currently, every group uses their own EPC definition, combining one, two or three
of these antigens (CD34/CD133/VEGFR2); summarised in Table 5.1. It is established
that the EPC population is in the mononuclear fraction of the total whole blood
cells, and accepted that EPCs share the CD34 marker with haematopoietic stem
cells. Some groups use expression of CD34 as their definition of an EPC, without
regard to co-expression of other markers (Asahara et al., 1997; Murohara, 2001; Shi
et al. (a), 1998). Others prefer the isolation of CD133+ cells as a better approach
since it discards any mature CEC which retain CD34 expression. For example some
CD133+ isolated cells differentiate into ECs in vitro under appropriate culture
conditions (Gehling et al., 2000; Kocher et al., 2001). Gehling et al., 2000 showed
that enriched CD133+ cells from G-CSF mobilised peripheral blood can be
differentiated along both endothelial and haematopoietic pathways. They also
demonstrated that injection of CD133+-derived cells together with tumour cells
enhanced tumour growth though tumour vascularisation and the vascular
component was derived from the injected human CD133+ cells. Overall, isolation of
CD133+ stem cells provides a selective population useful for transplantation and
tissue regeneration (Shmelkov et al., 2005). Most importantly, injection of CD34 or
CD133+ cells enhanced neovascularisation in animal models following ischaemic
injury (Asahara and Kawamoto, 2004; Hofmann et al., 2005) and recently,
transplanted CD133+bone marrow cells have been shown to improve function of
infarcted myocardium in human patients (Stamm et al., 2003). However, whether
enriched CD34+ and/or CD133 cells consist of a mixture of separate progenitors for
endothelial and haematopoietic cells, or whether there is a common precursor for
both lineages remains unknown.
Other groups have defined EPCs as a subset of CD34 cells also expressing VEGFR2
(KDR) antigen (Botta et al., 2004; Pelosi et al., 2002). Pelosi et al., (2002) identified a
"postnatal haemangioblast" in a CD34+KDR+cell subset with long term proliferative
potential and bi-lineage differentiation capacity. Alternatively, some studies have
recently demonstrated that CD133+VEGFR2+cells in the circulation have the capacity
to migrate and differentiate into adherent mature endothelial cells (Gehling et al.,
2000; Peichev et al., 2000; Quirici et al., 2001). Whereas others prefer to use a triple
positive EPC definition (CD34+CD133+VEGFR2+) (Peichev et al., 2000; Vasa et al.,
2001). Peichev et al., (2000) demonstrated that CD34+cells co-expressing CD133
and VEGFR2 have the capacity to migrate and differentiate into adherent mature
endothelial cells. It is very difficult to interpret and compare results between such
studies because each group uses their particular EPC definition based on their
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Table5.1Summarytofdifferent proposedEPCdefiniti ns EachgroupusestheirownPC definition,combiningone,tworthree oftheseantigens(CD34/CD133/ VEGFR2). +positive;Xnegatiblankottested.
5.1.4 Sources of endothelial progenitor cells
Identification of suitable EPC sources is of the highest importance as a prerequisite
for any clinical EPC use. If HSCs are the source of EPCs in adult life, sources rich
for HSCs are going to be the best candidates as an EPC reservoir. Bone marrow, G-
CSF mobilised blood and cord blood are sources with the highest number of HSCs
cells. In an autologous clinical context freshly isolated bone marrow mononuclear
cells, HSC-mobilised peripheral blood mononuclear cells, and the CD34+-enriched
or CD133+-enriched subpopulations of these have been injected locally in infarcted
myocardium or ischaemic limbs with, in most cases, some recorded clinical benefit
(see table 5.1.17 and table 5.2). While it cannot be used for autologous EPC
transplant, cord blood has also high numbers of HSCs and transfusion of severe
combined immunodeficiency (SCID) mice withhuman cord blood has demonstrated
repopulation of the bone marrow (Murohara, 2001). Cord blood HSCs were
differentiated to ECs in several experiments (Peichev et al., 2000; Murohara et al.,
2000). Pesce et al., (2003), showed that CD34+ cord blood cells injected into mouse
ischaemic adductor muscles gave rise to endothelial and to skeletal muscle cells.
Also, Boyer et al., (2000) showed that endothelial progenitor cells can be isolated
from cord blood and used to generate EC cultures as a source of cells for vascular
graft seeding and gene therapy. Currently, cord blood transplantation is allogeneic,
therefore CB-derived EPC could induce immunological reactions and thus implanted
cells would be rejected, in the absence of immunosuppression by the host's immune
defence mechanisms.
Shi et al. (a), (1998) proposed G-CSF administration as a therapy to mobilize and
increase EPCs in circulation since this is commonly used for HSC mobilisation.
Infusion of peripheral blood stem cells obtained by aphaeresis after G-CSF
administration was shown to increase vascularisation in patients after myocardial
infarction (Kang et al., 2004) and in limb ischaemia (Kawamura et al., 2005). Suzuki
et al., (2003) showed that G-CSF growth factor manipulation would be a low invasive
harvesting method and a good therapeutic strategy to ensure sufficient amounts of
progenitor cells for clinical application.
Peripheral blood, which is not rich in HSC, has been suggested as a possible source
of endothelial progenitor cells (Assmus et al., 2002). Peripheral blood MNCs were
enhanced ex vivo by culture on fibronectin and with the addition of growth factors
before use. In a comparative clinical trial of peripheral blood derived EPC versus
bone marrow derived EPC, implantation of both cell preparations into infarcted
myocardium gave similar positive effects showing an improvement of regional
myocardial contractility and viability (Schachinger et al., 2004). Peripheral blood
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has been generally overlooked as a source or stem cells because its low number of
HSCs. However it may have better potential than previously expected (Assmus et
al., 2002).
5.1.5 Gene expression profiling from various haematopoietic
stem cells sources
Comparative analysis of gene-expression profiles showed differential expression of
genes between different HSC sources. Several studies have demonstrated that cord
blood CD34+cells and G-CSF mobilised peripheral blood CD34+cells significally
differ from bone marrow CD34+ cells qualitatively and quantitatively (Ng et al.,
2004). Ng et al., (2004) showed that 51 genes differ between bone marrow and cord
blood stem cells and 64 genes between bone marrow and G-CSF mobilised peripheral
blood. The differential genes were mainly transcription factors, involved in cell-
cycle (proliferation, differentiation and apoptosis) and genes involved in stem cell
homing and adhesion. Few, if any, CD34+ G-CSF mobilised cells are in S phase, in
contrast to 30% to 60% of bone marrow CD34+ cells. The low expression of classic
markers of S phase and G2-M transition detected in G-CSF mobilised CD34+cells
in array analysis are in agreement with this quiescent phenotype (Graf et al., 2001).
Cord blood CD34+cells and G-CSF PB CD34+ cells showed reduced expression of
elastase, myeloperoxidase, and cathepsin G and lower CXCR4 than bone marrow
CD34+ cells. G-CSF mobilised CD34+cells also display a decrease of expression of
many cytokines, such as IL-8 (Graf et al., 2001).
5.1.6 Myeloid cells as EPC precursors.
Evidence is accumulating which demonstrates that endothelial cells can be generated
from bone marrow derived myeloid cells (Elsheikh et al., 2005; Schmeisser et al.,
2001; Urbich et al., 2003; Gulati et al., 2003; Rehman et al., 2003; Harraz et al.,
2001). Harraz et al., (2001) showed that CD34-negative CD14 monocytic cells had
the capacity to differentiate into endothelial cells. Moreover, Schmeisser et al., (2001)
showed that only CD14+CD34~ cell subtractions co-express endothelial and
monocyte/macrophagocytic markers and form tube-like structures ex vivo.
Likewise, infusion of bone marrow derived CD14+CD34" cells contributed to
endothelial regeneration, which was functionally active as shown by release of nitric
oxide (NO) (Fujiyama et al., 2003). Additionally, ex vivo expansion of purified CD14
mononuclear cells yielded cells with endothelial characteristics, which in vivo
incorporated in newly formed blood vessels (Urbich et al., 2003), and Fernandez-
Pujol et al. (2000) showed that under the appropriate culture conditions CD14+CD34~
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cells differentiate into EC-like cells exhibiting characteristics of both endothelial cells
and monocytes. Further, Ingram et al., (2005) suggested that monocyte-derived
EPCs have a similar capacity for augmenting neovascularisation as do HSCs or
cord blood derived EPCs in experimental models.
However, monocytes were thought to be mature stage cells with a limited potential
to proliferate in culture. Recently, it has been recognised that monocytes and
macrophages are difficult cell types to define in end stage terms. In fact, these cells
seem to be extremely flexible in their phenotype and function and could be
continuously adapting in response to changing microenvironmental states. Rohde
et al., (2005) demonstrated that recognised endothelial markers such as ac-LDL
uptake, lectin binding, and CD31, CD105, CD144 positive expression are also
genuine features of blood monocytes. Indeed, primary monocytes already expressed
most tested endothelial genes and proteins. Thus, this could indicate a closer
relationship and a possible common origin than previously thought between
endothelial and monocyte-macrophage lineage cells (Harraz et al., 2001).
Monocytes/macrophages are in intimate contact with endothelial cells of the blood
vessels and it is generally accepted that monocyte/macrophages can influence
angiogenesis by secretion of growth factors. However, it seems that they can also
have a more direct role in endothelial cell differentiation inducing neovascularisation
of injured vessels and in tumour vasculogenesis (Fernandez-Pujol et al., 2000). If
monocytes/macrophages are involved in the process of capillarisation not only by
the secretion of angiogenic growth factors but also by converting into a cell type at
least similar to endothelial phenotype, with the potential to form vascular channels,
this may offer new possibilities for diagnostic and therapeutic management of
patients with ischaemic diseases (Schmeisser et al., 2001).
5.1.6.1 CD14
CD14 was first described as a myeloid differentiation antigen in 1981 (Hailman et
al., 1994). It is a 55-KDa glycoprotein with multiple leucine-rich repeats and is encoded
on chromosome 5 (5q) together with granulocyte colony stimulating factor. CD14
is an important component of the innate immune system and has been identified as
the receptor for Gram-negative bacterial endotoxin (or lipopolysaccharide, LPS).
It is also implicated in initiating septic shock, through interaction of CD14 with
LPS complexed with LPS-binding protein (LBP) from plasma, but it also binds to
other bacterial products (Hailman et al., 1994, Kusunoki et al., 1995). Interestingly,
while endothelial cells are sensitive to low concentrations of LPS, it has been generally
accepted that endothelial cells do not express CD14 (Beekhuizen, et al., 1991).
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However, Jersmann et al., 2001 showed that vascular endothelial cells synthesized
and expressed CD14 both in vitro and in vivo on the cell surface and presented
evidence that the endothelial membrane-bound CD14 was functional in LPS-
mediated cell activation. However compared to monocytes, the number of CD14
molecules expressed on HUVEC was small.
5.1.7 Mature endothelial cells.
Endothelial cells (ECs) are a crucial component of the normal vascular wall, not
only providing a dynamic interface between blood and the extravascular matrix of
the blood vessel wall, but also as a source of molecules that influence both the
structural and functional integrity ofvessel wall permeability and circulation (Muller
et al., 2002). ECs are intimately involved with the processes of angiogenesis,
inflammation and thrombosis and there exists a considerably heterogeneity both
structurally and functionally of the vascular monolayers between different organs
(Cines et al., 1998).
ECs secrete a wide variety of molecules involved in formation of platelet and fibrin
thrombi such as von Willebrand factor (vWf). Indeed this monolayer of endothelial
cells acts as a non-adherent surface for platelets and leucocytes, is involved in immune
reactions and produces a variety of important regulatory factors such as
prostaglandins and nitric oxide (NO) (Cines et al., 1998). Von Willebrand factor, a
multimeric glycoprotein synthesized exclusively in ECs and megakaryocytes and
stored in Weibel-Palade bodies, is released from ECs and mediates initial platelet
adherence to the subendothelium by linking to specific platelet membrane receptors
(Mannucci, 1995; Muller et al., 2002). Mature endothelial cells also express PECAM-
1 (CD31), a 130 kDa transmembrane glycoprotein that plays a major role in a
number of cellular interactions. CD34 antigen is also express on mature endothelial
cells however, little is known about the significance and modulation of its expression
(Muller et al, 2002).
Unbalanced angiogenesis, resulting from excess or deficiency of blood vessel
formation is associated with certain disease states. Diseases such cancer, diabetic
retinopathy and rheumatoid arthritis are characterised by excessive blood vessel
formation. Peripheral and coronary ischaemia and infarction, chronic wound healing
failure and diabetic ulcers are characterized by damage to existing vessels and
possible failure of repair.
The frequency of circulating endothelial cells (CECs) in healthy blood is about 0.5-
2 cells/ml of whole blood. The basal level of endothelial turnover is low, however,
acute stress injury of the vascular endothelium causes an increase in CEC of up to
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10 fold or more (Blann et al., 2005; Dignat-George arid Sampol, 2000). Damage of
the endothelium results in EC death causing loss of the antithrombotic properties of
the vessel wall and enhances the number of circulating ECs.
CECs have been defined based on their morphology, their von Willebrand factor
intra-cellular staining and by the expression of CD146 (also known as S-endo).
Characterisation of CECs in a clinical setting has been performed by several groups
but has failed to further clarify their phenotype. Makin et ah, (2004) failed to identify
any CD146 CECs that co-stained with CD34. In contrast, Del Papa et al., (2004)
and Mancuso et al. 2001 defined CECs by the co-expression of CD146 and CD34,
whilst Zhang et ah, 2005 actually defined their CECs as those MNCs simultaneously
expressing CD105, CD146 and CD34. Almost all reports identified a rise in numbers
of CEC in a variety of pathological conditions and that this correlated with disease
severity and risk factors (Blann, 2006). Therefore, detection of CECs could be used
as a biomarker for predicting the presence and severity of vascular diseases (Dignat-
George and Sampol, 2000). Indeed the number of CECs may serve as diagnostic or
prognostic parameters of vascular injury and tumour growth (Hunting et al., 2005).
The hypothesis that cells in the adult circulation could proliferate, migrate and
contribute to growth of new endothelium and blood vessels dates back to (1963),
when Stump et al. suggested that new endothelium on the flow surface of the graft
was derived from blood borne cells. This was termed fallout healing and it was
unknown if it represented mature endothelial cells that detached from the mature
vascular wall or whether they were circulating endothelial cells. Fully differentiated
endothelial cells migrate to tumours and sites of injury from neighbouring blood
vessels (Hanahan et al., 1996, Holash et ah, 1999). However mature ECs are
terminally differentiated cells with a low proliferative potential and their capacity
to substitute damaged endothelium is limited. Therefore the repair may require the
support of other cell types and over the past few years it has become evident that
circulating EPCs were the responsible for that.
5.1.8 Endothelial growth factors
5.1.8.1 VEGF
VEGF is a homodimeric heparin-binding glycoprotein, an endothelial cell-specific
mitogen and survival factor, produced by most cell types. VEGF is an essential
determinant of hemangioblast differentiation into endothelial progenitor cells or
angioblasts, and haematopoietic stem cells (Risau and Flamme, 1995). It is possible
that VEGF may have a similar complementary function in adults to promote
vasculogenesis (Asahara et al. (b), 1999). In fact, VEGF has been shown to induce
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mobilisation of bone marrow derived EPCs and result in increased differentiation
of EPCs in vitro and to augment corneal neovascularisation in vivo (Asahara et al.
(b), 1999).
Members of the vascular endothelial growth factor (VEGF) family include five
structurally related members, VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental
growth factor (P1GF). VEGF-A acts mainly through the tyrosine kinase receptor 2
VEGFR2 (also known as kinase insert domain receptor (KDR), human homologue;
or Flk-1 murine homologue). VEGFR2 is a crucial receptor for transmitting cellular
signals for the proliferation, differentiation and migration of endothelial cells.
VEGF-B and P1GF only bind and activate VEGFR-1 (Flt-1). VEGFR1 might be
more important for vascular remodelling than for conveying signals essential for
angiogenesis and haematopoiesis (Neufeld et al., 1999). VEGF-C and VEGF-D bind
to both VEGFR2 and VEGFR3, and mediate angiogenic and lymphatic
neovascularisation signals, respectively (Cao, 2005). VEGF-C is also expressed in
various human cancers (Salven et al., 1998) and has a potent angiogenic effect in
vivo (Stacker et al., 2002, Cao et al., 1998). The role of VEGF and VEGFR2 in
haematopoiesis and angiogenesis is further supported by conventional gene
knockouts experiments, which resulted in early embryonic lethally owing to
impaired haematopoiesis and angiogenesis (Shalaby et al., 1995). The blocking of
VEGFR-1 with monoclonal antibodies successfully attenuated blood vessel formation
(Autiero et al., 2003).
PIGFs are members of a family that consists of PDGF-A,-B,-C and -D which are
structurally related to the VEGFs (Bergsten et al., 2001). PDGF-BB seems to be the
most promising pro-neovascularisation candidate, improving perfusion as well as
function in preclinical models of myocardium ischaemia (Post, 2002) inducing
collateralisation (Martins et al., 1994) and recruiting pericytes (Hirschi et al., 1999).
PDGF-CC has also been reported to be angiogenic (Cao et al., 2002).
Alternatively, it has been reported that VEGFR2 induces tyrosine phosphorylation
of the endothelial adherence junction components such as VE-cadherin (Esser et
al., 1998). Cadherins constitute a large family of membrane receptors involved in
calcium dependent homotypic cell-cell interactions. Endothelial cells contain two
types of cadherins; VE-cadherin, which is only found at endothelial adherence
junctions and N-cadherin, which is diffusely localised over the whole cell surface
(Angst et al., 2001). Absence of VE-cadherin leads to embryonic lethality at gestation
day 9.5 in mice because of calcium insufficiency (Carmeliet et al., 1999). Several
relationships between VE-cadherin and VEGFR2 have been reported recently.
Carmeliet et al., found that VEGF-dependent survival was dependent on expression
124
of VE-cadherin and Calera et al., (2004) proposed that VE-cadherin has an essential
role in maintaining the steady-state level of VEGFR2. Monocytes are thought to be
positive for VEGFR1 (Flt-1) but negative for the other two receptors of VEGF, VEGFR-
2 and -3 (Schmeisser et al., 2001).
To date there is little information on the endogenous regulation of growth factors
during conditions that favour neovascularisation The best described so far is the
hypoxia response system which is dependent on the oxygen tension. Hypoxia-
inducible factor 1 (HIF-1) induces transcription of angiogenic target genes such as
activation of VEGF gene expression (Kelly et al., 2003, Cao, 2005).
5.1.8.2 Fibroblast growth factors
Fibroblast growth factors (FGFs) have been shown to play an important role in
modulating vascular responses by increasing endothelial cell proliferation.
5.1.8.3 Insulin like growth factor
In vivo information on the angiogenic potency of insulin like growth factor (IGF-1)
is limited. IGF-1 is both cardioprotective against ischaemia and angiogenic (Su et
al., 2003), but concerns about aggrevation of diabetic retinopathy and coronary
artery disease (Delafontaine et al., 2004) have forestalled further clinical development
(Cao, 2005).
5.1.8.4 Hepatocyte growth factor
Hepatocyte growth factor (HGF) induces EPC mobilisation from the bone marrow
and enhances the proliferation of endothelial cells in vivo (Ishizawa et al., 2004).
There is growing evidence that protein and gene therapy with HGF improves blood
flow in various hindlimb (Morishita et al., 1999) and cardiac models (Ahmet et al.,
2003) of ischaemia. HGF/SF is currently in phase I trials in patients with peripheral
artery disease (PAD). Other growth factors are under study such as ascorbic acid,
which was shown to induce cardiac differentiation in ES cells (Takahashi et al.,
2003).
It is probable that in vivo most of the growth factors secondarily induce other factors
that are required to complete specialised tasks such as pericyte recruitment and it is
not known if a single growth factor could control a process so complex (Cao, 2005).
Numerous studies have shown that tumour growth and diabetic retinopathy can
be dependent on angiogenesis and angiogenic growth factors (for review see
Folkman, 2002; Witmer et al., 2003). However, little evidence exists as to how
exogenous growth factors actually simulate tumour growth and diabetic retinopathy
(Cao, 2005).
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Urbich et ah (a), (2005) compared the expression of potential angiogenic growth
factors by EPC and HUVEC cells. They found that the expression of and release of
growth factors such as VEGF-A, SDF-1, IGF-1 and HGF was higher in EPC by
comparison with HUVEC (mature endothelial cell line). Factors which can support
the survival and function of tissue residing cells in a paracrine manner, thereby
accelerating the process of new blood vessel formation and regeneration of ischaemic
tissues have been described as pro-angiogenic growth factors (Urbich et al. (a),
2005).
5.1.9 Ex vivo manipulation of EPC.
The ability to culture endothelial cells or endothelial-like cells from different sources
is important, since these rare cells can now be isolated and expanded for further
study. Isolation methods include the use of adherence to isolate cell subsets, the use
of specific monoclonal antibodies conjugated to magnetic microbeads or
fluorochrome to isolate specific cell populations by MACS or FACS respectively
from mononuclear cell pools of mobilised peripheral blood, cord blood or bone
marrow (Hristov et al. (a), 2003). Isolated putative EPCs are cultured in medium
with specific growth factors in order to expand and drive them to endothelial lineage
cells. The incubation in vitro with a mixture of growth factors, the adhesion on
specific substrates (e.g. on fibronectin, collagen or gelatin), or the contact with
extracellular matrix or with different cell types will influence their proliferation and
differentiation (Hristov et al. (a), 2003).
To date most of the experimental approaches to select EPCs are based on the plating
of low-density mononuclear cells on fibronectin-coated surfaces and growth in the
presence of endothelial growth factors such as VEGF (Vasa et al., 2001). Typically,
adherent cells have been classified as primary EPCs after 3-7 days on the basis of
endothelial-like morphology, endothelial markers, lectin binding, and uptake of
acetylated low-density lipoproteins or formation of tube-like structures on Matrigel.
(Walenta et al., 2005; Vasa et ah, 2001). Alternatively, MNCs have been pre-selected
for either CD34 or CD133 positive cells and then characterised by surface markers.
Although enriched CD34+ or CD133+ progenitors usually in the presence mostly of
VEGF can generate endothelial cells and exhibit revascularisation in vivo, these
cells represent a very small subset of the MNCs and only a minimal number of cells
can be isolated from mobilised blood, cord blood or bone marrow (Walenta et ah,
2005). However, if adherence related selection of cultured MNCs allows the recovery
of sufficient EPC numbers for therapeutic treatments.
Lin et ah, (2000) defined outgrowth endothelial cells (OEC), which developed after
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3 weeks in culture. Typically, they are endothelial cells with an extraordinary growth
capacity providing compelling evidence for a stem or progenitor origin. Gulati et
al., (2003) examined the relationship between angiogenic function of early endothelial
progenitor cells (EPCs) and late outgrowth endothelial cells in culture (OECs).
PBMNCs cultured for 7 days generated adherent spindle-shaped cells which
expressed endothelial markers and were strongly positive for the monocyte marker
CD14. When MNC were maintained in culture they produced proliferating OEC
colonies at 2 to 3 weeks (Gulati et al., 2003). The OECs were CD14-negative cells
(probably CD133+-derived), had more pronounced endothelial morphology and
proliferated up to 20 passages. Critically OEC never developed from CD14+ cultures
thus CD14+ EPC are not the precursors of OEC (Gulati et al., 2003).
Kaushal et al., 2001 demonstrated that seeding of the cellularised vascular grafts
with ovine OECs dramatically improved graft.
The mechanisms by which these different EPC populations contribute to new vessel
growth may differ. OEC and their progeny may integrate into growing endothelium,
whereas EPCs with monocytic features could enhance the angiogenic process in
general via release of paracrine signals, namely growth factors or cytokines (VEGF,
MCP-1, bFGF, IL-6) (Rookmaaker et al., 2003).
Alternatively, others in an attempt to avoid possible monocyte and mature endothelial
cell contamination in EPC cultures, used a preplating step of 24-48 hours on a
fibronectin coated surface. This step removes all adherent low-density MNCs and
the remaining non-adherent cells are replated again (Hill et al., 2003). Fulkes SM et
al. (from Stem Cell Technologies Inc report) showed that 33.1±5.3% mononuclear
cells including CD14+ and mature endothelial cells (CD105+CD45~) were removed
after incubation for 48h on fibronectin-coated plates.
Further research is required to identify optimal culture conditions for ex vivo
expansion of EPC, and for standardization of the procedures used for their isolation,
phenotypic characterization, and evaluation of their ability to re-endotheliase the
damaged endothelial areas. Identifying culture conditions that will allow EPC to
expand and/or differentiate is very important for their clinical application.
5.1.10 Mesenchymal cells as a source of endothelial cells
Non-haematopoietic mesenchymal stem cells (MSCs) were discovered by
Friedenstein, 1976. They were described as plastic adherent stromal cells from bone
marrow capable of differentiating into osteoblasts, adipocytes and chondrocytes.
More recently MSCs have been recovered from other tissues such as adipose tissue,
fetal liver, blood, lung and cord blood (reviewed in Le Blanc and Pittenger, 2005),
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and differentiated into numerous tissue lineages including endothelial, smooth
muscle, skeletal myoblasts, hepatocytes, neural, and cardiomyocytes (Pittenger and
Martin, 2004).
Panepucci et ah, 2004 compared MSCs isolated from cord blood with MSCs from
bone marrow and showed that both were functionally similar, shared most of the
expressed transcripts with the exception of some set of genes which may reflect
differences related to their origin. Genes related to antimicrobial activity and to
osteogenesis were predominantly expressed in BM-MSC, whereas higher expression
of genes which participate in matrix remodelling and angiogenesis were mainly
expressed in CB-MSCs.
There is a need for a quantitative assay to assess MSCs in a given population, because
there is no single marker or combination of markers that specifically identifies MSCs.
Controversy still exists over the in vivo phenotype of MSC. However, ex vivo
expanded MSCs are mostly defined by their high proliferative capacity and
multipotentiallity, their lack of expression of haematopoietic markers such as CD34,
CD45 or CD14 (Pittenger et al., 1999) and their positivity for CD73 (SH3), CD105
(SH2), CD166, CD90 and CD29 markers (Pittenger et al., 1999; Barry et al., 2001;
Deans and Moseley, 2000).
MSCs have a cell surface phenotype that is poorly immunogenic (Pittenger et al.,
1999) and one remarkable aspect of MSC physiology is that may actually suppress
inflammation and immunological responses (Gregory et al., 2005). In fact, these
immunomodulatory properties, with the inhibition of many T-cell interactions, are
probably explained by their lack of expression of HLA type II receptor and co-
stimulatory molecules such as B7-1 (CD80), B7-2 (CD86) and CD40 necessary for
instigation of T cell proliferation (Di Nicola et al., 2002; Tse et al., 2003; Krampera et
al., 2003; Angoulvant et al., 2004; Le Blanc et al., 2003; Bartholomew et al., 2002).
MSCs express MHC I, but class II molecules are seen at only a very low level (Zimmet
and Hare, 2005). Despite the increase in MHC II expression following differentiation,
MSCs did not show increased T cell interaction (Le Blanc et al., 2003).
The way in which MSCs suppress T-cell activation and modulate the immune
response has not been yet resolved. However, several mechanisms have been
proposed. Suppression seems to be mediated by a soluble factor or factors produced
by MSCs, because suppression still occurs if MSCs and lymphocytes are separated
in a transwell system (Rasmusson et al., 2003; Di Nicola et al., 2002; Tse et al., 2003).
There is an urgent need for better treatment and prevention of graft versus host
disease (GvHD) after autologous stem cell transplantation. Thus, in theory, allogeneic
MSCs could have an apparent clinical advantage (Silva et ah, 2005). Bartholomew
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et al., (2002) showed this immunosuppressive effect of MSCs in vivo, in which infusion
of ex vivo expanded matched donor MSCs delayed the time to rejection of
histoincompatible skin grafts in a baboon model. Silva et al, (2005) also showed
that implantation of MSCs is safe an effective. In addition to their
immunomodulatory properties in allogeneic transplantation, MSCs could be very
useful for the treatment of diseases of mesenchymal lineage tissues e.g. MSC
differentiated to osteoblasts could be used as an effective therapy for osteogenesis
imperfecta (Le Blanc and Pittenger, 2005).
Moreover, MSCs have been infused into the infarcted heart and showed improved
recovery. Gojo et al., (2003) showed that MSCs were able to differentiate into
cardiomyocytes, endothelial cells and smooth muscle cells by direct injection into
adult heart. MSCs did not transform into malignant cells or form excess extracellular
matrix. Therefore MSCs may supply an ideal donor source of cardiovascular cells.
Similarly, Nagaya et al., (2005) showed that MSCs differentiated into a variety of
cells, including beating cardiomyocytes and vascular endothelial cells. Others have
found similar positive encouraging results (Silva et al., 2005; Jiang et al., 2002;
Strauer et al., 2002). MSCs in addition to having high proliferative and self-renewal
capability also secrete a broad spectrum of angiogenic cytokines, critical for
maintaining lasting effects after clinical application (Tang et al., 2004).
In comparative experiments, Iwase et al., (2005) showed that transplantation of
MSC caused greater improvement in hindlimb ischaemia than did transplantation
of MNC. Compared to MNCs, MSCs survived well and differentiated into endothelial
cells, and also to vascular smooth much cells. Moreover perfusion recovery of lxlO6
MSC transplantation was equivalent to that of 5xlObMNC transplantation. MSCs
secreted larger amounts of VEGF and bFGF compared with the amounts secreted
by MNCs. Interestingly only MSCs secreted SDF-1, which has been shown to induce
angiogenesis in vivo and in vitro.
The relationship between MSCs, CD14+ cells and HSCs is not known (Romagnani
et al., 2005). Kuwana et al., (2003) described a population of CD14 monocytes
(MOMPs) that could differentiate into several distinct mesenchymal cell lineages.
These cells were isolated from circulating MNCs cultured on fibronectin for 7 days
and had unique molecular phenotype CD14+CD45+CD34+. Very recently, it has been
demonstrated that these cells could also differentiated into both mesodermal and
neuroectodermal lineages (Kodama et al., 2006).
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5.1.11 MAPC as a source of endothelial cells
Preliminary evidence that MAPC may be able to generate EC was provided by
Reyes and Verfaillie, (2001). These cells, possible within the MSCs, were called
multipotent adult progenitor cells (MAPC), could expand for greater than 70 to 150
population doublings and differentiated not only into mesenchymal lineage cells
but also into endothelium, neuroectoderm, and endoderm (Jiang et al., 2002). MAPC
cultured with VEGF at a high density in a serum free media were induced to
endothelial lineage whereas MAPC cultured with 10% FCS differentiated into
osteoblasts, chondroblasts and adipocytes (Reyes et al., 2002).
5.1.12 Adipose tissue as a source of endothelial cells
For a long time, adipose tissue was considered unimportant. However, recently its
endocrine functions emerged and appeared to play a key role in many physiological
situations such as inflammation and immunity. During embryonic development a
crucial link exists between adipose cells and the capillary network (Di Nicola et al.,
2002; Tse et al., 2003) and recent studies have demonstrated that adipose cells can
be now considered vascular progenitors. It is unknown whether these cells are MAPC
derived. Martinez-Estrada O.M et al., (2005) showed that it is possible to generate a
large number of Flk-1+ cells from adipose tissue and differentiate them into
endothelial cells. Similarly, Nakagami et al., 2005 showed that adipose tissue derived
cells significally increased endothelial cell viability, migration and tube formation
mainly through the secretion of VEGF and HGF.
Cao, (2005) identified adipose derived adult stem cells (ADAS cells) a CD3TCD34
CD106"Flkl+ cell population from adipose tissue which can be induced to differentiate
into cells of osteogenic and adipogenic lineages in vitro.
All of these recent results suggest that adipose tissue is another possible source of
cells for autologous therapeutic angiogenesis especially as adipose tissue is very
easy to obtain (Casteilla et al., 2005) and because of their capacity to expand ex vivo
(Planat-Benard et al., 2004; Casteilla et al., 2005).
5.1.13 Mobilisation. Modulators of EPC production
When minor new vessel formation is required in human adult life, these may arise
by outgrowth from in situ mature endothelial cells in existing vessels (angiogenesis).
However these cells are mature differentiated cells with low proliferative potential
and a limited life span and are thought to be unable to incorporate into remote
target sites. In a situation of larger-scale tissue repair, it is possible that quiescent
EPCs, in response to an increased plasma level of certain cytokines and growth
factors, may relocate to damaged areas promoting endothelial cell differentiation
130
(Hristov et al. (b), 2003; Murohara, 2001). However, if this does occur naturally, for
example in infracted hearts or ischaemic diabetic limbs, it is clear that the effect is
not sufficient to repair the damage to any significant extent. Translocation of EPCs
may be impeded by underlying vascular disease where circulation is poor due to
the damaged vasculature.
The administration of angiogenic cytokines to mobilise and expand putative EPC
to augment resident EPC populations in areas of endothelial damage might represent
an alternative means to increase post-natal vasculogenesis. This could address the
problem of endothelial dysfunction or deficiency in, for example, older, diabetic
and/or hypercholesterolemic patients (Murasawa and Asahara, 2005).
It is important to consider though, that aging and certain disease situations could
negatively influence the frequency of EPC mobilisation (Murasawa and Asahara,
2005). Tepper et al., (2002) have shown the impairment of EPC incorporation into
vascular structures in type II diabetes and Murayama and Asahara, (2001) showed
that EPCs from older patients compared with those from younger patients with
clinical ischaemia had significantly less therapeutic effect in rescuing ischaemic limbs
of mice.
Mobilisation of stem cells in the bone marrow is determined by the local
microenvironment (stem cell niche) (Papayannopoulou, 2004). Mobilising cytokines
impede the interactions between stem cells and stromal cells, and finally allow them
to leave the bone marrow via transendothelial migration. This is true for CD34+
HSC but it is unknown for endothelial progenitor cells.
EPC mobilisation requires further study as in some models adverse effects have
been described as EPCs contribute to tumour neovascularisation (Lyden et al., 2001).
5.1.13.1 Tissue ischaemia
Physiological ischaemia is believed to be a potent angiogenic stimulus and the
predominant signal to induce mobilisation of EPCs from the bone marrow. Ischaemia
or hypoxia may increase vascular permeability, enhance the release of
chemoattractant factors, and promote the expression of adhesion proteins which
may facilitate the homing process (Perin et al., 2003). Ischaemia thereby is believed
to upregulate VEGF or SDF-1 secretion (Lee et al., 2000; Pillarisetti and Gupta,
2001), which in turn are released to the circulation and induce mobilisation of
progenitor cells from bone marrow (Urbich and Dimmeler, 2004). Indeed, patients
undergoing coronary artery bypass grafting (CABG) or those who have suffered
extensive burns have elevated VEGF plasma levels, which promotes rapid
mobilisation of endothelial cells to the peripheral blood (Gill et al., 2001). However,
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the increase of the level of these cytokines and growth factors seems to depend on
the severity of the case. Shintani et al., (2001) have reported that plasma levels of
VEGF positively correlate with the number of CD34+ cells in circulation.
5.1.13.2 Growth factors
Equivalent to ischaemia, exogenously added cytokines act as chemoattractants and
lead to mobilisation of EPC therefore increasing the frequency of circulating EPCs
(Urbich and Dimmeler, 2004). At the present it is not known which growth factor
most potently elevates the number of EPCs. Vascular endothelial growth factor
(VEGF) is thought to be a critical angiogenic growth factor (Carmeliet et al., 1996;
Ferrara and Bunting, 1996; Shalaby et al., 1995). A number of studies have shown
that VEGF contributes to neovascularisation by mobilising bone marrow-derived
EPCs; in patients undergoing VEGF gene transfer for critical limb ischaemia (Kalka
et al. (b), 2000) and in patients after myocardial ischaemia (Kalka et al. (c), 2000).
VEGF165 was shown to rapidly mobilise haematopoietic stem cells and circulating
endothelial precursor cells (Moore et al., 2001; Flattori et al. (a), 2001). However,
further studies are needed to test possible side effects as some reports claimed that
systemic administration of VEGF induced oedema formation (Vajanto et al., 2002).
Administration of stromal-derived factor-1 (SDF-1) showed similar positive
angiogenic effects to VEGF whereas angiopoietin-1 induced a delayed and a less
pronounced mobilisation of endothelial and haematopoietic precursors (Moore et
al., 2001; Hattori et al. (a), 2001).
M-CSF, GM-CSF and G-CSF, initially discovered as stimulators of haematopoietic
progenitor cells and myeloid cells have also been shown to mobilise EPCs from BM
(Takahashi et al., 1999).
Nakano, K et al. 2006 suggested that M-CSF could mobilise EPCs through
augmenting the production of VEGF, mainly produced by myeloid lineage cells in
the bone marrow, resulting in the augmentation of blood flow and the increased
number of blood vessels in ischaemia-induced limbs. M-CSF administration has
the advantage that it does not augment mobilisation by raising VEGF serum levels,
thus avoiding the possibility of major side effects referred above (Nakano et al.,
2006).
GM-CSF is a relatively inexpensive and safe cytokine extensively used clinically.
Cho et al., (2003) showed an accelerating endothelialisation through EPC
mobilisation after GM-CSF administration. It has also been reported that not only
GM-CSF but also G-CSF can mobilise EPCs (Takahashi et al., 1999). Takahashi et
al., (1999) demonstrated that G-CSF administration induced EPC mobilisation and
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enhanced neovascularisation in severely ischaemic tissues as well as de novo corneal
vascularisation.
Different authors have stated the benefits of the use of G-CSF for mobilisation of
EPC (Ince et al., 2005; Kong et al., 2004; Yoshioka et al., 2006). For example, Kong
et al. (2004) reported that G-CSF induced mobilisation of EPCs enhanced
endothelialisation of the injured artery and inhibited neointimal formation in a rat
balloon injury model. Consistent with the Kong et al. results, Yoshioka et al., (2006)
showed that G-CSF pre-treatment accelerated re-endothelialisation and inhibition
of neointimal formation after vascular injury. However, the effects of G-CSF on
ischaemic lesions are still controversial (Kang et al., 2004; Ince et al., 2005). Kang et
al. (2004) demonstrated that G-CSF promoted angiogenesis and improved cardiac
function when administered in patients with coronary artery disease (CAD); however
increased restenosis was observed as a serious adverse effect after percutaneous
coronary intervention (PCI). There is a concern that the administration of G-SGF
could accelerate arteriosclerosis and may give rise to thrombosis (Lindemann and
Rumberger, 1993)
G-CSF also promotes inflammation by inducing a profound increase in the number
of circulating leucocytes (Morimoto et al., 1990; Adachi et al., 2003). Because
inflammation plays a key role for the development of atherosclerotic lesions and
restenosis, as well as in plaque instability leading to acute coronary syndromes, the
safety of G-CSF is still questioned.
Alternative EPC mobilisation agents with a lower pro-inflammatory profile, like
EPO, statins, or exercise, could more selectively enhance EPC levels without inducing
inflammation.
5.1.13.3 Erythropoietin (EPO) as an EPC mobilisation agent
Mature endothelial cells express erythropoietin (EPO) receptors (Heeschen et al.,
2003). Administration of the hormone EPO is known to increase proliferation and
maturation of erythrocytes and to augment neovascularisation in mice (Heeschen
et al., 2003) and in men at least in part by enhancing EPC mobilisation from the
bone marrow (Bahlmann et al., 2004). The correlation between EPO serum levels
and the number of CD34* or CD133+ HSCs in bone marrow in patients with
ischaemic coronary artery disease further supports the important role of endogenous
EPO levels (Heeschen et al., 2003). Hence, EPO serum levels may help in identifying
patients with impaired EPC recruitment capacity (Heeschen et al., 2003).
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5.1.13.4 Statins as EPC mobilisation agents
Therapeutic mobilisation of EPCs has been studied not only using natural
haematopoietic or angiogenic stimulants but also using anti-hypercholesterolaemia
drugs. The statin class of cholesterol-lowering hydroxyl-methyl-glutaryl-coenzyme
A (HMG-CoA) reductase inhibitors catalyse the synthesis of mevalonate, which is a
rate limiting step in the cholesterol synthesis.
Statins are not only believed to reduce cardiovascular events in patients at risk, but
also stimulate endothelial cell bioactivity in vitro and enhance angiogenesis in vivo
(Kureishi et ah, 2000). An increase of the functional activity of EPCs has been shown
in mice (Dimmeler et ah, 2001, Llevadot et ah, 2001) and in patients with stable
coronary artery disease (Vasa et ah, 2001). Statins also increase expression of adhesion
molecules by EPCs that facilitate their incorporation into sites of neoangiogenesis
(Walter et ah, 2002).
5.1.13.5 Exercise as an EPC mobilisation stimulus
The mechanisms by which physical exercise increase EPC levels are not entirely
clear. Aicher et ah, (2005) speculated that the induction of ischaemia in the muscles
enhances circulating cytokine levels and increases EPC mobilisation. Rehman et
ah, (2004) demonstrated that only 10 minutes of exercise acutely increases the
circulating EPC cell population. Steiner et ah, (2005) showed that exercise training
augmented the number of circulating EPCs in patients with cardiovascular risk
factors and coronary artery disease and is associated with improved vascular
function and NO synthesis. Plasma levels of VEGF did not change in response to
exercise. Exercise could be used as a complement for pharmacological interventions
such as statins or G-CSF therapy. At the same time, unravelling the mechanisms of
exercise-induced EPC mobilisation may result in the development of novel
pharmacological pathways to improved endothelial function and enhance
angiogenesis.
Although the molecular signalling pathways by which EPCs are mobilised to
peripheral circulation is not confirmed, several studies indicate that is via the
activation of the P13/Akt pathway. VEGF, EPO, oestrogens (Strehlow et ah, 2003;
Iwakura et ah, 2003) and exercise (Laufs et ah, 2004; Adams et ah, 2004) all appear
to exert their effect on EPCs through the P13K/Akt-pathway.
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5.1.14 Chemotaxis: migration and invasion of circulating
EPCs
It is not known which physiological or pathological factors influence the homing
signals that direct circulating EPCs to sites of injured vessels (Hristov et al. (b),
2003). The local bone marrow microenvironment, or stem cell niche, governs the
maintenance and mobilisation of bone marrow mobilisation stem cells (Calvi et al.,
2003; Zhang et al., 2003). Mechanistically, cytokines inducing mobilisation interfere
with the interactions between stem cells and bone marrow stromal cells, which allow
stem cells to disengage the bone marrow, and enter the blood stream. Stem cell
mobilisation is mediated by proteinases such as elastase, cathepsin G, and matrix
metaloproteinases (MMPs) (Lapidot and Petit, 2002). For example, G-CSF releases
proteinases (elastase, and cathepsin G) from the neutrophils and induces the release
of SDF-1 by the stromal cells, forcing CXCR4+ cells to leave the bone marrow. Several
investigators have reported that CD34+ cells express CXCR4 and that SDF-1 could
induce CD34+ cell migration in vitro (Mohle et al., 1998).
Homing is mediated through complex interactions between microenvironmental
endothelial/stromal cells and haematopoietic stem cells. Adhesion molecules
belonging to the integrin family, CXCR4, metalloproteinases and cathepsins seem
to have an important role.
5.1.14.1 Integrins in EPC homing
Integrins may be involved in the homing of progenitor cells to ischaemic tissues.
(Urbich and Dimmeler, 2004). The initial step of homing of the progenitor cells to
ischaemic tissues involves adhesion of progenitor cells to vascular endothelial cells
activated by cytokines and ischaemia and the transmigration of the progenitor
cells through the endothelial cell monolayer (Vajkoczy et al., 2003).
beta-1 Integrins are capable of mediating cell-cell interactions of various cells
including haematopoietic stem cells and leucocytes to extracellular matrix proteins
and to endothelial cells. Cell adhesion to the extracellular matrix is an important
process that controls cell migration, proliferation, survival and differentiation, and
it is hypothesized that the cellular expression of adhesion molecules such as integrins
and cadherins are critically important (Li et al., 2005).
Integrins are heterodimeric cell-surface receptors composed of an alfa and beta
subunit heterodimers, which integrate the extracellular matrix with the intracellular
cytoskeleton and mediate cell adhesion, survival, differentiation, growth and
migration, beta-1 integrin is one of the most important families of integrins mainly
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because it mediates cell-cell or cell-extracellular matrix interactions. However, there
is only very recent direct experimental evidence to support this suggestion. Antibody
perturbation to integrin beta-l significally decreased the cell survival and
incorporation of freshly unexpanded CD117+ cells after implantation (Li et al., 2005).
Moreover, Li et al., (2005) showed that integrin-freta-1 is a critical adhesion molecule
for inducing therapeutic angiogenesis by regulating survival and differentiation
after implantation into ischaemic tissue. Newly isolated bone-marrow CD117+cells
had the potential to induce angiogenesis but ex vivo expanded CD117+cells, with
significant decrease of beta-1 integrin expression, had low angiogenic potency (Li et
al., 2005).
5.1.14.2 SDF-1/CXCR4 in EPC homing
Understanding the factors that attract circulating EPCs to the ischaemic sites is
very important. Stromal cell-derived factor-1 (SDF-1) is a member of the chemokines
CXC subfamily considered to play an important role in the trafficking of
haematopoietic stem cells between the bone marrow and peripheral blood
(Yamaguchi etal, 2003). CXCR4, a 7-transmembrane-spanning G-protein-coupled
receptor is the only known receptor for SDF-1. SDF-1/CXCR4 interaction is reported
to play an important physiological role in haematopoiesis during embryogenesis
(Nagasawa et al., 1996), vascular development and cardiogenesis (Tachibana et al.,
1998). Murine bone marrow engraftment and repopulation by human SCID-
repopulating stem cells are completely blocked by neutralising antibody to CXCR4,
which suggests that the SDF-1/CXCR4 axis is essential for the homing of human
haematopoietic stem cells (Peled et al., 1999). In addition, Kortesidis et al., (2005)
showed that SDF-1 may play a role in the maintenance, survival and osteogenic
capacity of immature bone marrow stromal stem cells.
CXCR4 is also expressed by endothelial cells (Volin et al., 1998) and evidence suggests
that SDF-1 could have direct affects on vasculogenesis. Tachibana et al., (1998)
reported that mice lacking SDF-1 had defective formation of large vessels supplying
the gastrointestinal tract. Moreover Hattori et al., (b) (2001) reported that plasma
elevation of SDF-1 induced mobilisation of mature and immature stem cells
including EPCs. Further, Yamaguchi et al., (2003) showed that local administration
of SDF-1 in vivo stimulates recruitment of EPCs to the ischaemic tissue.
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5.1.14.3 Matrix Metalloproteinases (MMPs) in EPC homing
Endothelial cells are activated by and migrate toward angiogenic stimuli. In the
early stages of the neo-angiogenic process the activated endothelial cells act like
metastatic cancer cells. Activated endothelial cells express significant levels of matrix
degrading enzymes, particularly matrix metalloproteinases (MMPs) that degrade
and digest the capillary basement membrane and allow the cells to move toward
an angiogenic stimulus. In vitro techniques designed to investigate this process are
divided into migration and invasion assays.
5.1.14.4 Proteases (Elastases and Cathepsins) in EPC homing
Elastases and cathepsins are proteases, which are mainly found in the granules of
neutrophils, and their biological activity involves proteolytic degradation of proteins
(Ng et al, 2004). Inhibition of elastase activity prevents mobilisation of bone marrow
CD34+ cells into peripheral blood by reducing the degradation of stroma-derived
factors (SDF-1) and stimulation with G-CSF resulted in increased degradation of
SFD-1.
Cathepsins are cysteine endopeptidases that belong to the family of papain-like
proteolytic enzymes that are principally located in the endosomal/lysosomal
compartment of the cells (Turk et al., 2000).
Urbich et al. (b) (2005) indicated that EPCs express high levels of cathepsin. CathL
deficient mice showed impaired functional recovery following hind limb ischaemia
and infused CathL deficient progenitor cells neither homed to sites of ischaemia nor
augmented neovascularisation. Mature endothelial cells have low levels of CathL
by comparison to EPCs. Forced expression of CathL in mature endothelial cells
considerably enhanced their invasive activity. Thus, it seems that cathepsin L has a
critical role in the integration of circulating EPC into ischaemic tissue and is required
for EPC-mediated neovascularisation and invasion.
5.1.15 Gene modified EPC therapy
Gene therapy may be an alternative strategy to address the limited quantity of
EPCs in circulation even in healthy conditions. Isolated and expanded EPCs could
be genetically modified for subsequent autologous re-administrated (Murasawa
and Asahara, 2005). EPCs transfected with adenovirus vectors encoding for specific
genes such as VEGF would therefore overexpress angiogenic growth factors for
long periods of time and be able to enhance an angiogenic response (Masuda and
Asahara, 2003); (Asahara et al. (b), 1999). Iwaguro et al., (2002) demonstrated that
genetically modified EPCs rescued impaired neovascularisation in an animal model
137
of limb ischaemia and the injected mice significally improved neovascularisation
and blood flow recovery. In addition, limb necrosis and auto-amputation was
significally reduced by 63.7% by comparison with controls. Moreover, Kalka et al.
(c), (2000) showed that VEGF gene transfer in vivo mobilised EPCs in patients with
ischaemic coronary disease.
These gene-delivery data in animal studies, although limited, proposed gene therapy
as a safe approach for cell-based vascular therapies (Gulati and Simari, 2004).
However, more clinical experience is needed to resolve safety concerns as some recent
studies showed angioma formation after gene delivery (Carmeliet, 2000; Lee et al.,
2000).
5.1.16 Smooth muscle cell interactions with EPCs
Endothelial cells can initiate but not complete angiogenesis. This maturation requires
communication between ECs and supporting cells such as smooth muscle cells
(SMCs) and pericytes. In fact, once the primitive EC tubes are formed, the
endothelium secretes factors that lead to the recruitment of SMCs (Le Ricousse-
Roussanne et al., 2004). It is unknown whether EPC and SMC can be generated
from a common progenitor. Pesce et al., (2003) showed that CD34+cord blood cells
injected into an ischaemic adductor muscles gave rise to endothelial and to skeletal
muscle cells in mice. Similarly, Le Ricousse-Roussanne et al., (2004) showed that
both ECs and SMCs progenitors are present in cord blood, which can differentiate
into both mature ECs and SMCs. In vitro these two cell types collaborate with each
other in a three-dimensional culture to form vascular-like structures and to home to
the ischaemic site.
Sata et al., (2002) suggested that when endothelium is injured, circulating EPCs
may adhere to the underlying smooth muscle cells and contribute to the neointimal
formation by differentiation into smooth muscle cells.
Another potential source of SMCs may involve bone-marrow derived mesenchymal
stem cells, which have the potential to differentiate into smooth muscle-like cells
and may be recruited into the graft from the circulation (Shimizu et al., 2001).
5.1.17 Therapeutic angiogenesis
Amputation of limbs in patients with diabetic foot ulcers and arteriosclerosis
obliterans is a very serious problem. Vasodilators are the first choice of treatment,
but this is not always effective in preventing amputation (Kawamura et al., 2005).
Cell regenerative therapy could develop to be more effective than surgical treatments
(Kawamura et al., 2005). EPC cell transplantation not only improved
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neovascularisation and blood flow recovery, but notably also important biological
consequences such as limb necrosis and autoamputation (Kalka et al. (a), 2000;
Kawamura et al., 2005). Augmentation of vasculogenesis was detected in a hindlimb
ischaemia rat model after ex vivo CD34+ cell injection (Murohara et al., 2000). Also,
Schatteman et al., (2000) showed an increase in the restoration of limb blood flow
in diabetic nude mice with hindlimb ischaemia after CD34 ex utao-expanded cells
were injected.
Ischaemic heart disease is a leading cause of morbidity and mortality in the Western
world (Annex and Simons, 2005). Currently there are a large number of invasive
and non-invasive treatment options for patients with coronary artery disease.
Mechanical revascularisation techniques such as coronary bypass surgery and
angioplasty restore flow to the compromised myocardium. Therapeutic agents such
as nitrates and beta-blockers restore the perfusion supply/demand balance by
reducing myocardial oxygen requirements. Finally cholesterol-lowering drugs
influence further progression. However, after nearly a decade of trials, the
development of drugs capable of stimulating revascularisation remains an exciting
but unrealised goal in cardiovascular therapeutics (Annex and Simons, 2005). At
the time of end-stage heart failure, the effect of drug treatment is limited, and cardiac
transplantation is the only viable alternative. However, this strategy is costly and
severely limited by the availability of donor hearts. In addition complications arising
from the use of immunosuppressive agents may diminish the patient's quality of
life (Davani et al., 2005). Cell-based therapy has been the recent focus of attention
for repairing injured organs, and the induction of therapeutic angiogenesis by cell
implantation is a promising treatment option for ischaemic diseases.
The benefits of transplanting autologous EPCs for increasing tissue reperfusion have
been established in multiple studies of experimentally induced acute or chronic
ischaemia of heart or limbs (reviewed in Rafii and Lyden, 2003). In vivo preclinical
data showed that infusion or injection of adult EPCs after myocardial infarction
resulted in profound and sustained improvement of cardiac function (Kocher et al.,
2001; Fuchs et al., 2003; Kawamoto et al., 2001) (see table 5.2). Kocher et al., (2001)
injected 2x106 DiL-labeld G-CSF mobilised adult-human CD34+ cells (>98% purity)
from a single donor in the tail vein of rats and within 48h of left anterior descending
(LAD) coronary artery ligation resulted in new blood vessel formation and
proliferation of pre-existing vasculature. 20-25% of capillaries were from human
origin and they were exclusively located within the central infarct zone.
Measurements showed improvements by an increase of capillary density in the
infarct bed, decreased apoptosis of hypertrophied myocytes in the peri-infarct zone,
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salvage and survival of the viable myocardium, inhibition of fibrosis, and
improvement of left ventricular function (Zisch, 2004).
Early data obtained in human pilot trials of myocardial infarction (Assmus et ah,
2002; Britten et ah, 2003; Stamm et ah, 2003), advanced coronary artery disease
(Fuchs et ah, 2003) or leg ischaemia (Tateishi-Yuyama et ah, 2002; Higashi et ah,
2004; Kawamura et ah, 2005) (see table 5.2) suggest that cell-based reperfusion
therapy is both safe and feasible and capable of achieving revascularisation (Zisch,
2004).
Human adult EPCs have been isolated from bone marrow aspirates, peripheral
blood, and cord blood. EPCs isolates re-introduced by injection or infusion into
heart or limb have been shown to maintain their ability to participate in endothelial/
vessel growth at sites of ischaemic or vessel injury. Especially locally grafted EPCs
showed positive effects for improving regional blood flow supply in ischaemic heart
and peripheral disease, inhibiting neointimal hyperplasia by growing new
endothelium in denuded arteries after balloon angioplasty (Rafii and Lyden, 2003).
Taken together experimental studies performed so far by cell therapy generally
showed that improvement of neovascularisation is not exclusive to one cell type
because a variety of progenitors accomplish this (Davani et ah, 2005). However,
further studies are required to choose therapeutically which most successful kind of
bone marrow cells (global unfractioned bone marrow cells, or specifically selected
subtractions, as isolated cells fractions containing CD34+, CD133+, MSC) are the
most suitable cell populations for transplantation (Strauer and Kornowski, 2003).
Direct comparison of ex vivo expanded circulating progenitor cells peripheral blood
derived and bone marrow-derived EPCs in the TOPCARE-AMI trial (transplantation
of progenitor cells and regeneration enhancement in acute myocardial infarction)
(Assmus et ah, 2002; Britten et ah, 2003) showed that both preparations to be
comparably effective in improving contractility and viability of infarcted myocardial
segments. By contrast, in the leg ischaemia trial (Tateishi-Yuyama et ah, 2002), a
superior impact of MNCs from bone marrow compared with peripheral blood was
observed. Whether bone marrow is a richer source of EPC or not is unknown.
Tateishi-Yuyama et ah did not use in vitro expanded peripheral blood MNCs whereas
Assmus et ah did. Therefore, the inferior impact on neovascularisation detected in
peripheral blood mononuclear cells compared to bone marrow in Tateishi-Yuyama
et ah study could be due to the lack of expansion of these MNCs on fibronectin.
To date publications regarding adverse effects in experiment studies have been
relatively rare (Davani et ah, 2005). However, the development of microinfarction
has been reported when mesenchymal stem cells (MSCs) were infused directly into
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a dog's coronary artery (Vulliet et al., 2004). Moreover adverse calcification has
been shown to be a problem in a rat model in which 28% of the rats receiving total
bone marrow cells revealed some myocardial calcifications (Yoon et al., 2004).
Further optimisation of EPC-based reperfusion therapy may involve multiple
experimental parameters (e.g. the number of cells to inject, the placement and the
number of injections, cell engraftibility and viability at the target site). The efficacy
and the safety of this approach must also be established.
In current human studies of autologous mononuclear bone marrow cells, the number
of cells believed to be necessary to achieve an optimal effect is of 10 to 40x106 (Perin
et al., 2003). The cell responsible for this angiogenesis is not known but if we use
CD34+ as the cell required for transplantation, the optimal dose of CD34+ cells for
endothelial stem cell therapy remains undefined. Studies by Wollert and Drexler,
(2004) have used doses ranging from 106-108 cells. The optimum dose for
haematopoietic stem-cell therapy following myeloablative chemotherapy is >2x106
CD34+cells per Kg bodyweight (Siena et al., 2000). However, the dose requirement
in myocardial infarction will probably not be as high as that needed in HSC therapy,
because of the treatment territory involved (heart v bone marrow) and direct
intracoronary injection or infusion to the targeted ischaemic or infarcted
myocardium. However, further experiments are required to explore the efficacy of
different doses (Perin et al., 2003).
Kalka et al. (a), (2000) suggested that in their animal studies heterologous
transplantation required systemic injection of 0.5-2xl04human EPCs/g body weight
of the recipient animal to achieve satisfactory reperfusion of the ischaemic hindlimb.
Rough extrapolation of this data to human suggest that a blood volume of as much
as 12L may be necessary to obtain adequate numbers of EPCs to treat critical limb
ischaemia in patients, therefore the shortage of the EPCs in circulation combined
with their possible functional impairment associated with aging, diabetes,
hypercholesterolemia constitutes a major limitation of primary EPC transplantation
(Masuda and Asahara, 2003; Vasa et al., 2001; Tepper et al., 2002).
Local instead of systemic delivery of EPCs could reduce the dosage of cells needed.
Therefore targeted and regional administration of transplantation of cells should be
preferred (Strauer and Kornowski, 2003). Local co-injection of angiogenic
chemokines, such as SDF-1 or VEGF, into the target area together with EPC
transplantation could also augment target-specific accumulation of EPCs and
increase capillary density (Yamaguchi et al., 2003). Other devices utilising EPCs
for clinical application such as artificial grafts first seeded with autologous cells and
then implanted into the ischaemia sites were found to have increased surface
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endothelisation and vascularisation when compared with the controls (Bhattacharya
et al., 2000). When cultured autologous ovine EPCs were seeded onto carotid
interposition grafts, the EPC seeded grafts achieved physiologic motility and
remained patent for 130 days versus 15 days using a non-seeded graft (Kaushal et
al., 2001). Alternatively, cardiomyocytes cell sheets may be effective for the
improvement of cardiac function in damaged hearts (Shimizu et al., 2002). Another
approach to promote engraftment involves the genetic modification of EPCs to
overexpress factors such as VEGF (Iwaguro et al., 2002) or factors that specifically
increase their biological activity and viability (e.g. human telomerase reverse
transcriptase (Murasawa et al., 2002) or Akt; reviewed in (Alessandri et al., 2004)).
Another important clinical problem will be the identification and localisation of
transplanted autologous stem cells within the injured area to resolve the long-term
fate of transplanted stem cells in the recipient tissue (Strauer and Komowski, 2003).
For clinical detection of stem cells, myocardial biopsies in humans hardly will be
justifiable therefore, magnetic labelling and in vivo tracking of bone marrow cells
by the use of magnetodendrimers or radioactive detection methods may be useful
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5.1.18 Endothelial Cell Lines
Endothelial cell lines have been standards for cell-based assays in the field of
angiogenesis research, in anti-angiogenic drug discovery and for physiological and
pharmacological investigations, such as macromolecule transport, blood coagulation,
and fibrinolysis. The major part of the knowledge of endothelial cell functions comes
from in vitro experiments with HUVECs (human umbilical vein endothelial cells)
(Jaffe et al.r 1973). HUVECs are cryopreserved at the end of primary culture and
can be cultured and propagated at least 16 population doublings. This implies that
no long-term in vitro experiments can be performed with HUVEC (Bouis et al,
2001). Typical endothelial characteristics can be divided into phenotype and
function. Routine characterisation of HUVECs includes morphological and
phenotype observations through serial passages. Mature endothelial cells contain
Weibel-Palade-bodies, which store large amounts of von Willebrand factor (vWf).
Moreover, HUVECs are known to express adhesion molecules including PECAM,
ELAM, ICAM, V-CAM, E-selectin and VE-cadherin (Cambrex, technical sheet, UK).
Functionally, HUVECs bind ulex europaeus lectin agglutinin I, take up acetylated
low-density lipoproteins (ac-LDL), and present angiotensin-converting enzyme
(ACE)-activity.
The isolation of primary HUVEC is laborious and experimental results obtained
with different HUVEC isolates cannot easily be compared to each other because of
their different donor origin (Bouis et al., 2001). However, in recent years the use of
primary cells has become more attractive as there is a vast and still growing range
of commercially available primary ECs from almost any vascular origin.
Commercial primary EC circumvent the problems of laborious EC isolation and it
is possible to purchase ECs from the same original batch at a later moment if further
experiments are required (Bouis et al., 2001).
As an alternative, immortalised well-characterised EC lines obtained by transfection,
infection or fusion with an immortal cell are generally better characterized and
more stable in their endothelial traits than primary endothelial cell lines.
Presently the best-characterized immortalised macro-EC line is EA.hy926 (Bouis et
al., 2001). EA.hy 926 was generated in 1983 by fusion of HUVEC with human lung
carcinoma cell line A549 (Lieber et al., 1976). Stably presenting endothelial properties
and with an extended life span, EA.hy 926 was able to substitute for secondary
cultures of human umbilical vein endothelial cells (HUVEC) in a leucocyte/
endothelial adherent assay (Brown et al., 1993). This hybrid cell line had adhesive
properties similar to HUVEC and was shown to be beneficial for the study of factors
that govern leucocyte-endothelial cell interactions (Brown et al., 1993). EA.hy 926
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was also a useful cell line to identify the fibrinolytic characteristics in cultured
endothelial cells (Emeis and Edgell, 1988). Moreover, Pech-Amsellem et al, (1996)
concluded that EA.hy 926 cells were a good model for investigating endothelial
cell-induced modifications of low density Lipoproteins (LDL).
Different studies require different properties of EC and it is the aim of each
investigator to decide which cell line matches his or her research goal best. In our
study we used both HUVEC and EA.hy 926 cell lines as a positive endothelial control
to test our endothelial phenotypic and functional assays (5.2.1).
Specific studies performed in this Chapter 5
In this Chapter 5 we first investigate (5.2.2) the presence of the currently proposed
EPC phenotypes in the most common and practicable potential EPC sources such
as bone marrow, cord blood, G-CSF mobilised blood and normal peripheral blood
aiming to conclude which phenotype is the most consistent to use as an EPC
definition. To elucidate which source has the greatest potential to generate EPC and
again which cell phenotype was the closest to define a true EPC population, an in
vitro functional EPC colony assay (CFU-EPC) was used. Measurement of CFU-
EPC is able to identify very low frequencies of such cells which would be difficult to
quantify by flow cytometry. In the second part of this results (5.2.3) we examine
which subpopulation is associated with the CFU-EPC potential by enriching different
cell fractions and assessing their colony forming capacity. Different sources gave





5.2.1 (a) Mature endothelial cells
5.2.1.1 Immunophenotype characterisation of human
umbilical vein endothelial cells (HUVEC).
These cells were strongly positive for PECAM (CD31) (88.3%), ulex europaeus lectin
agglutinin I (UEA-1) (78.42%), CD146 (71.28%) and CD29 (75.48%) markers.
Moreover, these cells were positive for VEGFR2 (23%), VE-cadherin (73%), CD63
(41.6%), CD105 (61.68%) though were negative for CD45, CXCR4 and CD133
markers (Figure 5.1). Although these results are expressed as percentages of the
population not overlapping the unstained negative control, the peaks were single
and generally homogeneous and appear to represent general expression (or lack of
expression) by all cells rather than expression only by a subpopulation of cells.
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Figure 5.1 Flow cytometry analysis ofcultured human umbilical vein endothelial cells (HUVEC)
Flow cytometry analysis with (open green) and without (shaded, grey) anti-CD31-F1TC, anti-UEA-
1-F1TC, anti-CXCR4-PercP, anti-CD 146-FITC, anti-CD29-FITC, anti-CD 105-APC. anti-VEGFR2-PE,
anti-VE-cadherin-PE, anti-CD63-PE, anti-CD45-PercP and anti-CD 133-APC.
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5.2.1.2 Immunophenotype characterisation of human
endothelial hybridoma line EA.hy926.
Giemsa staining showed these cells were large and granular (Figure 5.2). This was
confirmed by flow cytometry analysis of EA.hy926 cells, which showed that the
majority of these cells presented high forward and side scatter (FSC/SSC) which is
characteristic of large granular cells. Viable cells (gated on FCS/SSC characteristics)
showed no expression of CD45, CD133 and CXCR4 surface markers. Around 30%
of the EA.hy926 cells expressed CD34; 12.6% were positive for VEGFR2; and 28.83%
expressed VE-cadherin. Moreover, most of the cells strongly expressed CD29 (86%),
CD31 (88%), UEA-1 (81.77%) and CD146 (98.11%) markers (Figure 5.3). As for the
HUVECs, although these results are expressed as percentages of the population not
overlapping the unstained negative control, the peaks were in most cases single
and generally homogeneous and appear to represent general expression (or lack of
expression) by all cells rather than expression only by a subpopulation of cells.
However, unlike the HUVECs, clearly for CD34 and to some extent for VE-cadherin
there is the appearance of dual peaks suggesting that some major subpopulation of
these EA.hy926 cells express these markers more strongly than the remainder, and
it may be that these markers reflect the status of these cells in the cell growth cycle.
The expression of VEGFR2, VE-cadherin, UEA-1 and CD31 markers on EA.hy926
cells was also demonstrated by immunostaining (Figure 5.4).
Figure 5.2. Morphology of the EA-hy926 hybridoma endothelial cell line
Harvested cells were used to prepare cytospin slides for Giemsa staining. (a,b) Hybridoma
endothelial cells were very large and highly granulated.
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Figure 5.3 Flow cytometry analysis of the EA-hy926 hybridoma endothelial cell line
Flow cytometry analysis with (open green) and without (shaded, grey) anti-CD31 -FITC, anti-UEA-
I -FITC, anti-CXCR4-PercP, anti-CD 146-F1TC, anti-CD29-FITC. anti-CD34-APC, anti-VEGFR2-PE,
anti-VE-cadlierin-PE, anti-CD45-PercP and anti-CD 133-APC.
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a) Control FITC b) Control PE
c) CD31-FITC d) VE-cadherin-PE
Figure 5.4 Immunofluorescence microscopy of the EA-hy926 hybridoma endothelial cell line.
Immunostaining illustrates that the hybridoma endothelial cell line EA-hy926 expressed mature
endothelial phenotype markers, a) Cells with no staining pictured under the FITC filter or b) under
PE filter, (c-f) cells stained with c) anti-CD31-FITC antibody, d) anti-VE-cadherin-PE, e) ulex
europaeus lectin agglutinin 1, f) anti-VEGFR2-PE antibody.
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5.2.1.3 Functional characterisation of human EC hybridoma
line EA.hy926
EA.hy926 cells were also shown to take up Dil-ac-LDL by both flow cytometry
(97%) and immunofluoresce staining (Figure 5.5).
EA.hy926 cells were able to form obvious tubular structures following one-week
culture in Matrigel (Figure 5.6).
Neither EA.hy926 or HUVEC produced CFU-EPCs in the Hill assay demonstrating





Figure 5.5 Dil-ac-LDL uptake by EA-hy926 hybridoma endothelial cell line.
Ea-hy926 cells took up Dil-ac-LDL like a mature endothelial cell a) negative control and b) with Dil-
ac-LDL. c) cells gated in SSC/FCS and d) histogram with (open blue) and without (shaded grey)
Dil-ac-LDL staining (FL1-H).
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Figure 5.6 Matrigel tubule formation assay by EA-hy926 hybridoma endothelial cell
line.
The hybridoma endothelial cells are able to generate capillary-like structures in Matrigel:
a) X40 field and b) X100 field
Figure 5.7 Endothelial progenitor cell colony formation (CFU-EPC) by EA-hy926 hybridoma
endothelial cell line.
No characteristic colonies are seen when EA-hy926 cells are cultured in CEEM culture.
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5.2.1 (b) Peripheral blood sampling
5.2.1.4 Effect of anticoagulants and washing on platelet
adherence to peripheral blood mononuclear cells.
(Data obtained in collaboration with Ida Flisijn; visiting student from Noordelijke
Hogeschool, Van Hall Instituut, The Netherlands).
Some markers, such as vWf, are expressed on mature endothelial cells and also on
platelets. We have found by flow cytometry an apparent high frequency of
expression of vWF in different leucocyte subpopulation clusters.The lack of
observation of any other antibody or any isotype control binding except CD41
strongly suggests that the binding of vWf, which like CD41 is expressed on platelets,
was due to platelet-leucocyte aggregration and not due to any form of non-specific
binding.
Different anticoagulants have different effects on platelet-leucocyte aggregation
(PLA). Blood taken in heparin tubes showed a high frequency of platelets aggregated
with leucocytes, detected by CD41 expression in flow cytometry (Figure 5.8). Similar
behaviour was observed using citrate anticoagulant. In contrast EDTA tubes
presented much lower platelet-leucocyte aggregation: here it was still present but
at a much reduced frequency. We prioritised the use of EDTA tubes for taking
blood samples. However, in some clinics blood sampling tubes with EDTA
anticoagulant were not available and instead blood was taken into tubes containing
heparin anticoagulant. To further study this, blood was taken into heparin tubes
and then washed (as whole blood) in PBS/EDTA or PBS/EDTA with trypsin. This
apparently reduced PLA formation down to the level seen if EDTA was used as the
anticoagulant. There was some gain in reduction of PLA if trypsin was added, but
the addition of trypsin could digest some cell antigens and hamper phenotype
analysis.
Lignocain (a local anaesthetic) and chloroquine (an antimalarial drug) are known
to reduce PLA (Yun et al., 2002) and (Nosal et al., 2000) respectively. Therefore,
blood was taken in heparin and then washed with lignocain and chloroquine alone
or in combination with EDTA, and compared to washing in EDTA alone or in EDTA/
trypsin (Figure 5.9). Blood taken into heparin and then washed in EDTA/PBS
presented a large reduction in platelet-leucocyte aggregation, which further reduced
when EDTA/Trypsin had an even a better reduction in PLA, confirming the results
shown in Figure 5.8. Washing with lignocain did not apparently reduce PLA
formation in heparinised samples, and the reduction seen when washed with
lignocain/EDTA probably comes solely from the EDTA. The apparent reduction in
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PLA following washing with chloroquine is actually a reduction in CD41 expression
by platelets and probably represents no reduction of PLA formation in heparinised
samples: as for lignocaine the further reduction seen when washed with chloroquine/
EDTA probably comes solely from the EDTA. The chloroquine did not affect CD45
expression on the leucocytes (not shown): no other markers were studied.
EDTA/PBS was used as a washing solution whenever heparinised samples were
received. Although we achieved a reduction in platelet-leucocyte aggregation by
choosing to collect blood whenever possible in EDTA tubes, or using EDTA/PBS as
a washing solution for blood taken in heparin, PLA formation was not completely
abolished. Although vWf is expressed on mature endothelial cells, it is not specific
for EC and is also expressed on platelets. Therefore we could not ensure that vWf
positive cells seen in flow cytometry in sample analyses were endothelial cells and
not more common circulating leucocytes decorated with platelets in PLAs. Therefore
vWf was not used as an endothelial marker in our studies.
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Figure 5.8 Platelet-Leukocyte Aggregation (PLA) in whole blood flow cytometry
analysis. Effect of different anticoagulants.
Samples analysed in flow cytometry by "lyse-wash" following immunostaining in
whole blood. A. Typical forward-scatter v side-scatter dot-plot showing discrete
cell clusters. B. The same cells shown as a density plot to set regions on the major
cell concentrations which are (approximately): R1 lymphocytes, R2 monocytes. R3
granulocytes, R4 free platelets. C. The effect of "back-gating" these regions by
colour on the forward-scatter v side-scatter dot-plot showing lymphocytes in red,
monocytes in green, granulocytes in blue, and free platelets in magenta.
D: Blood taken in EDTA. E: blood taken in Citrate. F: blood taken in Heparin. The
pattern of staining with the anti-platelet antibody CD41 shows that large numbers of
other leukocytes, especially monocytes and granulocytes, are decorated with adherent
platelets when heparin or citrate is used as anticoagulant. The effect is much less
when EDTA is used as an anticoagulant, but is not abolished completely.
G: blood taken in Heparin. H: blood taken in Heparin and washed (as whole
blood) in EDTA/PBS. 1: blood taken in Heparin and washed (as whole blood)
in EDTA/PBS with trypsin. Washing heparinised blood samples in the
presence of EDTA reduces PLA formation substantially (H). Washing
heparinised blood samples in the presence of EDTA and trypsin reduces
PLA formation further, but does not abolish it (I).
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Figure 5.9 Platelet-LeukocyteAggregation (PLA) in heparinised whole blood. Effect ofdifferent
washing protocols.
Samples analysed in flow cytometry by "lyse-wash" following immunostaining in whole blood.
Regions were set in a density plot on the major discrete cell foci which are R1 lymphocytes (red).
R2 monocytes (green), R3 granulocytes (blue), R4 free platelets (magenta) as for Figure 5.8, using
a different sample donor.
Blood taken in EDTA (a) shows much less PLA formation (seen as CD41 staining on different
leucocyte populations) compared to blood taken in heparin (b). Blood taken in heparin and washed
with (c) EDTA/PBS shows reduction but not abolition of PLA formation, which further reduces if
washed with EDTA/PBS containing trypsin (d). Blood taken in heparin and washed with lignocaine/
PBS (e) shows no reduction ofPLA formation, but PLA formation reduces if washed with lignocaine/
PBS containing trypsin (f). Blood taken in heparin and washed with chloroquine/PBS (g) shows
reduction of CD41 staining on leukocytes, but this appears to come from a reduction of CD41
expression on platelets and not a reduction of PLA formation, and there is some apparent further
reduction of CD41 staining if washed with chloroquine /PBS containing trypsin (h).
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5.2.1.5 Unexpected expression of VEGFR2
VEGFR2 is thought to be specifically expressed by endothelial precursors and mature
cells. However, analysis of whole blood showed that other cells, in particular
granulocytes and monocytes, expressed VEGFR2 (Figure 5.10). Though this was
not seen in all samples tested. The incidence apparently of aberrant VEGFR2
expression was highest in mobilised peripheral blood patient samples (60%, n=20)
whereas it was not detected in mobilised peripheral blood donor samples (0%, n=4),
though this latter group was very small. In the non-mobilised sources tested the
highest incidence was seen in bone marrow (33%, n=9) and the lowest in normal
peripheral blood (6.25%, n=16), whilst in cord blood it was intermediate (30%, n=20)
(Table 5.3). Similar results were seen in peripheral blood samples taken from patients
participating in a clinical study of angioplasty. VEGFR2 expression was detected in
samples taken before, immediately after and at 6h and 24h following procedure.
VEGFR2 expression did not appear to be specifically associated with any aspect of
the procedure. Some patients were null at all time points, other were positive at all
time points whereas some appeared to up-regulate expression immediately following
the procedure (Figure 5.11).
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Figure 5.10. VEGFR2 unexpected binding
Whole blood flow cytometry analysis of the expression of VEGFR2-PE (R&D systems), a) FCS/
SSC. b and c) without and with anti-VEGFR2-PE antibody (blue) gated in FCS/SSC. VEGFR2
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Figure 5.11 VEGFR2 unexpected binding: different expression patterns
Figures 5.11,A,B and C show whole blood flow cytometry expression of VEGFR2-PE (R&D
systems) in different sample patient samples. A) VEGFR2 expression was detected in
samples taken before, immediately after and at 6h and 24h following procedure, B) VEGFR2
expression was not seen in any of the samples time points and C) VEGFR2 expression
changed depending on the time point of the clinical procedure. Blood source: patient
samples undergoing percutaneous coronary intervention (PCI).
mPBP (n=20) mPBD (n=4) nPB (n=16) BM (n=9) CB (n=20)
VEGFR2 60% 0% 6.25% 33% 30%
VE-cadherin 90% 75% 93.75% 100% 100%
Table 5.3 VEGFR2 and VE-cadherin unexpected binding: percentage of the cases
Proportion of the samples with VEGFR2 and VE-cadherin unexpected expression in the different
sources analysed (non-mobilised) peripheral blood (nPB) from healthy volunteers, bone marrow
(BM), umbilical cord blood (CB) and G-CSF-mobilised peripheral blood samples (mPBP. patients
for autologous grafts; or rnPBD, donors for allogeneic grafts).
5.2.1.6 Unexpected expression of VE-cadherin
VE-cadherin has also been proposed as a marker of mature endothelial cells.
Endothelial cell populations in all sources were found to express VE-cadherin.
However, non-endothelial cell populations were also found to express VE-cadherin.
This was more frequent than the above expression of VEGFR2, and seemed to be
associated with different lineages. 90% of mobilised peripheral blood patient samples
(n=20) and 75% of mobilised peripheral blood donor (n=4) samples were positive,
whereas non-mobilised samples showed an even higher incidence, 100% of bone
marrow (n=9), 100% of cord blood (n=20) and 93.75% of normal peripheral blood
samples (n=16) (Figure 5.12) (Table 5.3).
VE-cadherin expression in mobilised peripheral blood samples was associated with
cells having scatter characteristics of monocytes and lymphocytes, whilst that in
cord blood appeared to be limited to lymphocytes, specifically CDST cells (Figure
5.13).
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Figure 5.12 VE-cadherin unexpected binding
Whole blood flow cytometry analysis of the expression of VE-cadherin-PE (Santa Cruz
Biotechnology), a) FCS/SSC, b and c) without and with anti-VE-cadherin-PE antibody (blue) gated
in FCS/SSC. VE-cadherin unexpected expression mostly in the area of monocytes. Blood source:
G-CSF mobilised peripheral blood.
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Figure 5,13 VF.-cadherin unexpected binding: Cord blood compared to G-CSF mobilised
sources.
(A) Cord blood, FSC/SSC, (B) Density plot (C) and Dot plot VE-cadherin against CD8. (D) G-
CSF mobilised blood, FSC/SSC, (E)Density plot and (F) Dot plot VE-cadherin against
CD8.Regions: Granulocytes (red), Monocytes (blue), and Lymphocytes (green).
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5.2.2 Analysis of markers associated with endothelial
progenitor phenotypes in sources of haematopoietic
stem cells and in normal peripheral blood.
5.2.2.1 Numbers of leucocytes in samples
Total white blood cells per ml (wbc/ml) in the various samples were counted in a
haemocytometer using white cell diluting fluid. No significant differences were
detected between the various sources used.
5.2.2.2 Quantification of CD34+ cells.
The expression of CD34 on leucocytes was analysed in 10 bone marrow (BM); 21
cord blood (CB); and 32 mobilised peripheral blood (mPB), of these 27 were patients
for autologous transplant (mPBP) and 5 were donors for allogeneic transplantation
(mPBD). The results showed that as a fraction of total wbc the proportion of CD34+
cells was highest in mPBP samples at 1.46% as compared with bone marrow samples
at 0.71% and CB samples at 0.42% and that many of these differences in percentages
were significant (Figure 5.14a and Table 5.4). When total numbers of CD34+ cells
are calculated from wbc/ml values, both mPBP and BM had significantly higher
numbers of CD34+ than cord blood (Table 5.5). Normal peripheral blood (not
mobilised) (nPB) (n=16) presented a very low percentage and number of CD34"
cells (0.09%) compared to the other sources tested (Figure 5.14a; Tables 5.4 and
5.5).
5.2.2.3 Quantification of CD133+ cells.
The expression of CD133 on leucocytes was analysed in 8 bone marrow (BM); 7
cord blood (CB); and 10 mobilised peripheral blood (mPB), of these 7 were patients
for autologous transplant (mPBP) and 3 were donors for allogeneic transplantation
(mPBD). The distribution of CD133+ cells between sample groups was similar to
that of CD34+ cells in that again mPBP had the highest proportion of CD133+ cells
(mPBP samples at 1.04% as compared with BM samples at 0.46% and CB samples
at 0.41%) (Figure 5.14b and Table 5.4). Total numbers of CD133+ were higher in
mPBP and BM compared to CB (Table 5.5). G-CSF administration appears to
mobilise CD34+ and CD133+ cells in similar ways. Similar to CD34+ cells, the
proportion and numbers of CD133+ cells in peripheral blood (nPB) (n=16) were
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Figure 5.14 Expression of CD34 or CD133 markers in haematopoietic stem cell clinical
transplant sources and normal blood.
Percentage (of the total white blood cells) of cells expressing CD34 (a) or CD133 (b) in the
different tested sources. Sources were normal (non-mobilised) peripheral blood (nPB)
from healthy volunteers (HV), bone marrow (BM), umbilical cord blood (CB) and G-CSF-
mobilised peripheral blood samples (mPBP, patients for autologous grafts; or mPBD,
donors for allogeneic grafts). (* = p<0.05; ** = p< 0.01; *** = p<0.001, Mann-Whitney test)
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5.2.2.4 Quantification of CD133 and CD34 co-expression.
Analysis of CD133 expression by CD34+ cells in each sample group showed that
both the mobilised blood (mPB) groups (mPBP and mPBD) (79.76% and 71.78%
respectively) had significantly higher co-expression of CD133 by CD34+ cells as
compared to CB (53%) or BM (13%). The low co-expression of CD133+ on CD34+
cells in BM was similarly low in normal peripheral blood (nPB) (Figure 5.15 and
Table 5.4).
Analysis of the proportion of CD133+ cells which were CD34-negative showed that
this population is higher in BM (31.2%), CB (21.7%) and in nPB (33.1%) by
comparison with that of mobilised blood, mPBP (9.13%) and mPBD (11.9%) (Figure
5.15 and Table 5.4).
Similarly, the proportion of CD34+ cells which are CD133-negative was higher in
BM (63%), CB (35%) and in nPB (62.1%) by comparison with mobilised blood,
mPBP (15.85%) and mPBD (21.22%) (Figure 5.15 and Table 5.4).
It was noted that mobilised blood from healthy allogeneic HSC donors showed
similar CD34 and CD133 characteristics to mobilised blood from patients donating
HSC for autologous transplant, which infers that these characteristics are related to
G-CSF administration and HSC mobilisation rather than any underlying condition
related to the patients leukaemic diseases (in remission) or their chemotherapy. This
was true for all the results in this chapter where these sets of samples were compared.
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■ CD34+CD133- DCD34+CD133+ HCD34-CD133+
Figure 5.15 Percentage of cells expressing CD34 without CD133, CD133 without CD34,
or co-expressing both markers in haematopoietic stem cell clinical transplant sources
and normal blood.
Percentages (of their summed populations) of CD34 cells negative for CD133 expression
(black), CD133' cells negative for CD34 expression (hatched) and cells co-expressing CD133
and CD34 markers (white) were compared between the various sources tested. Normal
peripheral (non-mobilised) blood (nPB) from healthy volunteers (HV) (n=16), Bone marrow
(BM) (n=8), Cord blood (CB) (n=7) and G-CSF mobilised peripheral blood samples (mPBP,
autologous patients (n=7); or mPBD, allogeneic donors (n=3)).
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5.2.2.5 Quantification of CD34+ CD45dim ceils
CD45 is a recognised pan-leucocyte and haematopoietic cell marker. Apreponderance
of CD34+ cells express CD45 brightly, however a small number of CD34+ cells are
CD45 dim or negative. These CD34+ CD45dim cells are virtually absent in mobilised
blood sources; mPBP (1.93%) or mPBD (1.81%).
BM (11.08%), CB (15.08%) or nPB (37.34%) (Figure 5.16 and Table 5.4) showed a
significantly higher proportion of CD34+CD45dim than mobilised blood sources. The
majority of CD34+ cells in mPB have bright expression of CD45, which may indicate
that these cells are already destined to generate haematopoietic cells and their
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Figure 5.16 Percentage ofcells expressing CD34 but weak for CD45 expression in haematopoietic
stem cell clinical transplant sources and normal blood
Percentage of CD34+ cells which are weak to negative for CD45 expression in the different sources
tested. Normal (non-mobilised) peripheral blood (nPB) (n=16), bone marrow (BM) (n=10), cord
blood (CB) (n=21) and G-CSF-mobilised peripheral blood samples (mPBP. patient (n=27); or mPBD,
donor (n=5)). (* = p<0.05; ** = p< 0.01; *** = p<0.001. Mann-Whitney test)
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5.2.2.6 Quantification of VEGFR2+ cells as a proportion of the
CD34+ cells (CD34+VEGFR2+).
In the CD34+-rich HSC sources (i.e. excluding nPB), CB (8.93%) was the source
with the highest percentage of CD34+ expressing VEGFR2 cells, compared to BM
(5.43%), mPBP (3.92%) or mPBD (4.19%), (Figure 5.17 and Table 5.4). Although
cord blood had the highest percentage of CD34+VEGFR2+ it was the HSC source
with the lowest total number of CD34+ cells and therefore showed no significant
difference from BM and mobilised peripheral blood samples in terms of numbers
of CD34+VEGFR2+ cells (Table 5.5).
The percentage of CD34+ cells co-expressing VEGFR2 was significally higher in
normal peripheral blood (24.49%) than in any other source tested, even though
normal peripheral blood is relatively poor in CD34" by comparison (Figure 5.16
and Table 5.4). However, due to the very low number of CD34+ cells in normal
peripheral blood, the total number of CD34+VEGFR2+ co-expressing cells was
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Figure 5.17 Percentage of VEGFR2+ cells as a fraction of the CD34+ cells in haematopoietic
stem cell clinical transplant sources and normal blood
Percentage of CD34+ cells co-expressing VEGFR2 in the different sources tested. Normal peripheral
blood (nPB) (n=16), bone marrow (BM) (n=10), cord blood (CB) (n=21) and G-CSF-mobilised
peripheral blood samples (mPBP, patient (n=27); or mPBD. donor (n—5)). (* = p<0.05; ** = p< 0.01:
*** = p<0.001, Mann-Whitney test)
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5.2.2.7 Quantification of VEGFR2+ cells as a fraction of the
CD133+ cells (CD133+VEGFR2+)
Normal peripheral blood (nPB) was also the source with highest percentage of
CD133+VEGFR2+ (23.79%) cells compared to the other sources tested whereas bone
marrow had the lowest percentage (0.32%) (Figure 5.18a and Table 5.4). However
due to the low number of CD133+ cells in normal peripheral blood the total number
of CD133+ VEGFR2+ cells was similar to the numbers obtained in cord blood and
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Figure 5.18 Pattern of VEGFR2 expression with CD34 and/or CD133 expression in
haematopoietic stem cell clinical transplant sources and normal blood
(a) Percentage ofCD 133+ cells co-expressing VEGFR2, (b) Percentage ofCD133+ cells co-expressing
CD34 and VEGFR2 (c) Percentage ofCD34+ cells expressing VEGFR2 without expressing CD 133,
(d) Percentage of CD 133+ expressing VEGFR2 without expressing CD34, in tire different sources
tested. Normal peripheral blood (nPB)(n= 16), bone marrow (BM)(n=8), cord blood (CB) (n=7) and
G-CSF-mobilised peripheral blood samples (nrPBP, patient (n=7); or mPBD, donor (n=3)). (* =
p<0.05; ** = p< 0.01; *** = pcO.001. Mann-Whitney test)
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5.2.2.8 Quantification of CD133" VEGFR2+ cells as a fraction
of the CD34+ cells (CD34+CD133VEGFR2+).
The highest percentage of CD34" cells co-expressing VEGFR2 but not CD133 was
seen in cord blood (10.59%) and normal peripheral blood (20.42%) whereas the
percentage in BM and mPBP was much lower at (4.47%) and (0.89%) respectively.
Therefore, the majority of CD34 VEGFR2" cells in cord blood and normal peripheral
blood were CD133-negative (Figure 5.18c and Table 5.4).
5.2.2.9 Quantification of CD34+VEGFR2+ ceiis as a fraction of
the CD133+ cells (CD133+CD34+VEGFR2+).
The CD133+CD34+VEGFR2* population, positive for all three markers, was almost
below limits of detection by flow cytometry when acquisition of a minimum of
50,000 leucocyte events was used. The sources with higher proportions of
CD34CD133+VEGFR2+ were mPB (3.27% mPBP; 2.59% mPBD) and nPB (3.29%)
as compared to BM (0.43%) and CB (2.05%) (Figure 5.18b and Table 5.4).
5.2.2.10 Quantification of CD34VEGFR2+ cells as a fraction
of CD133+ cells (CD133+CD34 VEGFR2+).
This population did not show significant differences in terms of percentages between
the different sources analysed with the exception of peripheral blood which was
significantly higher than the other sources tested (Figure 5.18d and Table 5.4).
5.2.2.11 Mature circulating endothelial cells (CEC).
Circulating endothelial cells (CEC) are extremely rare in peripheral blood. To
demonstrate the presence of these cells in the sources studied, the frequency of cells
expressing CD146 but negative for expression of CD3 and CD45 were assessed
(CD146+CD3"CD45 ). As shown in Figure 5.19 and Table 5.4 these cells were highest
in bone marrow followed by cord blood, and lower in mobilised peripheral blood




























Figure 5.19 Percentage of mature circulating endothelial cells in haematopoietic stem cell
clinical transplant sources and normal blood
Percentage of cells expressing CD 146 hut negative for expression of CD3 and CD45 markers
(CD146+CD3"CD45). Normal peripheral blood (nPB)(n=6), bone marrow (BM)(n=6). cord blood
(CB) (n=6) and G-CSF-mobilised peripheral blood samples (mPBP, patients)(n=8) (* = p<().()5; ** =
p< 0.01; *** = pcO.001, Mann-Whitney test)
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5.2.3 Analysis of endothelial progenitor cells in sources
of haematopoietic stem cells and in normal peripheral
blood using a colony assay (CFU-EPC).
5.2.3 (a) Endothelial progenitor cell colony forming unit (CFU-
EPC) frequencies in sources of haematopoietic stem cells
and in normal peripheral blood
The endothelial colony assay described by Hill et al., (2003) was used to assess the
frequency of CFU-EPC for each of the potential sources of EPC studied. Hill et al.,
(2003) used a 48h primary fibronectin adhesion step to deplete mature EC and
phagocytes. CFU-EPC develop from the non-adherent cells on secondary culture
on fibronectin for a further 3 days. CFU-EPC are described as a core of round cells
surrounded by spindle-shaped cells (see Chapter 2 section 2.4.1.2).
Of the sources shown to be rich in CD34+ cells (i.e. BM, CB and mPBP), bone marrow
gave the highest frequency of CFU-EPC. Of these HSC-rich sources, bone marrow
was by far the best source, cord blood was lower, and G-CSF mobilised peripheral
blood (mPB) was virtually incapable of CFU-EPC generation, again similar for
both autologous patients (mPBP) or allogeneic donors (mPBD) (BM: 15.7 CFU-
EPC/106 cells plated; CB: 6.4 CFU-EPC/106 cells plated; mPBP: 0.9 CFU-EPC/106
cells plated; mPBD: 0.6 CFU-EPC/106 cells plated) (Figure 5.20 and Table 5.4).
However, the source which gave much the highest frequency of CFU-EPC was
normal peripheral blood, where the numbers of CD34+ and CD133+ cells are very
low. Following the primary depletion step peripheral blood MNCs generated an
average of 39.37 CFU-EPC/106 cells plated; thus 1 in 25,400 cells had the potential
to proliferate and generate endothelial colonies. After further time in culture, CFU-
EPC dissociated and the round cells from the core of the colony died or became
spindle shaped cells. By day 14 all cells were spindle-shaped, did not appear to
proliferate, but had elongated and interacted. These cells stained positive for Dil-




































Figure 5.20 Endothelial progenitor cell colony assay (CFU-EPC) in haematopoietic stem cell
clinical transplant sources and normal blood
Endothelial progenitor cell colonies (CFU-EPC) per 106 cells plated in the different sources
tested. Normal peripheral blood (nPB)(n=15), bone marrow (BM)(n=7), cord blood (CB)(n=ll)
and G-CSF-mobilised peripheral blood samples (mPBP, patient (n=ll); or mPBD, donor (n=5)).
(* = p<0.05; ** = p< 0.01; *** = p<0.001, Mann-Whitney test)
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5.2.3 (b) Endothelial progenitor cell colony forming unit (CFU-
EPC) appearance in sources of haematopoietic stem cells
and in normal peripheral blood
Where CFU-EPC from bone marrow, CB or mobilised peripheral blood sources
were seen they were morphologically different and much smaller than those
generated from peripheral blood mononuclear cells. All cord blood cells acquired
spindle shaped morphology while most of those from G-CSF mobilised samples
remained rounded, Figure 5.21
The CFU-EPC potential of the adherent cells normally discarded after the primary
adherence step was also tested. None of the sources tested showed colony formation
at the end of the 3 days nor were CFU-EPC seen even after 2 weeks in culture.




b) CB d) MB (Donors)
Figure 5.21 Images from endothelial progenitor cell colony assay cultures in different
haematopoietic stem cell clinical transplant sources and normal blood
Representative phase contrast images from CFU-EPC assay cultures from (a) bone marrow, (b)
cord blood, (c) mobilised peripheral blood (patients), (d) mobilised peripheral blood (donors) and
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Characterisation of endothelial progenitor cell colony forming
(CFU-EPC) potential in subpopulations of mononuclear cells
from haematopoietic stem cell sources and normal
peripheral blood
5.2.3.1 Flow cytometry characterisation of the cells used for
the CFU-EPC assay
A flow cytometry phenotype characterisation was performed on the cells which are
used in the final phase of the colony assay for endothelial progenitors (CFU-EPC).
These are the mononuclear cells (MNC) which remain non-adherent after the 2-
day of primary culture step on fibronectin-coated plates. The MNC sources (see
Figure 5.20 and Table 5.4) which were demonstrated to generate CFU-EPC (normal
peripheral blood and bone marrow) were compared with those sources which
generate few or no CFU-EPC (cord blood and G-CSF-mobilised peripheral blood),
for expression of a range of surface markers CD45, CD34, CD14, CD3, CD16, CD133,
VEGFR2, VE-cadherin, CD29, CXCR4, and GPla.
The number of non-adherent leucocytes recovered per ml of MNC sample was
similar in all the different sources analysed (~2xl06 wbc/ml). Equally, similar CD45
expression was detected in all sources although the percentage of CD45+ cells was
lower in cord blood and mobilised peripheral blood sources, probably due to the
presence of immature CD45-negative red cells, resistant to lysis (in flow cytometry
protocols), which frequently contaminate buoyant-density MNC isolates from cord
and mobilised blood. Percentages of CD45+ cells (gated in FSC/SSC) and percentages
of CD34+, CD133+, VEGFR2+, VE-cadherin+, CD29+, CXCR4+, CD3+, CD14+ and
CD16+ (gated on CD45+ (PercP bright) population) are shown below (Table 5.6).
VEGFR2+ cells as a fraction of the CD34+ cells and CD34 cells co-expressing VEGFR2
as a fraction of the CD133+ cells are also illustrated in table 5.6. As expected bone
marrow, cord blood and mobilised peripheral blood sources had significantly higher
numbers of CD34 and CD133+ FISCs by comparison with normal peripheral blood.
It was also noted that mobilised peripheral blood samples had a notably lower
number of CD3+cells (T-lymphocytes) and higher numbers of total VEGFR2+ cells
by comparison to the other sources. These were evidently not VEGFR2-expressing
HSC, since CD34+VEGFR2+ or CD34+CD133+VEGFR2+ EPC phenotypes were
significantly higher in normal peripheral blood and bone marrow by comparison
with cord blood and mobilised peripheral blood samples. No substantial differences
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5.2.3.2 Expression of CD29 (13-1 integrin) in cells used for the
CFU-EPC assay
Figure 5.22a shows the percentage these CFU-EPC primary culture (fibronectin
non-adherent) cells expressing CD29 (E-l integrin). The percentage of CD29+ cells
was much lower in sources which did not generate EPC colonies (cord blood and
mobilised peripheral blood sources) by comparison with those which did produce
CFU-EPC (normal peripheral blood and bone marrow) (cord blood v mobilised
peripheral blood p=0.03; cord blood v bone marrow p=0.001 and mobilised
peripheral blood v bone marrow p=0.015, Mann-Whitney test) (BM n=5, CB n=9,
mPBP n=6, mPBD n=2 and nPB n=6). Within the CD29+ population (gated in flow
cytometry), in all sources, no difference was seen in frequency of co-expression of
VEGFR2 or VE-Cadherin.
5.2.3.3 Expression of CXCR4 (SDF-1) in cells used for the
CFU-EPC assay
The percentage of cells (fibronectin non-adherent) staining positive for CXCR4 was
significantly lower in the sources which did not generate EPC colonies (cord blood
and mobilised peripheral blood) compared to those which did produce CFU-EPC
(normal peripheral blood and bone marrow) (Figure 5.22b) (cord blood v normal
peripheral blood p=0.0016, mobilised peripheral blood v normal peripheral blood
p=0.031, Mann-Whitney test) (BM n=5, CB n=9, mPBP n=6, mPBD n=2 and nPB
n=6). No differences between sources were seen of the co-expression of CXCR4 CD34
or CXCR4+CD133+. Percentage of CD34+ cells co-expressing CXCR4 ((47.4 CB)(47.8
BM)(50.1 mPBP)(66.4 mPBD) and (65.6 nPB)). Similarly percentage of CD133+
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Figure 5.22 CD29 and CXCR4 expression on cells which are non-adherent on fibronectin-coated
plates after the 2-day primary culture of the CFU-EPC assay
Non-adherent cells after 2-day primary CFU-EPC culture of MNC from different sources were
analysed and compared for the expression of CD29 (a) and for the expression of CXCR4 markers
(b).
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5.2.3.4 Effect of normal peripheral blood selective
mononuclear cell subpopulation enrichments on CFU-EPC
frequency.
5.2.3.4.1 Depletion/enrichment of CD34+ cells
Peripheral blood CD34+ cells were enriched from MNC by magnetic bead separation,
and the CD34-negative population was also recovered, and the two populations
were plated separately in a 24-well fibronectin-coated plate in complete endothelial
culture medium (CECM) (Stem cell Technologies, UK). After 5 days of culture the
number of spindle-shaped cells and the number of CFU-EPC colonies were counted
by microscopy. The CD34+ enriched cell fraction, with an average of 65% CD34+
purity, did not produce CFU-EPC, suggesting that these cells are probably not
directly the source of CFU-EPC. After 5 days the cells remained very small and
rounded (Figures 5.23a and 5.24) and after extended cultures started to die. By,
contrast the CD34 depleted fraction contained healthy spindle-shaped cells and did
generate some CFU-EPC, though at a much lower frequency than did unseparated
MNC (Figure 5.23b and 5.24).
5.2.3.4.2 Depletion/enrichment or depletion of CD133+cells
Peripheral blood CD133+ cells were magnetically separated from the CD133 negative
population and the two populations were plated separately in a 24-well fibronectin
plate with complete endothelial culture medium (CECM) (Stem cells Technologies,
UK). The CD133+ fraction (average of 70% purity), unlike CD34+ fraction (above),
did acquire 100% spindle-shaped cell morphology. These cells appeared to expand
but did not generate localised CFU-EPC colonies (see methods, described in chapter
2 section 2.4.1.2). After 12 days in culture the cells started to die, probably due to
the exhaustion of cytokines in the media. The CD133-depleted fraction behaved
very similar to the CD34-depleted fraction (above) and gave spindle-shaped cells,
which generated some CFU-EPC colonies though at a much lower frequency than
did unseparated MNC (Figure 5.23c and d and 5.24).
5.2.3.4.3 Cell-enrichment by adherence to tissue-culture plastic.
Peripheral blood MNCs were allowed to adhere to plastic for 2 hours in a 25cm2
tissue culture flask in IMDM medium. Cells remaining non-adherent after 2h were
recovered, then the plastic adherent cells were recovered by desorption. 81% of the
2h plastic adherent cell population were CD14 positive. The non-adherent cells did
not generate CFU-EPC colonies, whereas adherent cells had the capacity to generate
very large and characteristic CFU-EPC colonies at a much higher frequency than
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did unseparated MNC. (Figure 5.23e and f and 5.24). Thus, it appears that all CFU-
EPC are located in the plastic-adherent population from MNC.
5.2.3.4.4 CD14-positive cells are responsible for CFU-EPC, not CD14-
negative cells.
Peripheral blood MNCs following 2h plastic adherence were magnetically separated
or sorted by flow cytometry for expression of CD14, giving an average purity of
84% and 98%, respectively. Both CD14+ and CD14 negative cells were recovered
and plated in 24-well fibronectin-coated plates in CECM. After 5 days culture, only
the CD14+ cells from the plastic adherent MNC had generated CFU-EPC colonies
(Figure 5.23g and 5.24). No colonies were seen in wells containing CD14-negative
cells from the plastic adherent MNC (Figure 5.23h and 5.24). Thus, it appears that
all CFU-EPC are located in the CD14-positive population of the plastic-adherent
population from MNC
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Figure 5.23 CFU-EPC detection following selective cell-enrichments from normal peripheral
blood mononuclear cells. Phase contrast images
Phase-contrast images showing CFU-EPC and/or cell morphology of sub-populations of cells
isolated from peripheral blood MNC. a) CD34-enriched cells, b) CD34-depleted cells, c) CD 133-
enriched cells, d) CD133-depleted cells, e) cells not adherent to plastic after 2h, f) 2h plastic






































Figure 5.24 Frequency ofCFU-EPC detected following selective cell-enrichments from normal
peripheral blood mononuclear cells.
Number ofCFU-EPC derived from CD34+ cells, CD34 cells, CD133+ cells. CD133 cells, 2h plastic
adherent cells, 2h plastic-non-adherent cells, CD 14+ FACS-sorted cells and CD 14' FACS-depleted
cells were represented in this graph.
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5.2.3.5 Immunostaining and flow cytometry of the CFU-EPC
and accompanying cells.
Spindle-shaped cells and CFU-EPC generated from peripheral blood CD14+ sorted
cells were brightly positive for expression of Dil-Ac-LDL and retained CD14. These
cells also expressed CD45, VE-cadherin and the receptor for ulex europaeus
agglutinin-1 (UEA-1), though they did not express CD34 (Figure 5.25). Flow
cytometry results showed (in Figure 5.26) that increasing time of culture (up to 10
days) results in a concomitant down-regulation of expression of CD45, SDF-1 and
CD14, accompanied by up-regulation of VEGFR2 and CD146, presumably as cells
differentiate along an endothelial pathway. Expression of VE-cadherin, CD34 and






Figure 5.25 Immunostaining of cells in CFU-EPC assay cultures
Fluorescence microscopy images of immunohistology staining of CFU-EPC (a-d) and spindle-
shaped cells (e-g) derived from peripheral blood: (a and e) CD45 staining, (b and f) double positive
of Dil-Ac-LDL (green) and CD 14 PE (red), c) CD34-FITC staining (most of the cells were CD34




Figure 5.26 Comparison of the percentage of a panel of different surface markers before and
after CFU-EPC culture
Changes in expression of surface markers hy 2h plastic adherence CD 14+ peripheral blood derived
cells before (grey) and recovered following 10 day culture on fibronectin in the CFU-EPC assay
medium (orange). Results shown: panel a) down-regulation, b) no change and c) up-regulation of
markers.
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5.2.3.6 Which subset of the CD14+ cells?
CD14-positive cells are increasingly recognised as functionally heterogeneous, but
it is not known whether they are polyfunctional or whether different functions derive
from discrete subpopulations of CD14-positive cells. 2h plastic adherent peripheral
blood CD14+ cells gave an average of 40 CFU-EPC colonies/106 cells plated, giving
a frequency of about 1 cell out of 25,000 CD14+ cells plated being able to proliferate
to generate CFU-EPC in culture. Phenotypically distinct subsets of CD14+ cells were
isolated by flow cytometry sorting and subjected to the CFU-EPC assay in order to
further define the phenotype of the cell which generates CFU-EPC (Figure 5.27 a-
d).
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Figure 5.27 Regions set for sorting CD14+ cell subsets by flow cytometry
Cell sorting populations, a) CD 14+ and CD 14 cell sort, b) CD45-bright and CD45-dim staining, c)
CD 14+ VE-cadherin-positive cells and CD 14+ VE-cadherin-negative cells, d) CD 14+ VEGFR2-bright
cells and CD 14+ VEGFR2-dim cells. Gates were set by reference to appropriate unstained controls.
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5.2.3.6.1 CFU-EPC frequency in CD45-bright and CD45-dim cell
subpopulations of CD14-positive cells
2h plastic adherent peripheral blood CD14+ cells were sorted into CD45-bright and
CD45-dim subpopulations by flow cytometry and plated separately in fibronectin-
coated 24-well plates in CECM for at least 5 days. Both subpopulations of the CD14+
cells generated CFU-EPC colonies at a comparable frequency (Figure 5.28). However,
after an extended 14 days of culture 100% of the surviving cells in the CD14 CD45dim
fraction acquired a spindle-shaped morphology, whereas only about 70% of the
surviving cells in the CD14~CD45brlght fraction showed the same morphology. Some
cells in the CD14+CD45brightfraction became detached and died.
5.2.3.6.2 CFU-EPC frequency in VE-Cadherin+/- cell subpopulations of
CD14-positive cells
2h plastic adherent peripheral blood CD14+ cells were fractioned by flow cytometry
sorting into VE-Cadherin-positive or VE-cadherin-negative cell populations.
Following 5 days culture in CECM in fibronectin coated plates both fractions
generated CFU-EPC colonies. No significant difference in frequency was seen
between the two fractions (Figure 5.28).
5.2.3.6.3 CFU-EPC frequency in VEGFR2+/- cell subpopulations of CD14-
positive cells
Similarly, following 5 day culture in CECM on fibronectin coated plates no
significant difference in CFU-EPC numbers was seen between VEGFR2 or VEGFR2-


































Figure 5.28 CFU-EPC frequency in CD14-negative, CD14-positive and in various subsets of
CD14-positive plastic-adherent MSNC sorted by flow cytometry
Number ofCFU-EPC per 106 cells plated obtained from the different cell sorted populations; CD 14+
and CD 14". CD 14+CD45hnsht and CD 14+CD45dim, CD 14+VE-cadherin+ cells and CD 14+VE-cadherin
cells, d) CD 14+VEGFR2 bri«h' cells and CD 14+VEGFR2,lim cells.
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5.2.3.7 Flow cytometry analysis of the different CD14-positive
subtractions in whole blood between all putative EPC
sources.
Although CFU-EPC potential differed dramatically between sources, proportions
of CD14+ cells remained unchanged in the different putative EPC sources. It is
probable that not all CD14+ cells have this proliferative colony forming capacity.
Therefore different analysis of CD14+ subsets were repeated for all the putative EPC
sources studied (Table 5.7). No significant difference was seen between peripheral
blood and all the other sources studied for co-expression of CD14+ and the panel of
antigens tested. The only subsets where normal peripheral blood was significally
different to other sources were CD14+VE-cadherin+ cells (nPB v CB p=0.009) where
normal peripheral blood had a lower proportion compared to cord blood, and
CD14+CD29+ cells (nPB v BM p=0.03, nPB v CB p=0.01 and nPB v mPB p=0.01)
where normal peripheral blood had also a lower proportion of CD14+CD29+ cells
compared to the others. However no clear conclusion could be drawn to associate
these phenotypes with CFU-EPC potential.
Sample ADHERENT CD14+CD45+ CD14+VEGFR2+ CD14+VE-CAD+ CD14+CD29+ CD14+CXCR4 CD14+CD34+
average CB 95.71 53.08 24.42 99.47 49.26 1.74
average mPB 86.75 28.28 19.81 98.67 87.60 1.45
average BM 84.75 63.93 24.18 95.32 58.52 2.90
average nPB 99.00 52.84 4.55 67.99 82.84 0.37
Table 5.7 Phenotvpe characterisation of'CD14+ cells
2h plastic adherent cells CD 14+ cells from all-putative EPC sources studied were analysed for co-
expression of a panel of endothelial and haematopoietic markers: CD45, VEGFR2, VE-Cadherin.
CD29, CXCR4 and CD34. (BM n=5, CB n=9,mPBP n=5, mPBD n=2 and nPB n=6).
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5.2.3.8 Flow cytometry characterisation of plastic adherent
cells
Flow cytometry phenotype characterisation of the 2h plastic adherent population
was carried out, and a comparison between peripheral blood, bone marrow, cord
blood and G-CSF mobilised sources was made (Table 5.8). The percentage of CD45+
cells in 2h plastic adherent cells from peripheral blood and bone marrow was lower
than that seen in cord blood and mobilised blood. Peripheral blood contained lower
percentage of CD16+ cells compared to the other sources. It maybe indicates that
peripheral blood contains less CD16 immature neutrophils, which could be retained
after Ficoll MNC separation in the other sources. Moreover peripheral blood
contained slightly more VE-cadherin+ and CD14+ cells than all other sources tested










































































Table5.8Phenotypecharacterisationof2pl s icad er ntc ll Characterisationof2hplasticadh rentcellsbyflowcytometryusingp nfantib di specificforendothelialandhaem to ieticc lls.
5.2.3.9 Studies of reduced frequency CFU-EPC in cord blood
and G-CSF-mobilised peripheral blood MNC.
For comparison with results obtained using peripheral blood, selective enrichments
were also performed using cord blood and G-CSF mobilised blood. In both cases,
none of the CD34+ or CD133+ enriched populations were able to generate CFU-
EPC colonies (Figure 5.29). However, 2h plastic adherent cells from cord blood and
mobilised peripheral blood (75% and 74% CD14+ respectively) did generate some
CFU-EPC, but they were less frequent and not of the same size as those from
peripheral blood 2h plastic adherent cells (Figure 5.29).
Figure 5.29 CFU-EPC frequency in mononuclear cell subpopulations enriched from cord blood
and mobilised peripheral blood.
Number ofCFU-EPC derived from CD34-enriched cells, CD34-depleted cells, CD 133-enriched cells,
CD133-depleted cells, 2h plastic adherent cells, 2h plastic-non-adherent cells. From a) umbilical












5.2.3.9.1 Has cord blood inhibitory factors in its plasma to block the
endothelial colony capacity?
To test the hypothesis that the low frequency of CFU-EPC seen in cord blood samples
was due to inhibitory factors, increasing volumes of cord blood-derived plasma
was added to wells of peripheral blood non-adherent cells. Increasing plasma
concentration did correlate with a reduction in CFU-EPC (Figure 5.30). To rule out
the possibility that complement components in the plasma were responsible for the
effect the titration was repeated using plasma heated to 56C for 30 minutes to
inactivate complement activity. No difference was seen in CFU-EPC generation
using native or heat-inactivated cord blood plasma (data not shown). Further
investigation showed that inhibition of CFU-EPC by increasing concentration of
plasma was not specific to cord blood-derived plasma. Increasing concentrations of













Figure 5.30 Effect ofaddition ofcord blood plasma on assay ofCFU-EPC frequency in peripheral
blood MNC
Non-adherent peripheral blood cells after 2-day primary culture were plated. The number of CFU-
EPC per cells plated were counted in situations of increasing concentrations of plasma (0%, 5%,
10% and 20%) added to the CFU-EPC assay cultures. Cord-blood-derived plasma (orange) and
peripheral blood plasma from a healthy volunteer- derived plasma (magenta).
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5.2.3.9.2 Primitive erythrocytes present in cord blood and mobilised blood
MNC cultures
As both cord blood and mobilised peripheral blood have higher numbers of
immature erythrocytes by comparison to normal peripheral blood or bone marrow,
it was possible that these may have an effect on colony formation. Cord blood
samples lysis-treated by a short isotonic shock, were compared to non-lysed cord
blood samples. Results showed no difference in terms of number of CFU-EPC (data
not shown). In most of these samples isotonic shock was not enough for the exclusion
of all red cells, especially primitive red cells. An alternative method was tried, where
cord blood MNC were layered over a diluted Ficoll-Histopaque (1.057 density),
and centrifuged for 20 minutes at 500g. The cells floating above the Ficoll fraction
were the less dense cells such as red cells and platelets; all the leucocytes should
have sedimented in to the pellet. Such samples did not show any CFU-EPC frequency
difference either (data not shown).
5.2.3.10 Effect of G-CSF addition in vitro on peripheral blood
MNC CFU-EPC frequency
Low CFU-EPC generation was consistently observed in mobilised peripheral blood
in both autologous patients (mPBP) and allogeneic donors (mPBD), which were
virtually incapable of CFU-EPC formation (mPBP: 0.9 CFU-EPC/106 cells plated;
mPBD: 0.6 CFU-EPC/106 cells plated). To investigate whether this was a consequence
of a direct effect of the administered G-CSF, exogenous G-CSF was added to CFU-
EPC assay cultures at a final concentration of lOOng/ml (the concentration optimal
for ex vivo neutrophil differentiation from CD34+ cells, see Chapter 3). Control wells
received an equal volume of CECM without supplement. The results from 3
experiments showed a dramatic decrease in CFU-EPC number in the presence of
























Figure 5.31 Effect ofaddition ofG-CSF to the CFU-EPC assay
1 OOng/ml G-CSF in complete endothelial culture medium (CECM) was added to the non-adherent
peripheral blood cells after 2-day primary culture to assess CFU-EPC potential. Control wells
received an equal volume of CECM without supplement.
5.2.3.10.1 Effect of G-CSF administration on healthy individuals' peripheral
blood CFU-EPC frequency
To confirm that G-CSF is directly modulating CFU-EPC generation, longitudinal
peripheral blood samples were obtained before (pre) G-CSF administration, at PBSC
apheresis harvest (peri) and at 2 months follow-up (post). Previously studies samples
(above) were obtained at the time of PBSC apheresis harvest, which corresponds to
the "peri" samples in this study. Colony formation was drastically reduced (p=0.02)
(Mann-Whitney test, n=4) after G-CSF administration (26.72 CFU-EPC/106 cells
plated & 0.67/106 cells plated CFU-EPC average respectively) (Figure 5.32). In
samples taken 2 months after completion of G-CSF treatment (follow-up) CFU-




Figure 5.32 Effect ofG-CSF administration on CFU-EPC generation in a longitudinal study
Colony formation was assessed in peripheral blood samples obtained from the same healthy
donors (for allogeneic PBSC transplant) pre-, peri- and post G-CSF administration (follow up) (pre
n=4. peri n=4 and post n=l). a) histogram and b) graph with connected dots for each individual.
Data was statistically analysed using Wilcoxon paired test. The changes between pre and peri
samples were not significant probably due to the low number of samples analysed. Stats were not
used to post (follow-up) samples because of the only one sample analysed). Further recruitment of
samples is under study.
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5.2.3.10.2 Effect of G-CSF administration on healthy individuals' peripheral
blood putative EPC phenotype frequencies
Phenotyping by flow cytometry did not show any difference between the 3 sampling
points which could be associated with the alteration in CFU-EPC potential during
G-CSF administration. Following G-CSF administration cell populations expressing
CD34+, CD133+, and VEGFR2+ alone or in combination; i.e. CD34+CD133+ or
CD34+CD133+VEGFR2+ increased by comparison with the same samples before G-
CSF administration. CD45+, VE-cadherin, CD14+ and other marker combinations
remained unchanged (Figure 5.33 and table 5.9). A reduction in CD34+CD45dlm,
CD14+VE-cadherin+, and CD29+ cell populations was detected in samples at the
end of-G-CSF administration (Figure 5.33 and table 5.9).
G-CSF administration significally reduced the capacity of EPC colony formation.
I lowever the reason for this decrease is as yet unknown. Further analysis is required
before any conclusions can be drawn.
PRE PERI POST
%CD45+ 88.42 88.26 87.81
% CD14+ 5.24 5.72 5.86
%CD34+ 0.07 0.38 0.01
% CD133+ 0.02 0.26 0.04
%CD29+ 67.76 37.77 61.5
%CXCR4+ 43.72 45.58 69.8
% VE-cadherin 4.78 5.59 5.83
% VEGFR2+ 1.34 2.48 1.4
%CD34+CD45dim 44 0.2 25
%CD34+VEGFR2+ 33.25 37.93 25
CD34+CD133+ 30 84.95 87.5
%CD34+CD133+VEGFR2+ 9.05 16.89 37.5
%CD14+CD34+ 0.08 0.07 0
%CD14+VE-cadherin+ 85.97 48 75.42
%CD14+VEGFR2+ 3.63 17.67 0.42
%CD14+CD45+ 98.98 99.67 99.92
%CD14+CD29+ 99.05 96.35 99.19
%CD14+CXCR4+ 91.2 90.8 99.11
Table 5.9 Comparison of the percentage ofa panel ofdifferent surface markers pre, peri and post
G-CSF administration.
Characterisation of non-adherent peripheral blood cells after 2-day primary culture by flow
cytometry using a panel of antibodies specific for endothelial and haematopoietic cells pre, peri
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Figure 5.33 Changes in expression ofsurface markers by non-adherent peripheral blood cells
after 2-day primary culture pre, peri and post G-CSF administration
Results show down-regulation, no change or up-regulation of a panel of antibodies specific for
endothelial and haematopoietic cell markers in peripheral blood samples of healthy individuals
before (pre), during (peri) and after (post) G-CSF administration.
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5.2.3.11 Dose the addition of other growth factors influence
CFU-EPC generation?
To examine the possibility that other growth factors could also affect CFU-EPC
generation, peripheral blood MNC which remain non-adherent after the 2-day
primary culture step on fibronectin-coated plates were treated with lOOng/ml of a
range of different growth factors. Flt3-L, SDF-1, VEGF and GM-CSF enhanced
CFU-EPC generation whereas treatment with lOOng/ml of G-CSF or TPO caused
a reduction in CFU-EPC generation. Addition of lOOng/ml of bFGF and SCF did
not change the number of CFU-EPC (Figure 5.34).
Figure 5.34 Effect ofaddition of different cytokines to the CFU-EPC assay
The addition of I OOng/ml of SCF, SDF-1, Flt-3L, G-CSF, TPO, GM-CSF, VEGF and bFGF was studied
in terms ofnumbers of CFU-EPC. Results were expressed by the mean (SD) (n=2)
204
5.2.3.12 In vitro expansion of CD34+ VEGFR2+ (endothelial
precursor phenotype) cells and maturation to the endothelial
lineage
From previous studies on myeloid precursors (Chapter 3) we found that lOOng/ml
SCF plus lOng/ml Flt-3L was the optimal combination of cytokines for CD34+ cell
expansion in vitro, giving around 15-20 fold expansion in 14-day cultures (fold
expansion being the number of cells after 14 days expansion divided by the number
of CD34+ cells before culture). Most of the cells after culture expressed CD34 brightly
(see Chapter 3.3.3). In this study, we wanted to check if we could achieve (i) EPC
expansion and (ii) endothelial differentiation. In order to expand/differentiate stem
cells into the endothelial lineage we searched for specific growth factors with the
capacity to drive these CD34+-stem cells into the endothelial lineage.
5.2.3.12.1 Expansion of cell numbers
One of the first questions that we asked was if the presence of vascular endothelial
growth factor (VEGF) would inhibit the expansion of CD34 expressing cells compared
to our known optimal cytokine cocktail (SCF/Flt-3L) for CD34" expansion. VEGF
is a potent growth and angiogenic cytokine. It stimulates proliferation and survival
of endothelial cells, and promotes angiogenesis and vascular permeability (Shalaby
et al.r 1995; Plate et al., 1992). Basic fibroblast growth factor (bFGF) is a potent
angiogenic factor as well as a stimulator of blood vessel growth and an important
player in wound healing (Slavin et al.,1995). Cells cultured with VEGF growth factor
alone show minimal cell expansion. The presence of VEGF to the SCF/Flt-3L
expansion cocktail did not increase the expansion neither did reduce it (33.01-fold
expansion without VEGF versus 33.62 when VEGF was present) (Figure 5.35). 50ng/
ml of VEGF instead of lOOng/ml VEGF also did not have any significant alteration
of expansion numbers (Figure 5.36).
The addition of bFGF in the culture did not significally increase or reduce the
expansion cell numbers (20.71-fold expansion with bFGF versus a 26.56 expansion
without bFGF) (Figure 5.37). Similarly, the addition of lOOng/ml of the Sigma
cytokine complex, an extract of bovine neural tissue containing growth promoting
factors for vascular endothelial cells (Maciag et al., 1982), to the previous culture
conditions did not significally increase or reduce the expansion numbers (8.56 fold
expansion with Sigma complex compared to 9.85 expansion with SCF/Flt3-L+VEGF
alone)(Figure 5.38).
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The presence of Heparin in endothelial cultures have been shown to optimise
endothelial growth (Gargett et al, 2000; Bagley, 2003). Thus,the addition of 10 Units/
ml of heparin in the culture increased cell expansion though the result did not reach
significance (11.04 with SCF/Flt3-L+VEGF+heparin) compared to without it (9.85
SCF/Flt3-L+VEGF) (Figure 5.38).
None of these growth factors gave significant improvements in the expansion
numbers compared to SCF/FLT-3L/VEGF cytokine cocktail.
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Figure 5.35 CD34+ cell expansion with or without the presence of VEGF growth factor
Fold expansion (number of cells after 14 days / number of cells at day 0 of culture) after
cells culture with VEGF alone or with SCF/Flt3-L with or without the presence of VEGF.









Figure 5.36 Effect of the addition of 50 or lOOng/ml of VEGF to the SCF/Flt3-L expansion
cocktail.
Fold cell expansion of cells cultured with 50 or 100 ng/ml of VEGF growth factor with












Figure 5.37 Effect of the addition of lOng/ml of bFGF to the SCF/Flt3-L+50VEGF
combination of cytokines
Fold cell expansion of cells cultured with lOng/ml of bFGF with the SCF/Flt3-L+50 VEGF























Figure 5.38 Effect of the addition of heparin or of an endothelial cytokine complex
(Sigma, UK) to the SCF/Flt3-L+50VEGF combination of cytokines
Fold cell expansion of cells cultured with lOU/ml of heparin or with lOOng/ml of an
endothelial cytokine complex created by Sigma together with SCF/FH3-L+VEGF growth
factors. Data is presented as mean±SD (n=4 independent experiments).
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5.2.3.12.2 Endothelial cell differentiation
After 14 days of cytokine culture the percentage and the numbers of cells expressing
VEGFR2 in the different cytokine combinations was calculated. The presence of
VEGF growth factor induced an increase of the percent of VEGR2 and the total
number of VEGFR2+ cells/ml (Figure 5.39). Cells cultured with VEGF growth factor
alone had a high percentage of VEGFR2+ cells compared with the other combinations
(45% VEGFR2+ cells in the well of VEGF alone versus 37% SCF/FLT3-L+VEGF)
(data not shown). However, the cell expansion was almost none (0.03xl06 VEGFR2+
cells/ml) (Figure 5.39). VEGF alone may protect the VEGFR2+ cells but not the
other cells, so they survive and the other cells die.
Cells cultured in the presence of SCF/Flt-3L+VEGF growth factors showed significant
higher number of VEGFR2+ cells (0.18xl06 VEGFR2+cells/ml) compared to cells
cultured with SCF/Flt-3L without VEGF (O.llxlO6 VEGFR2+/ml) (p=0.007)(Figure
5.39) (being number of VEGFR2+ cell/ml as the % of VEGFR2+ cells x the number of
VEGFR2+ cells after 14 days of culture).
The use of 50ng/ml instead of lOOng/ml of VEGF did not significally matter in
terms of the number of VEGR2+ cells/ml after culture (0.20xl06/ml using lOOng/ml
versus 0.19xl06/ml using 50ng/ml of VEGF)(Figure 5.40). Therefore, we selected
lOOng/ml SCF+ lOng/ml Flt-3L + 50ng/ml VEGF as the endothelial expansion
cocktail.
Figure 5.41 shows how we calculate the percentages based on the flow cytometer
data.
Addition of lOng/ml of bFGF to the base endothelial differentiation cocktail (lOOng/
ml SCF+ lOng/ml Flt-3L + 50ng/ml VEGF) did not increase the numbers of VEGR2+
cells after culture. (0.17xl06 VEGFR2+/ml with bFGF versus 0.18 xlO6 with SCF/
Flt3-L+VEGF) (data not shown).
lOOng/ml of a Sigma Endothelial growth supplement (ECGS) that contain growth-
promoting factors for vascular endothelial cells used in endothelial cell lines was
added to the SCF/Flt3-L+VEGF cytokine combination as well of 10-100ng/ml of
Heparin. Figure 5.42 shows that addition either heparin or the sigma cytokine
complex did not increase significally the number of VEGFR2+/ml after 14 days of
culture (0.39xl06 VEGFR2" cells/ml with heparin, 0.33xl06 VEFGFR2" cells/ml with
the sigma cytokine complex versus 0.25xl06 VEGFR2" cells/ml with SCF/Flt-
3L+VEGF).
On the other hand, high proportion of VEGFR2 expression but no expansion was
observed when cells were cultured with the Sigma cytokine complex alone without
the expansion SCF/Flt3-L cocktail (data not shown). Like cells cultured with VEGF
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growth factor alone, Sigma cytokine complex might selectively protect VEGFR2+
cells, while without (SCF/Flt-3L) growth factors the rest of the cells die.
0.25n
Figure 5.39 Endothelial cell differentiation
Number of CD34f-derived VEGFR2 cells after ex vivo culture (% of VEGFR2" cells/
number of cells after 14 days of culture) after culture with VEGF alone (0.03xl06
VEGFR2- cells/ml) or with SCF/FH-3L with (0.18xl06 VEGFR2" cells/ml) or without
(O.llxlO6 VEGFR2 cells/ml) the presence of VEGF. Data is presented as mean+SD (n=8
independent experiments).
Figure 5.40 Endothelial cell numbers. Effect of the addition of 50 or lOOng/ml of VEGF
to the SCF/Flt3-L growth factors.
Number of VEGFR2 cells after culture with 50 or 100 ng/ml VEGF to the SCF/Flt-3L
combination of cytokines. Data is presented as mean±SD (n=5 independent experiments).
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Figure 5.41 Flow cytometry analysis of the ex vivo endothelial differentiated cells.
Flow cytometry analysis with a) FSC/SSC and h) percentage of VEGFR2* gated on the FSC/SSC
(magenta).
. Effect of the addition of heparin or of an endothelial
cytokine complex (Sigma, UK) to the SCF/FH3-L+50VEGF combination of cytokines
Number of VEGFR2 cells after culture with the presence of heparin or Sigma endothelial
cytokine cocktail with SCF/F13-L+VEGF cytokine combination. Data is presented as
mean±SD (n=4 independent experiments).
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5.2.3.12.2.1 Clonetics endothelial rich media
No significant improvement in terms of cell expansion or endothelial cell
differentiation was detected when the endothelial basal medium (EBM) (Clonetics,
UK) plus added growth supplements (hydrocortisone, hFGF-B, VEGF, R3-IGF-1,
Ascorbic acid, Heparin, hEGF, FBS, GA-1000) (Clonetics, UK) was used in
comparison to the Iscove's Modified Dulbecco Media (IMDM) with 10% FCS
(Biowhittaker,UK) 1% Antibiotic (penicillin/streptomycin) (lOOOOUnits/ml /10ug/
ml)respectively (Sigma, UK) (p=0.25) (Figure 5.43).
Eigure2L43 Endothelial cell numbers. Different culture mediums
Comparison of number of VEGFR2 cells/ml between IMDM (Iscove's, Modified Dulbecco's
media) (Invitrogen, UK) with EBM (endothelial basal medium) (Clonetics, UK). Data is
presented as mean±SD (n=3 independent experiments).
5.2.3.12.2.2.Culture on different substrates
No significant differences were detected in terms of number of VEGFR2' cells/ml
when cells were plated on fibronectin pre-coated wells or on gelatin pre-coated wells














Figure 5.44 Endothelial cell numbers. Culture on different substrates
Number of VEGFR2" cells/ml cultured in none, fibronectin or gelatin substrates. Data is
presented as mean+SD (n=3 independent experiments).
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5.2.3.13 CD34+ cells cultured with VEGF and subsequent CFU-
EPC potential.
Expansion of CD34+ cells from cord blood, G-CSF mobilised peripheral blood,
peripheral blood or bone marrow in the presence or absence of VEGF (SCF/Flt-
3L±VEGF) prior to CFU-EPC assay showed that both conditions generate spindle-
shaped cells but few endothelial colonies which were small (Figure 5.45). However,
this was more frequent following exposure to VEGF, which also resulted in some
cases in the formation of structures. Comparing different sources, cord blood gave
slightly higher numbers of spindle-shaped cells and CFU-EPC than did mobilised
peripheral blood (data not shown). Spindle-shaped cells were also shown to be
positive for Dil-Ac-LDL staining.
SCF/Flt-3L SCF/Flt-3L+ VEGF
a) After 3 days C) After 3 days
Figure 5.45 Endothelial progenitor cell colony assay (CFU-EPC) in ex vivo endothelial
differentiated cells
CD34" cells differentiated after 14 days culture with SCF/FH-3L alone (a,b)or with the
addition of VEGF (c,d) were then assessed for the CFU-EPC potential. Spindle-shaped cell
morphology and endothelial colonies were observed a,c) after 3 days , b,d) after 7 days
culture. Blood source: Cord blood
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5.2.3.14 CD34+ cells cultured with GM-CSF and subsequent
CFU-EPC potential
CD34+ cells were enriched and expanded with SCF/Flt-3L in the presence of GM-
CSF for 14 days prior to CFU-EPC assay. GM-CSF is a haematopoietic growth
factor that stimulates the development of neutrophils and macrophages and
enhances the functional activity of the mature end-cells (Jones, 1996). At 7 days,
expanded cells from all sources tested showed a rounded morphology and a high
expansion potential as observed in culture. After an extended culture period in CFU-
EPC assay (14-25 days) some spindle-shaped cells and CFU-EPC colonies appeared
(Figure 5.46). These occurred earlier in cells derived from nPB and BM than was
the case for CB and MB sources. Cultured BM derived CD34+ cells showed formation




EPCpotential CD34cellsfromdifferentsources(b nmarrow,no malperiph rall odmobilised peripheralbloodanc rl od)differe tiatedfter14yswi hSCF/Flt3-L+GM- CSF.Recoveredcellsw reth nassess dfCD14expres ionanCFU-EPCpot tial. Spindle-shapedcellmorphologyanndoth liac lonieswerobs rv daft r14-25 daysincompleteendoth lialul urmedium(CECM).
i of CFU-EPC over different time points
Differential speed of endothelial colony formation in the different sources used (normal
peripheral blood, bone marrow, cord blood and mobilised peripheral blood) of the CD34-
derived cells after SCF/Flt3-L/GM-CSF culture
5.2.3.15 MNCs differentiated to dendritic cells
Peripheral blood CD14+ cells produce both CFU-EPCs and dendritic cells. CD14+
cells differentiated to dendritic cells in the presence of GM-CSF and IL-4 (See 2.5.3).
When the CFU-EPC was assessed for such cells no colonies were detected (Figure
5.48) and the cells had typical dendritic cell morphology and phenotype as assessed
by flow cytometry. Cells high in forward and side scatter were brightly positive for















Figure5.48Schematicr presentationofdendric lliffe nti tiofr mCD14+ l s Mononuclearce lswereadhe edf2iplasticl sk,recov r dnc ltuIMDM withthepres nceofGM-CSFandIL-4growthfact rs.Aft r7d ycover dc llsw assessedforCFU-EPCpot ntial.
Figure 5.49 Dendritic cell characterisation
Flow cytometry analysis was used to phenotype 2h adherent cells recovered after 7 days
in GM-CSF and IL-4 growth factors. Expression of a panel of dendritic markers showed
that these cells were positive for the most common dendritic markers. First line show
from left to right; FCS/SSC, FL1-H (FITC), FL2-H (PE) and FL3-H (PercP) negative controls.
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5.2.3.16 Matrigel endothelial tube formation assay.
Mature endothelial cell lines have been shown to generate tubule structures in
matrigel cultures. However, in this study tubule formation was not seen either using
ex vivo cultured endothelial cells nor peripheral blood derived sub-populations
including CD133+, CD34+, 2h plastic adherent, 2h plastic non-adherent, CD14+ or
CD14" populations (data not shown).
5.2.3.17 Is there any relationship between adherent CFU-EPC
CD14+ cells and Mesenchymal stem cells (MSC)?
(Study in collaboration with Kay Samuel, SNBTS)
MNCs were plated into a flask for 4 days in Mesencult media (Stem Cell Technologies,
UK). Adherent cells after culture were considered putative MSCs able to differentiate
into bone cells (Kay Samuel, unpublished)
These putative mesenchymal stem cells (MSCs) were also plated in 24-well
fibronectin-coated plate in CECM to assess their CFU-EPC potential. After 5 days
in culture putative MSCs formed 35 CFU-EPC/106cells plated.
In parallel, non-adherent cells also harvested after 2 days on fibronectin as for the
primary step of the CFU-EPC assay described by Hill et al, (2003) generated 10
CFU-EPC/106 cells plated, but also after various expansion passages were positive
for bone cell markers (Figure 5.50). Further, different enriched cell populations such
as CD14+, CD14", CD34", CD34+, CD133+, CD133", were also capable to differentiate
to bone cells (data not shown).
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and osteogenic differentiation potential of the non-adherent 2-
day fibronectin cells.
Double differentiation potential of non-adherent cells harvested after 2 days on fibronectin
as for the primary step of the CFU-EPC a) osteogenic cell differentiation assessed by
Alizarin Red S staining and b) CFU-EPC potential (Hill et al, 2003).
5.2.3.18 Characterisation and CFU-EPC capacity assessment
through selective adhesion time points
Peripheral blood MNCs were allowed to adhere to plastic for 2, 24,48, 72 or 120
hours in 25cm2 tissue culture flasks in IMDM media. Cells remaining non-adherent
were discarded.
There was a gradual decrease in terms of CFU-EPC potential and endothelial
cellurarity thought the time points. 2h-adherent cells were the cell population which
generated the highest number of endothelial progenitor colonies whereas recovered
adherent cells after 72 hours in culture had no CFU-EPC potential (Figure 5.51).
Surface markers were analysed by flow cytometry and compared between the
adherent cells at the different time points.
VEGFR2, VE-cadherin, CD14, CD16, CD146, CD3 and CXCR4 positive expression
increased through the time points with a peak at 48h. CD45 and CD29 expression
decreased with longer adherent culture times and CD34 and CD133 expression
remained unchanged. CD14+ cell subsets were also analysed. CD14+ cells co-
expressing CD34 or VE-cadherin increased through the longer time points with a
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peak at 48h. CD14" cells co-expressing CD45 decreased though the time points and
no-significant change was detected in other CD14+ cell subsets such as CD14+CD29+or
CD14+CXCR4^ (Table 5.10).
T3
time of plastic adherence
Figure 5.51 Characterisation and CFU-EPC potential through selective adhesion time
points
Gradual decrease in terms of CFU-EPC numbers thought 2, 24, 48, 72 or 120 hours
adherence in 25cm2 uncoated tissue culture flasks.
041005 BC adherent cells 2h 72h I120K
%CD45+ 93.43 85.62 68 51.11 50
%CD34+ 0.08 0.06 0 0 0.1
%CD133+ 0.05 0.05 0 0 0.05
%CD34+CD45- 12.12 25 0 0
%CD34+VEGFR2+ 54.55 62.5 0 0
% VEGFR2+ 2.42 22 67.69 29.63 20.18
% VE-CAD+ 0.27 40.17 27.66 ? 11.77
% CD3+ 5.11 0.31 4.36 47.15 37.46
% CEC 3.5 3.22 55.31 15.56 25.48
% CXCR4+ 41 65.75 66 39.85 33.98
% C029+ 67.52 ? 58.43 25.81 43
% CD16+ 0.71 32.77 59.41 20.71 12
% CD14+ 26.42 65.61 58 12.42 12.28
% CD14+CD45+ 100 99.19 94.92 80 85
%CD14+CD34+ 0.3 0.58 1.69 0 0
%CD14+VEGFR2+ 97.48 ? 97.46 78 87
%CD14+VE-CAD+ 9.57 25 95.12 87 80
%CD14+CD29+ 99 98.7 95 92.5 97
%CD14+CXCR4+ 96.12 79.62 97.56 90 65
Table 5.10 Phenotype analysis by proportions in cells after different adherence time
points
Surface expression of a panel of markers specific for endothelial or haematopoietic cells





5.3.1.1 Use of endothelial cell lines as indicators of mature
EC phenotype and function
Endothelial cell lines expressing markers of mature endothelial cells and having
mature endothelial cell function were used in this study as controls for the assays
used to identify endothelial cells (EC) and endothelial progenitor cells (EPC). Both
HUVEC and the immortalised hybridoma endothelial EA.hy926 cell line showed
characteristic endothelial cell properties based on expression of markers detected
by flow cytometry, immunofluorescence and endothelial tube formation capacity.
However, EA.hy926 cells were much easier to culture, grew more quickly and had
indefinite expansion potential. Therefore, the EA.hy926 cell line was used in
preference to HUVECs.
The functional capacity difference between progenitor and mature endothelial cells
is currently unknown. The EA.hy926 cells appear to act like mature endothelial
cells and were capable of endothelial tube formation in Matrigel, but were not able
to form endothelial progenitor colonies in Hill's assay. Other studies have shown
that differentiated mature endothelial cells do not improve neovascularisation (Kalka
et al. a), 2000; Hur et al., 2004; Kocher et al., 2001). This suggests that an as yet
undefined functional characteristic of EPC compared to EC is essential for vascular
repair and regeneration following damage of endothelium leading to ischaemia
(Urbich and Dimmeler, 2004).
5.3.1.2 Platelet-leucocyte aggregates preclude use of
antibody to markers shared by platelets and endothelial cells.
Anumber of reports employ anti-Von Willebrand factor (vWf) antibody to determine
vWf expression as a marker of EC maturity. However, flow cytometry results
showed unexpected high expression of vWf by different freshly isolated leucocyte
subpopulations because of platelets adhered to their surface. Our results indicate
that EDTA anticoagulant has a lower effect on this platelet-leucocyte aggregation
effect and it was prioritised for the collection of our blood samples. Moreover EDTA/
PBS was used as a washing solution whenever samples were taken with heparin
anticoagulant. EDTA/PBS washing solution presented a reduction in platelet-
leucocyte aggregation compared to other washing solutions used. Even though
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platelet-leucocyte aggregation was reduced high amounts of vWf positive cells were
still detected by flow cytometry. Thus, we could not assure that all vWf seen were
indeed mature endothelial cells. vWf was not used as endothelial marker in our
panel of endothelial antibodies
5.3.1.3 Unexpected expression of VEGFR2 and VE-cadherin
on PBMNC populations
Monoclonal anti-humanVEGFR2 (KDR) (R&D systems) is thought to be specifically
a marker of endothelial cells. When tested in mature endothelial cell lines the
expression is specific. However, analysis of whole blood showed that other cells, in
particular granulocytes and monocytes expressed VEGFR2. This was not seen in all
samples tested. The incidence of VEGFR2 expression changed in the different sources
and in different samples collected at different time points following a clinical
procedure. Similarly, cells other than endothelial cell populations in all sources were
found to express VE-cadherin. VE-cadherin expression was mostly associated with
cells having scatter characteristics of monocytes (mainly in mobilised peripheral
blood samples) find lymphocytes (mainly in cord blood samples). The cause of this
VEGFR2 and VE-cadherin unexpected expression by these cells is unknown.
However, these markers specifically stained cultured mature endothelial cell lines
and cells after ex vivo culture. CD34+ and/or CD133+ cells did not experience this
unexpected expression Therefore, VEGFR2 and VE-cadherin markers were still used
as endothelial markers in these situations.
5.3.2 Putative EPC phenotypes in different HSC
sources
Identification and enumeration of angiogenic stem cells present in the adult remains
difficult and non-standardised. No single marker, truly specific for endothelial cells
has been identified; therefore it is currently necessary to use combinations of markers
to best identify mature circulating endothelial cells (CEC) and immature endothelial
progenitor cells (EPC). We have investigated the presence of the currently proposed
EPC phenotypes in the most common and practicable potential EPC sources. All
sources except normal peripheral blood (nPB) had substantial numbers of CD3A
and CD133+ cells, with mobilised peripheral blood being the source that had
significantly higher total numbers of CD34+ and CD133* by comparison to the
other sources. We found that mobilised peripheral blood also had higher proportions
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of CD34+ cells which co-expressed CD133+. This result agrees with findings of de
Wynter et al., (1998) who showed that 75% of CD34+ from post-G-CSF aphaeresis
samples were CD133+ compared with 50% in cord blood and 35% in bone marrow.
Thus in mobilised peripheral blood there is a strong correlation between expression
of CD34 and CD133 markers.
It is acknowledged that CD133 is expressed ontogenetically before CD34 and may
therefore be an antigen marking more primitive cells. Thus a CD34-negativeCD133+
cell may represent a more multipotent immature cell population. Our results show
(table 5.4) that bone marrow, cord blood and normal peripheral blood had higher
proportions of CD34-negativeCD133+ cells than mobilised peripheral blood sources.
This could suggest that normal peripheral blood, bone marrow and then cord blood
are sources that contain stem/progenitor cell populations with a higher proportion
of more immature cells than mobilised peripheral blood. Bone marrow, normal
peripheral blood and cord blood also had higher proportions of CD34+CD133 cells,
which by this reasoning can be considered a more mature stem cell population,
compared to mobilised peripheral blood sources.
The pathway of HSC maturation is not fully defined, and it is possible that expression
of CD34 and CD133 may be continuously up and down-regulated. Indeed
Quesenberry et al., (2002) have suggested that stem cells are continuously altering
their phenotype and that these alterations are reversible. Thus, many described cell
phenotypes could represent a single cell in different functional states. Moreover,
Lemoli et al., (2005) suggested that rather than a hierarchical transition from stem
cells to progenitor cells, fluctuation continues to exist in which stem cells adjust
their phenotype depending on the kinetic state of the cell; activated by their genetic
program or microenvironmental stimuli.
Overall, the characteristic expression of the CD34 and CD133 markers in mobilised
peripheral blood samples is completely different from that seen in normal peripheral
blood, bone marrow and cord blood and its clinical relevance is unknown. It may
be that G-CSF administration drives stem cells to a different kinetic state altering
their HSC phenotype and may be priorising myeloid HSC differentiation. In
contrast, phenotype expression of the proportions of CD34 and CD133 co-expression
innon-mobilised peripheral blood follows a closer pattern to that seen in bone marrow
than to mobilised peripheral blood samples.
Expression of CD45 is used to define cells of the haematopoietic lineage. CD34+ cells
with no or dim CD45 expression could represent a more primitive stage of HSC
differentiation, which may generate CD34+CD45+ cells. These more primitive cells
could give rise to cells of the haematopoietic lineage and also to non-haematopoietic
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cells such as EPCs. Conversely, it is possible that CD34+CD45dim cells represent a
more mature CD34+ cell differentiating into an endothelial cell type having lost
CD45, since CD34 is also expressed on mature EC. In either case, our results show
that the proportion of CD34+CD45dim cells is much lower in mobilised peripheral
blood samples, from both patients and allogeneic healthy donors, than is detected
in normal peripheral blood, cord blood or bone marrow.
Again it is the mobilised blood samples that presented a very different characteristic
expression of CD34+CD45dim cells compared to the other sources tested, and normal
peripheral blood CD34+ cells had much similar proportions of CD45dim cells to bone
marrow and cord blood despite their having much smaller numbers of CD34+ cells
in total. This may be due to the stimulatory effect of G-CSF administration. Again
G-CSF could selectively drive HSC myeloid differentiation which are CD45 bright
cells. In general, results for mobilised peripheral blood for both patients and donors
are similar, and probably indicate that the findings are not a reflection of underlying
differences in the patients whose blood was mobilised relating to any preceding
therapy for their leukaemia, since normally healthy donors PBHSC show similar
results following G-CSF administration. The significance and clinical relevance of
these differences between mobilised peripheral blood HSC and non-mobilised
peripheral blood and other HSC sources has not been addressed, though it does
raise the possibility that some loss of stem cell multipotency has occurred.
Endothelial progenitor cells (EPC) are defined by some (Pelosi et al., 2002; Botta et
al., 2004; Vasa et al., 2001; Quirici et al., 2001; Hristovef al. b), 2003)(see table 5.1)
as cells that share haematopoietic stem cell markers such as CD34 and/or CD133
and also express a more specific endothelial marker such as VEGFR2. In our results
cord blood is the haematopoietic stem cell-rich source that had the highest proportion
of VEGFR2+ cells as a fraction of the gated CD34+ population, followed by bone
marrow and then mobilised peripheral blood. However, normal peripheral blood
shows almost three times the proportion of CD34+ cells which are VEGFR2+
compared to cord blood. Conversely, due to the low CD34+ cell numbers in normal
peripheral blood the absolute numbers of CD34+VEGFR2+ cells/ml are much lower
in nPB than in BM, CB and mPB sources. Most of the CD34+VEGFR2+ cells in cord
blood and normal peripheral blood do not express CD133.
The presence of EPCs as defined by other groups was also investigated, such as
CD133+VEGFR2+ cells. Normal peripheral blood had the highest proportion of
CD133+VEGFR2+ cells compared to the other sources and bone marrow had the
lowest. For CD133+ cells co-expressing CD34 and VEGFR2, though this population
was almost below our limits of detection, mobilised peripheral blood and normal
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peripheral blood had the highest number compared to bone marrow or cord blood.
There was no significant difference between the HSC-rich sources analysed when
the CD34 VEGFR2 sub-population of CD133+ cells was compared. However normal
peripheral blood CD133+ cells had a 3-fold higher proportion of these cells than did
bone marrow.
In normal peripheral blood, proportions of the co-expression combinations of CD34,
CD133 and VEGFR2 were much higher than in bone marrow, cord blood or
mobilised peripheral blood. There was a lower percentage of CD34+ cells or CD133+
cells which did not co-express VEGFR2 compared to the other sources. However
few of them stained all together. Higher proportions of CD34+VEGFR2+ cells were
negative for CD133+ compared to the other sources and equally higher proportions
of CD133+VEGFR2+ were negative for CD34+ cells. Even though peripheral blood is
the source with higher proportions of these putative EPC phenotype cells it also has
the lowest number of CD34" and CD133+ cells. Therefore, in total numbers these
phenotypes were similar or lower them the other studied sources.
Subpopulations of cells showing different combinations of expression and co-
expression of CD34, CD133 and VEGFR2, which may represent EPC phenotypes
according to different publications, differ widely in proportion in the sources tested.
It is very difficult to interpret and compare results between published studies because
each group uses an individual EPC definition based on their experimental and/or
clinical preferences. CD34 and CD133 are both haematopoietic markers, but these
populations are only partially overlapping. Only about 53% in cord blood and even
a lower proportion in bone marrow and normal peripheral blood of the CD34+ cells
share the expression of the CD133 marker (see 5.2.2.4). Similarly, VEGFR2 antigen
is expressed by subpopulations of each of these fractions and only a very low
percentage of these cells co-express all three markers together (see 5.2.2.9). Therefore,
there is little chance that all published definitions of EPC refer to the same cell
population. The combination of the expression of these three markers could reflect
an hierarchy of EPC differentiation or cells in different kinetic states. Thus many of
these phenotypes may partly define endothelial progenitors of different ontogenic
status, which would explain why different groups using differently defined cell
subpopulations achieved similar results clinically. However, this cannot be
determined without the availability of individual clonogenic assays for each EPC
phenotype (Ingram et al., 2004). Ingram et al., (2004) described a single cell approach
that identifies a novel hierarchy of endopoiesis (analogue to haematopoiesis) based
on the single EPC clonogenic and proliferate potential. They proposed a terminology
similar to that used for defining haematopoietic cell progenitors. High proliferative
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potential endothelial colony-forming cell (HPP-ECFCs) give rise to macroscopic
colonies that form secondary and tertiary colonies on replating. These cells can give
rise to all subsequent stages of endothelial progenitors. The next endothelial stage is
a cell called LPP-ECFC that form colonies but they do not form secondary colonies
on replating. They can give rise to endothelial cell clusters that do not replate into
colonies or clusters and differentiate to a more mature endothelial cell.
The determination of which phenotype more accurately defines an EPC is essential
for further applications. With a better understanding of EPC origin and a more
precise EPC phenotype definition, more consensus between results, better and purer
EPC isolations and fewer opportunities for misinterpretation will follow.
The CD34+VEGFR2+ phenotype is currently the most widely used to define
endothelial progenitor cells (Pelosi et al., 2002; Botta et al., 2004; Vasa et al. 2001),
but CD133+VEGFR2+ (Gill et al, 2001) and CD34CD133+VEGFR2+ (Quirici et al.,
2001; Vasa et al., 2001; Peichev et al., 2000) are also popular, (also summarised in
table 5.1).
To elucidate which source has the greatest potential to generate EPC, an in vitro
functional EPC colony assay (CFU-EPC) was used. Measurement of CFU-EPC,
which is able to identify very low frequencies of such cells which would be difficult
to quantify by flow cytometry, should provide a sensitive indicator of the capacity
of circulating mononuclear cells to form endothelial cells. Unexpectedly, cord blood
which was found to have the highest proportion of CD34 VEGFR2* cells between
the haematopoietic stem cell-rich sources, generated one of the lowest CFU-EPC
numbers. Bone marrow was identified as the best source of CFU-EPC within the
HSC sources, as compared to both cord blood and mobilised peripheral blood.
Mobilised blood both from patients and from healthy donors was almost unable to
generate any CFU-EPC. However, normal (non-mobilised) peripheral blood, though
it had the lowest number by far of CD34+ and/or CD133+ cells, was the source with
the best potential to generate CFU-EPC colonies, more than double that seen for
bone marrow.
We found no association between the number of cells expressing CD34 and CD133
alone or in combination with VEGF and the number of CFU-EPCs generated.
Therefore, cells identified as EPCs using current phenotype definitions do not appear
necessarily to be the population of cells as defined by the in vitro CFU-EPC
functional assay. Though peripheral blood had high proportions of cells co-
expressing CD34, CD133 and or VEGFR2, the total cell numbers were lower than
or similar to the other sources studied. Yet normal peripheral blood had the highest
numbers of EPC colony forming cells. Therefore, it is unlikely that CD34+ cells or
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CD133+ cells identify circulating EPC in adult peripheral blood.
It is possible that the phenotype definitions of EPC currently in use are not definitive,
that the in vitro CFU-EPC does not detect true EPCs, or that the two methods used
detect different EPC populations. Whichever is the case, the results presented here
show no association between the diverse EPC phenotypes described in the literature
and the functional CFU-EPC assay.
5.3.3 Characterisation of endothelial progenitor cell
colony forming (CFU-EPC) potential in subpopulations
of mononuclear cells from haematopoietic stem cell
sources and normal peripheral blood.
As an alternative to a phenotype definition, Hill et ah, 2003 have proposed that
EPC may be quantified by their ability to form colonies under appropriate culture
conditions (CFU-EPC). Here we have tried to identify the EPC present in adult
tissues, by enriching for the different putative cell populations to establish which
subpopulation is associated with CFU-EPC potential. Cells were selectively separated
to high purity by plastic adherence or cell sorting using MACS or flow cytometry.
Cells were phenotyped and CFU-EPC forming ability was tested in the Hill assay.
We have shown that CD34+ cells in the absence of other cell types were unable to
proliferate or generate CFU-EPC in CECM media and that the cells died after a
short time in culture. CD133+-enriched cells behaved very differently than CD34 -
enriched cells even though CD133+ cells partially over lap with CD34+ cells. Despite
not being able to generate CFU-EPC colonies, 90% of the surviving CD133 cultured
cells presented a spindle-shaped morphology and stained positive for Dil-Ac-LDL.
In contrast to our expectation, of all the cell fractions tested CD14+-enriched plastic
adherent cells gave rise to the highest number of CFU-EPC. These CFU-EPC
outgrowths maintained CD14 and CD45 expression in culture and were also positive
for expression of UEA-1 receptor, and VE-cadherin and took up Dil-Ac-LDL.
However, they were negative for CD34 expression.
Initial discoveries of the existence of EPCs in the adult described the formation of
adherent endothelial cell precursors from enriched CD344 cells (Asahara et ah, 1997).
CD34+-enriched MNCs were also injected in mice with unilateral hind limb
ischaemia, and EPCs were localised after 1-6 weeks mainly in the capillaries of the
neovascularisated ischaemic tissue (Asahara et al., 1997). However, since the authors
did not use pure CD34+ cells (only 15% CD34+ cells), the EPC precise origin in their
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cultures remains unclear. In fact, the highest proportion of EPCs was obtained when
the CD34+-enriched population was cultured in the presence of CD34-negative cells,
containing high percentage of peripheral blood CD14+ cells. The relationship between
EPCs and monocytes is complex. There clearly seem to be non-monocytic EPCs,
but there also appear to be monocytes that have functional characteristics of CEC
and EPCs. Harraz et al., (2001) questioned whether CD34+ cells (being only 0.1% of
the total leucocytes) and as yet as many 10% of endothelial cells in the mouse
neovasculature are blood derived cells, whether such small population could have
such a profound effect on neovascularisation.
Since monocytes traverse the vascular wall during injury, share many antigenic
characteristics with endothelial cells, and are responsive to vascular endothelial
growth factor (VEGF), Harraz et al., (2001) considered the possibility that monocytic
cells might also function as EC progenitors. Monocytes could represent an
intermediate phenotype in the endothelial pathway, which leads to mature
endothelial cells. Camargo et al., (2003) showed by lineage tracking, that myeloid
cells are the haematopoietic stem cell-derived intermediates, which contribute to
muscle regeneration.
CD14 is a well-known monocyte marker. Monocytes are thought to be mature
end-stage cells with a limited potential to proliferate in culture. However, here some
cells within the CD14+ cells enriched by 2h plastic adherence, magnetic bead or
flow cytometry sorting have been shown to have high proliferative potential. After
only 3 days they formed relatively large CFU-EPC colonies.
CD14+ cells were also shown to differentiate to dendritic cells when cultured in the
presence of appropriate cytokines. These cells had typical dendritic cell morphology
and phenotype. When the CFU-EPC potential of these dendritic cells was assessed
in the Hill assay no colonies were detected.
Thus the CD14+ cell population may be extremely flexible, adapting to changes in
the external microenvironment. Ingram et al., (2005) hypothesised that these cells
could represent a unique form of macrophage differentiation, the angiogenic
macrophage, indicating a possible common origin for monocyte-macrophage and
endothelial lineages. Alternatively, it is possible that this is a heterogeneous population
comprising several independent cell types including CD14+ endothelial cell
precursors with a unique proliferative capacity. To determine the adaptability or
heterogeneity of this cell population will require further experimentation utilising
CD14+ cells derived from a single precursor cell.
Whichever is the case, only a specific subset of CD14+ cells, whether true monocytes
or independent endothelial precursors, act as stem cells with the ability to generate
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endothelial cells (Zhao et al., 2003). Although sorting of CD14" cells increased the
frequency of CFU-EPC formation the proportion of the enriched cells able to
generate CFU-EPC colonies was still low.
Subtractions of the CD14+-enriched 2h plastic adherent cells; CD14+CD45dim/
CD14+CD45brigh, CD14+VE-cadherin+, CDF4+Ve-cadherin-, CD14+VEGFR2+ and
CD14+VEGFR2" were isolated by flow cytometry sorting and put through the CFU-
EPC assay. CD45+ is a haematopoietic marker that is thought to be lost with
endothelial maturation. Fiowever, both CD14+CD45 bright and dim subtractions
formed CFU-EPC without major differences. Similar results were seen for the other
separations. Elsheikh et al., (2005) reported that peripheral blood monocytes co-
expressing CD14+VEGFR2" but not CD14+VEGFR2 monocytes had the potential
to differentiate in vitro into cells with endothelial characteristics and contributed
significantly after injury to the re-endothelialisation of femoral arteries. In our hands,
sorted CD14+VEGFR2+ and CD14"VEGFR2 both generated comparable numbers
of CFU-EPC.
Recently, Romagnani et al., (2005) reported a peripheral blood-derived cell
population with both endothelial and stem cell properties including high expression
of mRNA for Nanog and Oct4 suggesting multipotent properties. These CD14+
cells were negative for CD34 expression by conventional cytoflurometric techniques
but were found to express low levels of CD34 when assessed by the highly sensitive
antibody-conjugated magnetofluorescence amplification (ACMFL).
In our study attempts to isolate CD14+CD34~ and CD14+CD34low cell fractions
generated too few cells to assess their potential in the Hill assay.
Clanchy et al., (2006) showed recently that a subpopulation(s) of human monocytes
could proliferate in vitro in response to M-CSF. Presumably, these proliferative
monocytes aire less mature than the other monocytes. Carboxyfluorescein diacetate
succinimidyl ester (CFSE) labelling enabled the estimation of the number of
peripheral monocyte divisions over time. Following CFSE labelling and culture,
proliferative monocytes have shown to have a distinctive, spindle-shaped
morphology compared to non-proliferating population (Clanchy et al., 2006).
Fiowever, these authors have not linked any monocyte subpopulation with
endothelial properties. Future experiments will attempt to sort proliferative and non¬
proliferative CD14+ cells and assess their endothelial colony forming capacity and
phenotype.
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5.3.3.1 Putative EPC sources
Bone marrow, cord blood and G-CSF mobilised peripheral blood are sources rich in
CD34 and CD133 positive HSC which have been proposed as a possible common
precursor of EPC. In this study, results from the Hill assay showed that of these,
mobilised peripheral blood gave almostno colonies and cord blood gave few colonies.
Bone marrow had the highest frequency of CFU-EPC, but this was sill lower than
that achieved using HSC poor normal peripheral blood. Further, bone marrow and
cord blood colonies were much smaller and morphologically different from those
produced from peripheral blood. Whether it is because bone marrow and cord blood
contain less mature circulating CFU-EPC compared to normal peripheral blood is
unknown. These results, with those of experiments using CD34+ or CD133+ cell
populations suggest that HSC are not the cell population directly responsible for
CFU-EPC.
The data presented here is the first to show that immediately following G-CSF
treatment peripheral blood from healthy donors and patients is virtually unable to
generate CFU-EPC. Further investigations showed that prior to G-CSF
administration and 2 months following completion of treatment samples from
healthy donors showed good CFU-EPC potential, which was virtually abolished
immediately following G-CSF administration. This would be a cause of concern
regarding the use of G-CSF mPB for patients requiring endothelial reconstitution.
Moreover, a dramatic decrease in CFU-EPC numbers was seen after the exogenous
addition of G-CSF (see 5.2.3.10).
Unlike our results, Powell et ah, (2004) showed a 10-fold EPC colony-forming units
(CFU) increase over baseline measurements after G-CSF administration in patients
with coronary artery disease. However, similar to our results they showed an increase
co-expression of CD34+/CD133+ haematopoietic surface markers in samples after
G-CSF administration (see 5.2.2.4 and 5.2.3.10.2). Powell et ah, (2004) also reported
that there was no correlation between numbers of CD133/VEGFR2 cells measured
by flow cytometry and EPC colony-forming units in the culture, despite the increase
in circulating cells after G-CSF. Differences in CFU-EPC potential between our data
and Powell et al. data may be due to the two different patient groups analysed.
We are confident in our results obtained in the G-CSF mobilised samples as in all
the cases a dramatic decrease in CFU-EPC was found compared to non-mobilised
samples. Powell et ah started from a population of coronary artery patients where
they originally have a reduced CFU-EPC potential compared to healthy individuals.
Therefore, the CFU-EPC capacity starting levels were different in the two studies.
G-CSF mobilised samples showed similar flow cytometry numbers of CD14+ cells
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by comparison to peripheral blood, cord blood and bone marrow withno significant
differences between all the CD14+ subpopulations studied. 30 CFU-EPC/106 cells
plated were counted in samples before G-CSF administration. Thus, it means that
only 1 in 33,000 cells had the potential to proliferate and generate endothelial colonies.
In most cases 50,000 events were collected in each sample by flow cytometry and
even if 100,000 had been collected this would reflect less than 4 cells in total. Therefore,
any change of expression of these 4 cells in samples prior or after G-CSF
administration would have been below our limits of detection. How G-CSF
administration negatively affects CFU-EPC generation is currently being studied.
Also intriguing is the diminished colony potential in the Hill assay seen in cord
blood samples by comparison with bone marrow and even more strikingly to normal
peripheral blood samples. Ingram et al., (2005) suggested that cord blood and
peripheral blood EPCs could be derived from different populations of progenitors.
Lin et al., (2000) demonstrated outgrowth from CD14-negative cells of typically
endothelial cells (OEC) with long-term proliferative capacity. An increase of 15-fold
in this "late" colony potential was found in cord blood samples when compared to
peripheral blood colonies. CFU-EPC potential measured by Hill's assay may detect
early EPCs, and although cord blood may contain late outgrowth endothelial cells
it may not contain early EPCs which are being detected in peripheral blood and
bone marrow.
Currently EPC are defined as a bone marrow derived cells which incorporate into
sites of ischaemia and neovascularise damaged tissue. This is a general description
based on the outcomes of clinical trials where unselected, total bone marrow or
bone marrow mononuclear cells have been used rather than specific cell fractions.
It includes cells expressing CD34 and/or CD133, CD14+ adherent cells or
mesenchymal stem cells (MSC), therefore it is impossible to say which cell is
responsible for any beneficial effect seen.
The culture of unprocessed MNCs is one of the most common used methods to
obtain EPC (Tepper et al., 2002) and since adherence to the culture plate is an intrinsic
property of EPCs, this method could be used to obtain EPCs regardless of their real
origin (Zhang et al., 2006). Cytofluorimetric techniques have shown that these
adherent cells, considered as EPCs by a number of groups, consist of a cell population
which shares monocytic markers and EC markers (Romagnani et al., 2005; Kalka
et al. a), 2000; Rehman et al., 2005; Zhang et al., 2006). All these cells were positive
for endothelial markers such as ac-LDL, Ulex lectin (90%), CD31, and CD105; but
also positive for haematopoietic and monocyte/macrophage markers: CD45, CD14,
CDllc, CD16, CD86 and negative for CD34 or CD133 markers (Romagnani et al.,
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2005). Similarly, Kalka et al. a), (2000) showed that 90% of these primary adherent
EPCs after 7 days of ex vivo expansion also expressed CD14 monocyte marker.
Rehman et al., (2003) showed that MNCs after 4 days culture plated in fibronectin
coated flasks, were positive for ac-LDL and Ulex lectin, but also positive for CD45,
CD14 (95%) and CDllc (90.8%). Therefore, experiments that have defined EPCs
only as cells positive for ac-LDL and Ulex-lectin in fact fail to add that they were
also probably positive for the expression of monocyte/macrophage markers. Further
Zhang et al., (2006) believes that the so-called EPCs obtained by in vitro culture of
MNCs are in fact monocytes derived from CD34" haematopoietic cell, which can
express endothelial characteristics. These monocytes as well as being positive for
ac-LDL uptake performed a phagocytosis function of leucocytes/monocytes
maintaining their macrophage function throughout the in vitro culture (Zhang et
al., 2006). Conversely, Peichev et al., 2000 demonstrated that CD34+VEGFR2+CD133+
primary non-adherent endothelial precursors mature to endothelial cells and did
not show any expression of CD14. Thus, a second population of CD14-negative
cells seems to exist which is capable of forming endothelial colonies of long-term
proliferative capacity, referred as late outgrowth endothelial cells (OECs). Due to
their long term proliferation, these cells could provide higher cell counts typically
desired in tissue engineering applications (Zisch, 2004).
In summary, as measured by the Hill assay for CFU-EPC, the cell population able
to proliferate and generate colonies at the highest frequency are adherent CD14+
cells. Though immediately following in vivo G-CSF treatment this ability was lost.
5.3.3.2 Ex vivo expansion
Previous studies on myeloid precursors (Chapter 3) showed that CD34+ cells expand
up to 15-20-fold after 14 days culture in a simple SCF/Flt-3L cytokine combination.
We have studied the further addition of known endothelial growth factors as VEGF,
bFGF and others to evaluate cell expansion and endothelial differentiation. Repeated
experiments showed that none of these factors had any adverse effect on the cell
expansion numbers, but no significant benefit either.
Using expression of VEGFR2 as an index of endothelial differentiation it was found
that the addition of VEGF together with SCF and Flt-3L increased the number of
VEGFR2+ cells after 14 days as compared to that when VEGF was absent. Also the
addition of heparin in the SCF/Flt-3L expansion cocktail promoted endothelial
differentiation with an increase of the number of VEGFR2+ cells/ml after culture,
though this did not achieve significance.
Commercially available media specifically formulated for culture of mature
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endothelial cells and the use of fibronectin or gelatin coated plates were ineffective
in increasing the number of VEGFR2 cells derived from CD34+ enriched cells as
compared to controls cultured in basic cell media.
After 14 days culture with the SCF/Flt-3L+VEGF cytokine cocktail, about 24% of
the cells (0.3xl06 cells/ml) expressed VEGFR2. Similar numbers were achieved in
terms of VE-cadherin and UEA-l expression. Moreover, cultured cells generated
outgrowth endothelial colonies and cord structures. These cells were also positive
for Dil-Ac-LDL staining.
To investigate the relationship if any, between CD34+ and CD133+ cells and CD14+
cells, the generation of CFU-EPC by CD14+ cells derived ex vivo from CD34+ cells
from all the sources was tested. CD34 cells were enriched and cultured with cytokines
to generate CD14+ cells in first instance, which were then used in the Hill assay for
comparison with the results from CD14+ cells isolated directly from all sources tested.
The generation of CD14+ cells from CD34+ cells was achieved from all sources and
the cells were characterised by flow cytometry. In the Hill assay, spindle-shaped
cells and some CFU-EPC colonies were seen using cells derived from all sources,
though the colonies were smaller by comparison to those detected when CD14+
adherent cells were used. Importantly, the CD14+ cells derived by ex vivo expansion
of CD34+ cells from G-CSF mobilised peripheral blood and cord blood generated
spindle-shaped cells and CFU-EPC after 2 weeks of culture. CD14+ cells could
represent an intermediate phenotype in the endothelial pathway, which leads to
mature endothelial cells. Therefore CD34 and/or CD133+ cells could be the original
cell population which after culture develops into an intermediate CD14+ cell able to
generate CFU-EPC. Whether the CD14+ cell has a limited proliferative potential
compared to a more multipotent CD34+ and/or CD133" is still not resolved.
It is not known if there is any relationship between mesenchymal stem cells (MSC)
and CD14+ cells. Putative MSC isolated from peripheral blood were able to generate
CFU-EPC after 5-day culture in endothelial culture media comparable to that
achieved using selected CD14+ cell populations. Further, following the primary
fibronectin adherence step in the Hill assay, cells remaining non-adherent, cultured
in conditions optimal for expansion of MSC could be differentiated along the
osteogenic lineage.
Thus, whether a single cell has the potential to act as a mesenchymal and an
endothelial progenitor cell exist in the progenitor cell or same starting material
remains an aim of further study.
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Chapter 6
Endothelial progenitor cell frequencies in peripheral
blood: clinical studies
6.1 Introduction
The traditional paradigm of vascular repair is based on the proliferation and
migration of pre-existing mature endothelial cells from the adjacent vasculature
(Risau, 1995). The discovery by Asahara and colleagues that mononuclear cells in
peripheral blood have the potential to differentiate into endothelial cells has launched
a new field of cardiovascular research (Asahara et al., 1997). As discussed in Chapter
5, endothelial progenitor cells (EPCs) are increasingly characterised by their
expression of both haematopoietic (CD34 and/or CD133) and endothelial cell markers
VEGFR2 (also known as KDR), but a definitive phenotype remains elusive. These
putative EPCs or their progeny form vascular structures in vitro and are incorporated
into the vessel wall in experimental models of neovascularisation (Murohara et al,
2000). These cells may have an important role in the maintenance and repair of the
vascular endothelium, and in the pathogenesis of atherosclerotic plaque formation
and its consequences. A number of recent experimental and clinical studies have
revealed that ischaemic heart diseases and peripheral vascular disease can effectively
be treated by autologous EPC transplantation into affected tissue as presented in
5.1.17 section of the Introduction.
Endothelial progenitor cells can be isolated and cultured from a variety of cell
populations in peripheral blood and bone marrow, but as yet no definitive phenotype
has been ascribed to EPCs. Comparisons between clinical studies have been limited
by the use of a variety of phenotypic markers to discriminate EPCs and by the lack
of comparable functional assays. In the face of an uncertain phenotype, the EPC
colony forming unit assay (CFU-EPC) has emerged as an alternative specific
enumeration system for EPCs (Hill et al., 2003). Although groups are increasingly
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quantifying either phenotypic EPCs (CD34+KDR+) or functional CFU-EPCs, few
clinical studies had reported both or commented on the relationship between
phenotype and function at the time when we undertook these studies.
Using various parameters of measurement, endothelial progenitor cells have been
reported to be infrequent in peripheral blood. In cardiovascular diseases they may
be even lower, but numbers seem to increase in response to myocardial ischaemia
and acute myocardial infarction (Adams et al., 2004; Massa et al., 2005). Reduced
numbers of EPCs have been demonstrated in cigarette smokers (Vasa et al., 2001),
patients with diabetes mellitus (Fadini et al., 2005), and in those with evidence of
endothelial dysfunction (Herbrig et al., 2006). These patients are at high risk of
complications following percutaneous coronary intervention (PCI). Furthermore,
patients with diffuse in-stent re-stenosis have reduced EPC number and function in
comparison with matched controls at the time of presentation (George et al., 2003).
Inadequate EPC number and function prior to angioplasty, as well as inadequate
early and sustained EPC recruitment, may favour a maladaptive response to arterial
injury and result in an increased incidence of in-stent thrombosis, re-stenosis and
ischaemic complications. The immediate effects of local vascular injury during
angioplasty and stenting on the mobilisation of EPCs are not known.
Patients with type 1 diabetes experience poor wound healing secondary to a reduced
capacity to form collateral vessels in areas of tissue ischaemia (Tamarat et al., 2004).
Until recently the reasons for this have remained unknown. However, with the
identification of bone marrow-derived endothelial progenitor cells (EPCs), it is now
thought that the quantitative and qualitative changes seen in this cell group in
patients with both type 1 and type 2 diabetes are critical to the process of impaired
neovascularisation (Loomans et al., 2004; Asahara et al., 1997; Fadini et al., 2005;
Awad et al., 2005).
Ischaemic heart disease is a major cause of morbidity and mortality worldwide.
Despite advances in percutaneous coronary intervention (PCI), major adverse
cardiac events occur in up to 30% of patients following balloon angioplasty and
20% following stenting (Serruys et al., 1994). Vascular trauma, induced by
percutaneous intervention, initiates a sequence of events in which the release of
cytokines and growth factors result in the proliferation of smooth muscle and
deposition of platelets and leucocytes at the site of injury, accelerating vascular repair.
Endothelialisation is necessary to prevent mural thrombus formation and neointimal
hyperplasia that may otherwise lead to ischaemic complications and restenosis.
The aim of these clinical studies presented in this last chapter was to measure both
circulating phenotypic EPCs by flow cytometry analysis, functional CFU-EPCs by
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cell culture and endothelial cell marker message mRNA by real-time PCR following
a) PCI in patients with stable coronary disease b) elective abdominal aortic aneurysm
repair in patients as a model of tissue ischaemia and blood vessel damage and c) in
type 1 diabetes patients.
6.2 Results
Clinical assessments, interventions and blood sampling, were carried out by Dr.
Nick Mills (Centre for Cardiovascular Science, Edinburgh University).
Total and differential blood cell counts and serum C-reactive protein concentrations
were measured in the Department of Haematology, University of Edinburgh).
Leucocyte m-RNA values for specific genes were analysed by Dr. Chris Millar,
Department of Haematology, University of Edinburgh).
Peripheral blood phenotyping by flow cytometry and endothelial colony assays
(CFU-EPC) on all samples were carried out by me.
6.2.1 Coronary angiography and percutaneous coronary
intervention (PCI) (Study in collaboration with Dr. Nick Mills(Centre for Cardiovascular
Science,Edinburgh University)
There were no complications arising from angiography or PCI and all patients (Table
6.1) were discharged home 24 hours after procedure.
6.2.1.1 Inflammation and myocyte necrosis
Diagnostic angiography did not increase peripheral blood leucocyte count or serum
C-reactive protein concentrations (Table 6.2). Coronary intervention increased
neutrophil count (Dl.31±0.35xl09/L, P<0.001) and serum C-reactive protein
concentrations (D2.5±1.5mg/L, P=0.001) at 24-hours. There was an apparent
transient significant reduction in monocyte count immediately following
catheterisation alone (D-0.08 ±0.05xl09/L, P=0.15) that was present after PCI (D-
0.10±0.0.3xl09/L, P=0.005). Monocyte count returned to pre-procedure levels by 24
hours. There was no evidence of significant myocyte necrosis 24 hours following
diagnostic angiography or PCI.
6.2.1.2 Endothelial progenitor cells
Mononuclear cells plated on fibronectin formed typical colony forming units (CFU-
EPCs), characterized previously as a central cluster of rounded cells surrounded by
radiating thin, flat cells (Hill et ah, 2003) . Although unaffected by diagnostic
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angiography, the number and cellularity of CFU-EPCs were increased 24 hours
after PCI (Figures 6.1 and 6.2). Direct staining confirmed that CFU-EPCs, like mature
endothelial cells, bound ulex europaeus lectin and integrated acetylated-LDL. The
majority of both small round cells and spindle shaped cells expressed CD14 (See
5.2.3.5)
The increase in CFU-EPCs or functional endothelial progenitor cells was not
associated with an increase in the number of circulating CD34+KDR+ cells (Table
6.3). Interestingly there was no correlation between EPCs identified by phenotype
(CD34+KDR+ cells) and the number of functional EPCs quantified using cell culture
(CFU-EPCs) either before (r=-0.15, P=0.58) or 24 hours (r=0.02, P=0.94) after
angiography. Similarly, there was not a significant increase in leucocyte CD34
mRNA following angiography or PCI (Table 6.4). There was however, a significant
reduction in the leucocyte CD14, CD34, VE-cadherin, and vWF mRNA immediately
after catheterisation in both diagnostic and interventional studies, which coincided
with the reduction in circulating monocytes. Relative quantities of leucocyte mRNA





Age (years) 62±2. 59±3
Sex (male/female) 11/9 14/6
Cigarette smokers 4 3
Diabetes mellitus 7 2
Hypertension 12 12
Previous MI 2 3
Previous PCI 1 7
Prior CABG 0 1




Fasting Glucose (mg/dL) 151±18 10044
C-reactive protein(mg/L) 3.9±0.7 2.540.8
Number of diseased vessels
Normal/minor disease 12 0
1 vessel disease 0 9
2 vessel disease 4 8
3 vessel disease 4 3
Stent implantation







ACE inhibitor/ARB 10 12
Values are presented as number or mean 4 SEM
Table 6.1
Clinical characterisation and angiographic findings of patients undergoing diagnostic




6 hours 24 hours
Angiography
^e1unC9°,^teS 6.5 ±0.3 6.7 ±0.4 6.9 ±0.4 6.3 ± 0.4(xlO /L)
??Ar0Tphlls 3.8 ±0.2 4.3 ±0.4 4.2 ± 0.3 3.7 ±0.3(xlO /L)
Ly-ecytes 1.9 ±0.1 1.7 ±0.1 1.9 ±0.2 1.8 ±0.2
(xlO /L)





Leucocytes 7.1 ±0.4 6.7 ±0.3 7.2 ± 0.2 8.2 ±0.3*
(xlO /L)
^nWl1118 4.4 ±0.3 4.2 ±0.3 4.5 ± 0.2 5.7 ± 0.3f(xlO /L)
^y™?J°.CyteS 1.8 ± 0.1 1.7 ± 0.1 1.9 ± 0.1 1.7 ±0.1(xlO /L)
(xU)°/L)eS 0.58 ±0.03 0.48 ±0.04* 0.58 ±0.02 J 0.56±0.03J
C-reactive protein 2.5±0.8 . . 5±L6*
(mg/L)
Values are presented as mean ± SEM
*P<0.05, t<0.001 pre-procedure versus time point
JP<0.05 post-procedure versus time point
Table 6.2 Markers of inflammation following diagnostic angiography or percutaneous
coronary intervention
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Figure 6.1 Phase contrast images of CFU-EPC detected before and after PCI




















Baseline 24 hours Baseline 24 hours
Figure 6.2 Frequency of CFU-EPC detected before and after diagnostic angiography or
PQ
Number of CFU-EPCs before and 24h following diagnostic angiography (P=0.8) or PCI
(P=0.05).
242
**r^r P°!i~ ^ hours 24 hoursprocedure procedure
Angiography
CD34+cells (% 0.100 ±0.019 0.082 ±0.015
leucocytes) 0.016 0.028
CD34+KDR± cells
0 030±0 0io 0.020 ±0.005 ^nirfleucocytes) 0.004 0.007
CD34± cells (x
103/mL blood)
6.54 ±0.92 5.43 ±0.80 5.98 ±0.81 5.67 ±1.15
S34T+^RiCellS (X 2.11 ±0.69 1.45 ±0.41 1.47 ±0.26 1.52 ±0.3810 /mL blood)
PCI
CD34+ cells (% 0.083 ±0.011 0.105 ±0.011 °n°7,1± Ymrfleucocytes) 0.012 0.010
CD34+KDR+ cells (% a019±Q003 0.029 ± 0.006
leucocytes) 0.004 0.004
CD34± cells fx
InV t u T 5.40 ±0.61 7.00 ±0.82 6.33 ± 0.84 6.55 ±0.7610 /mL blood)
?5/34jH^PRtCellS ** 1.15 ±0.19 1.91 ±0.47 1.28 ±0.29 1.65 ±0.3610 /mL blood)
Values are presented as mean ± SEM








6 hours 24 hours
CD34 1.7 ±0.3 1.1 ±0.2* 1.6 ±0.3 2.5 ±0.8
CD14 3.1 ±0.4 2.1 ±0.3* 2.2 ±0.3 2.9± 0.5
vWF 2.5 ±0.5 1.7 ±0.2* 1.8 ±0.4 2.3 ±0.7
VE-cadherin 4.4 ±2.0 2.8 ± 1.3* 3.3 ± 1.7 6.9 ±4.6
PCI
CD34 2.3 ±0.5 1.6 ±0.5* 1.9 ±0.4 2.1 ±0.4
CD14 3.3 ±0.5 2.1 ±0.4* 3.1 ±0.7 4.7 ± 1.0J
vWF 2.3 ±0.4 2.0 ±0.4* 1.9 ±0.3 2.5 ±0.5
VE-cadherin 1.5 ±0.3 0.9 ± 0.2 f 1.3 ±0.3 1.5 ±0.4
Values are presented asrelative quantities,mean ± SEM
*P<0.05, t<0.001 pre-procedureversus time point
£P<0.05 post-procedure versus time point
Table 6.4 Leukocyte mRNA levels following angiography or percutaneous coronary
intervention
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6.2.2 Aortic Aneurysm repair
(Study in collaboration with Dr. Chris Millar, Department of Haematology, University of
Edinburgh).
6.2.2.1 Comparison between patients prior to aortic aneurysm repair and
control subjects
Prior to surgery differences between the patient group and control subjects were
analysed. The mean number of functional CFU-EPCs was significally lower in
patients by comparison to that detected in the control group (Figure 6.3). In contrast
flow cytometry measurements of CD34, CD133, VEGFR-2 and VE-cadherin did
not differ significally in patients prior to aortic aneurysm compared to the control
group (table 6.5). Furthermore, there was no significant difference between the
patient group and control group in the relative quantity of mRNA for CD34, VEGFR-


















EigureAS. Comparison of median colony numbers and median percentage positivity of
EPCs in control versus pre-treatment patient group.
The control group was not cohort matched with the patient group. The control group
had a higher median number of cell colonies (0.27x10^:0.06xl04) compared with the patient
group (0.07xl04±0.03xl04). This difference was statistically significant (p=0.005).
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Table 6.5. There were no statistically significant differences between the groups in the
median percentage of cells expressing CD34 (p=0.7), CD133 (p=0.93), VEGFR2 (p=0.18) and
VE-cadherin (p=0.08)
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Table 6l6. Comparison of median relative mRNA levels between the control group and
the pre-treatment patient group.
The control group was cohort matched for age and gender with the patient group. There
were no statistically significant differences found between the two groups in the RQ
values for CD34 mRNA (p=0.237), VEGFR2 (p=0.6454), VE-cadherin (p=0.863) and vWF
(p=0.999).
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6.2.2.2 Leucocyte and CFU-EPC quantitation following surgery for aortic
aneurysm repair.
6.2.2.2.1 Total white cell count and monocyte count. CD14 expression by PCR.
Patients demonstrated an increase in the mean total white cell count by 24 and 48
hours compared to pre-operative levels. This was followed by a return to pre¬
operative levels by day 5 (Figure 6.4a). There was also an increase, although no
significant, in the mean monocyte count by 48 hours post-operatively(Figure 6.4b).
Samples from 14 patients out of 15 patients were assessed for the relative quantity
(RQ) of CD14 mRNA. There was an increase in CD14 mRNA levels by 24 and 48
hours, followed by a reduction by day 5 post-operatively (Figure 6.4c).
pre day5
24h post 48h post
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Figure 6.4. Total white cell count, monocyte count and CD14 expression by PCR.
Effect of aortic aneurysm repair on the total white cell count (WBC), the monocyte count
and the RQ of CD14 mRNA. (a). Mean (±SEM) WBC increases from a baseline of 7.13xl09/
1 (±0.55) to 8.71xl09/l (±0.79) by 24 hours, to a peak of 10.23xl09/l (±0.49) by 48 hours. The
WBC then decreases by day 5 to 7.67xl09/l (±0.5) (p=0.0001). (b). Mean (±SEM) monocyte
count increases from a baseline of 0.51xl09/l (±0.07) to 0.68xl09/l (±0.06) by 48 hours. The
monocyte count is 0.64xl09/l (±0.05) by day 5. The change in monocyte count is not
significant (p=0.1). (c). The mean (±SEM) RQ of CD14 mRNA mirrors the change in the
mean WBC count. There is an increase from a pre-operative value of 1.06 (±0.16) to 1.74
6.2.2.2.2 CFU-EPC colony assay
Samples from 10 patients were assessed in the CFU-EPC colony assay. There was a
transient reduction, although not significant, in the mean number of CFU-EPC
colonies by 24 hours after the operation followed by an increase of CFU-EPC at

















Figure 6.5 CFU-EPC colony assay
The median number of CFU-EPC in culture is reduced by 24 hours after the operation, but
this does not reach statistical significance (p=0.41).
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6.2.2.2.3 CD34 expression
There was a reduction, although not significant, in the median number of CD34+
cells by 24 hours post-operatively, before a recovery to the pre-operative level by 48
hours (Figure 6.6a). In addition, there was a significant reduction in the median
mRNA levels of CD34 by 24 hours post-operatively (p=0.03), with a recovery to the
median pre-operative level by day 5 (p=0.03) (Figure 6.6b).
6.2.2.2.4 CD133 expression
Similarly, there was a significant reduction in the median number of CD133+ cells
by 24 hours (p=0.01), before a return to baseline levels by day 5 post operatively
(p=0.007 day 5 versus 24h)(Figure 6.6c). There also was a significative increase in




































































24h 48h day 5
Figure 6.6 Effect of aortic aneurysm repair on markers of EPCs
a) There is a reduction in the median number of CD34" cells by 24 hours, with recovery by
48 hours, b) The median RQ of CD34 mRNA transiently decreases by 24 hours before
recovering to baseline by 48 hours, c) the median number of CD133 cells transiently
decreases by 24 hours after procedure and it returns to baseline or higher levels by day
5 after the operation, d) the median RQ of CD133 increases at 24h after operation and
returns to baseline levels by day 5.
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6.2.2.2.5 VEGFR-2 expression
Samples from 9 patients were assessed for the expression of VEGFR2. There was
not a significance change in VEGFR2 protein surface expression or mRNA levels
over procedure(data not shown).
6.2.2.2.6 Dual CD34 and VEGFR-2 expression
There was a transient reduction in the number of VEGFR2' CD34+ co-expressing
cells by 24 hours after the operation (p=0.007) returning to baseline levels at day 5


































24h 48h day 5
Figure 6.7 Effect of aortic aneurysm repair on EPCs, using dual staining of markers by
flow cytometry.
When gated on all cells, the number of CD34"VEGFR-2" co-expressing cells falls significantly
by 24 hours post operatively, before recovering to baseline by day 5.
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6.2.3 Diabetes mellitus
Study in collaboration with Dr. Chris Millar, Department of Haematology, University of
Edinburgh).
The mean number of functional CFU-EPC was significally lower in patients with















t m f • •
Diabetics
Figure 6.8 Comparison of median colony numbers and median percentage positivity of
CFU-EPC in control group versus diabetic patient group.
The control group was not cohort matched with the patient group. The control group
had a higher median number of cell colonies (0.27xl04±0.06xl04) compared with the patient
group (O.OhxlOhzO.CBxlO4). This difference was statistically significant (p=0.004).
The patient group had a significantly lower median percentage of cells positive for
CD34 compared to control group (Figure 6.9 and table 6.7).No other significant
differences were found for the other markers studied (VEGFR2, VE-cadherin or for
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0.23 0.160.335 0.032 0-0.059 0.004
Median %CD34+
cells
0.06 0.050.09 0.02 0.020.05 0.0003
Median
%VEGFR2+ cells
1.89 0.8853.06 4 1.21-32.33 0.14
Median %V&
cadherin+ cells




24.39 5.7337.345 15.08 0.22243.5 0.35
Table 6.7
Comparison between the patient group and control group of the number of EPCs detected
by real-time PCR, flow cytometry and cell culture. Results are expressed as medians
with interquartile ranges. The unpaired t-test was used to compare mean ages of patient























The percentage of cells expressing CD34 is significantly lower in the patient group
compared to control group (p=0.003).
No significant differences were found in the median mRNA levels of CD34, VEGFR2
and vWF between patients with type 1-diabetes and control group (table 6.7).
However, the patient group had a significantly lower median mRNA levels of VE-
cadherin compared with the control group (Table 6.7) Furthermore, no differences
were found in the mRNA levels in patients with or without microvascular disease or
in patients with poorly controlled diabetes (Table 6.7).
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6.3 Discussion
Circulating EPCs phenotyped by flow cytometry analysis and functional CFU-
EPCs assessed by colony assay were measured in the different clinical situations
and compared with healthy individual controls. The numbers of circulating
endothelial progenitor cells have been reported to be reduced in individuals with
ischaemic diseases (Hill et al., 2003) for example in patients with cardiovascular
risk factors (Vasa et al., 2001) or in patients with diabetes mellitus type 2 (Tepper et
ah, 2002).
Circulating endothelial progenitor cells in patients receiving elective surgery for
abdominal aortic aneurysm repair and in type 1-diabetes patients selected as models
ofblood vessel damage and tissue ischaemia respectively were compared to a control
group of healthy individuals. The mean number of functional CFU-EPCs in both
clinical settings was significally reduced with comparison to that detected in the
control group. However, the proportion and total numbers of CD34+, CD133+ and
VEGFR2+ cells alone or in combination did not differ significally in patients prior to
aortic aneurysm repair or type 1-diabetes patients compared to control subjects
with the exception of a significant reduction of CD34+ cell numbers in type 1-diabetes
patients compared to healthy individual controls. Circulating EPC numbers were
reduced in patients with type 1-diabetes. In culture, blood derived CD34 cells from
type 1-diabetes subjects produced fewer endothelial cells than those from non-
diabetic controls (Schatteman et al., 2000) which could be explained due to their
lower number of CFU-EPC. This may have important consequences in terms of
their ability to form collateral vessels as part of the vascular repair mechanism.
Supporting the data showed in Chapter 5 no correlation between the number of
peripheral blood CD34' cells and the number of CFU-EPCs was found. Healthy
individuals had higher number of CFU-EPCs compared to the patient groups but
these effects were not associated with increases in circulating CD34+KDR+phenotypic
EPCs or leucocyte CD34 mRNA.
It is known that EPCs are mobilised from the bone marrow in response to vascular
injury and tissue ischaemia and that this is cytokine driven. Previous studies have
demonstrated early mobilisation of EPCs following vascular injury in patients with
acute myocardial infarction (Massa et al., 2005), major burns and following coronary
artery bypass grafting (CABG)(Gill et al., 2001).Acute myocardial infarction was
associated with a rapid increase of EPCs in the circulation (Shintani et al., 2001).
These clinical events involve extensive damage to a number of tissues in addition to
the vasculature, which may contribute to the mobilisation of progenitors. In this
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Chapter we demonstrate that local selective vascular injury can also influence the
number of circulating progenitor cells. Percutaneous coronary intervention, but
not diagnostic angiography, was associated with a mild systemic inflammatory
response and an increase in functional CFU-EPCs in the peripheral blood. Coronary
intervention increased the number of CFU-EPC. However, these effects were not
associated with increases in circulating CD34TCDR+phenotypic EPCs or leucocyte
CD34 mRNA. Therefore, again no correlation between the number of peripheral
blood CD34+ cells and the number of CFU-EPCs was found.
Gill et al., (2001) suggested that vascular trauma induced a rapid but transient
mobilisation of endothelial precursors. In this study, following elective abdominal
aortic aneurysm repair patients showed a transient reduction in the mean number
of CFU-EPC colonies by 24h after the procedure followed by an increase in CFU-
EPC at 48h. This did not reach significance but further data needs to be collected to
confirm this trend. A significant decrease in the proportion of CD34+ and CD133+
cells was also detected after 24h post-operatively, with recovery at 48h. In this case
both flow cytometry, mRNA analysis and CFU-EPC colony assay correlated with
each other. In addition to the flow cytometry analysis real-time PCR showed a rapid
but transient reduction in the relative quantities of mRNA for CD34 VEGFR2 and
CD133, with a subsequent increase in the relative expression of mRNA for VE-
cadherin and vWf following aneurysm repair. Our studies demonstrate that there
is mobilisation of a circulating pool of EPCs, which may reflect a rapid maturation
process as part of the post-operative vascular repair mechanism.
The original description of the putative endothelial progenitor cell was based on cell
culture and adhesion techniques. Asahara et al., (1997). described a population of
adult human circulating CD34+ cells that could differentiate into cells with
endothelial-like characteristics in vitro. The exact origin and phenotype of these
progenitors remains a matter of debate in part because the purity of CD34+ cells
used in this initial study was only 15% Asahara et al., 1997). Subsequently the co-
expression of transmembrane glycoproteins CD34 and vascular endothelial growth
factor receptor-2 (VEGFR-2 or KDR) have been used in an increasing number of
clinical studies to phenotype and to quantify circulating EPCs. As the field has
developed, an increasing number of methods have emerged to define vascular
progenitors and quantify regenerative capacity. The CFU-EPC assay has been used
widely since it was first described by Hill et al., (2003). Whilst quantification of
CFU-EPC provides a measure of the capacity of circulating mononuclear cells to
form endothelial cells, it is doubtful whether these colonies arise directly from the
circulating CD34+ stem cells (see 5.2.3.4). Studies addressing the origin of endothelial
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progenitor lineage in adult peripheral blood have demonstrated that monocytes
also express endothelial lineage markers such as VEGFR-2 and can differentiate
into mature endothelial cells (as presented in 5.1.6). Direct staining of our colonies
demonstrated that CFU-EPCs not only behave like mature endothelial cells and
incorporate acetylated LDL, but that they also strongly express CD14. In keeping
with recent reports (as reviewed in 5.1.6), we have found that isolated CD34+ cells
do not give rise to spontaneous CFU-EPCs but die in this assay. In contrast, all
CFU-EPC activity is found in CD14+ enriched, but not in CD14+ depleted, fractions
of peripheral blood mononuclear cells (see 5.2.3.4). This population of circulating
CD14+ monocyte-like endothelial precursors appear more functionally mature than
CD34+ cells and are more abundant in normal peripheral blood than in bone marrow.
In contrast, while CD34+KDR+ cells may ultimately give rise to endothelial cells,
they are much less frequent in peripheral blood than in bone marrow, and may
only be the precursors of the functionally more mature CFU-EPC cells that appear
to be crucial for the immediate response to vascular injury.
Whilst in these clinical studies we did not specifically measure CD14+ cells by flow
cytometry, we did quantify monocyte numbers and total leucocyte CD14 mRNA.
We identified a reproducible decrease in both immediately after cardiac
catheterisation. It is possible that these cells immediately localize to the site of vessel
damage: both at the site of arterial puncture and at the site of coronary angioplasty
and stenting. The number of peripheral blood monocytes was restored to pre-
procedural levels by 24 hours, and CD14 mRNA levels increased 24 hours after
PCI. Mobilisation of CD14+ monocyte-like cells may explain the increase in CFU-
EPCs in peripheral blood observed 24 hours after arterial injury. These cells may
contribute to vascular repair either through formation of mature endothelial cells
and incorporation into the vessel wall, or through the release of angiogenic growth
factors at the site of vessel injury. Further studies are required to explore specifically
the role of CD14+ cells in vascular injury and repair.
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General conclusions
In the first part of this thesis (Chapter 3), we have developed a simplified method,
compared to a range of complex published systems, to generate mature functional
neutrophils from CD34+ cells. Future clinical application as a possible means of
reducing neutropenia following autologous peripheral blood stem cell
transplantation, still not solved by availability of donor granulocyte transfusions,
remains to be tested and cost effectiveness examined. Our results showed that
adddition of thrombopoietin employed by other methods especially where joint
neutrophil and maegakaryocyte expansion/maturation is intended, is not necessary
for selective neutrophil expansion and it showed an inhibitory effect on neutrophil
maturation. If megakaryocyte expansion is to be considered then separate protocols
should be devised to optimise this in distinct cultures rather than attempting
simultaneous neutrophil and megakaryocyte growth in the same system.In addition,
this in vitro CD34+ neutrophil differentiation system is being demonstrated in
Chapter 4 as a good model to study changes in the expression of molecules, in our
case phosphatases, that might occur through the neutrophil differentiation pathway.
In the second part of this thesis we examined the endothelial progenitor potential of
feasible sources of autologous EPCs, and we have completed a systematic study of
a range of proposed phenotypes of EPC with regard to HSC markers. In addition,
a CFU-EPC assay has also been tested in all the different EPC sources. No
relationship between phenotype definition and CFU-EPC function has been found.
CD34+ cells from any source do not form colonies, do not take up typical spindle-
shaped morphology, and die after a few days in the CFU-EPC. CD14+ cells contain
all CFU-EPC. When purified CD34+ cells are expanded in the presence of certain
growth factors and other cytokines they will survive, assume spindle-shaped
morphology, and some will form colonies in the CFU-EPC assay. This implies that
CD34+ cells have the potential to develop into CFU-EPC capable cells. Therefore,
precursors of the CD14+ cells CFU-EPC exist within the HSC-rich sources. These
CFU-EPC precursors may be the CD34+VEGFR2+ identified by others, and represent
an earlier state of differentiation of the same lineage which gives rise to CFU-EPC
and ultimately to mature endothelial cells incorporated in vessels. However, while
CD14+ give rise to endothelial-like cells it is still under investigation whether these
CDI4+ EPC precursor are monocytes with a retained considerable proliferative
potential, or a true independent EPC precursor resembling monocytes by expression
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of CD14.
Using in vitro assays such as phenotype and CFU-EPC can not determine
vasculogenic potential directly. In the next 3 years, models of vasculogenesis in
SCID-NOD mice will be used to evaluate the potential of human mononuclear cells
in the contribution to de novo angiogenesis and vascular repair in vivo. This may
enable correlation of the in vitro assays with vasculogenic potential, or indicate
alternative assays which better indicate vasculogenic potential. This study should
then provide information on the relative angiogenic potential of available sources
of endothelial progenitor cell for autologous clinical engraftment procedures
envisaged for cardiac and critical limb ischaemia, and whether these can be improved
by selective subpopulation enrichment of ex vivo endothelial promoting
manipulation. These should also offer informed choices for design and
implementation of trials of clinical procedures, especially where the angiogenic
potential of such sources in target patient groups may be impaired.
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